Archives

Prepping Pharmacist Preceptors on the Pharmacists’ Patient Care Process (PPCP)

Learning Objectives

 

After completing this application-based continuing education activity, pharmacists will be able to

    • Describe the PPCP model and its uses
    • Apply the PPCP when students address clinical problems in the workplace
    • Identify areas where pharmacy students need the most guidance when using the PPCP

    Two healthcare professionals talking while looking at a vial filled with medication capsules

     

    Release Date: July 21, 2023

    Expiration Date: July 21, 2026

    Course Fee

    Pharmacists: $7

    UConn Faculty & Adjuncts:  FREE

    There is no grant funding for this CE activity

    ACPE UANs

    Pharmacist: 0009-0000-23-028-H04-P

    Session Code

    Pharmacist:  23PC28-XPK68

    Accreditation Hours

    2.0 hours of CE

    Accreditation Statements

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-028-H04-P  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

     

    Disclosure of Discussions of Off-label and Investigational Drug Use

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Faculty

    Kimberly Ma
    PharmD Candidate 2024
    UConn School of Pharmacy
    Storrs, CT

    Jeannette Y. Wick, RPh, MBA, FASCP
    Director, Office of Pharmacy Professional Development
    UConn School of Pharmacy
    Storrs, CT

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    Kimberly Ma and Jeannette Wick do not have any relationships with ineligible companies

     

    ABSTRACT

    Preceptors often work with students to review patient cases in an organized way. Experts developed the Pharmacists’ Patient Care Process (PPCP) in 2014 to provide a template that is consistent and concise, but also comprehensive. Using this process, students and licensed pharmacists develop SOAP notes to document the subjective and objective data they need to complete an assessment, and ultimately make a plan. PPCP stresses an important point: follow-up is critical and a well-written SOAP note can be extremely helpful in the follow-up process. This continuing education activity uses a case study to demonstrate how the PPCP process should work and emphasize areas where preceptors can provide tangential learning. It includes PRO TIPS for preceptors when they supervise students who are attempting to complete PPCP. It highlights the most common errors and suggest ways that preceptors can work with students to improve their experiential education.

    CONTENT

    Content

    INTRODUCTION: A PATIENT CASE

    JM, an 8-year-old white male presents to your clinic. It’s a pediatric care clinic located in an area where many financially challenged families live. After talking with his parents, you learn he was recently diagnosed with central precocious puberty (CPP). His endocrinologist recommends initiating therapy and would like to know what treatment you recommend. His parents also have questions.

    Your spry pharmacy student jumps at the opportunity to write a SOAP note using the “PPCP.” To you, PPCP sounds like an illegal drug that was abused in the 1980s. She explains that the Pharmacists’ Patient Care Process (PPCP) is a standardized model for collaborative medication management. She clarifies what it entails and how to apply the process in a clinical setting.

    PPCP’s Importance

    Schools of pharmacy have taught the PPCP for the past few years. Preceptors who are unfamiliar with the process may find it helpful to review the PPCP as many students will take this approach when addressing clinical problems in the workplace.

    PPCP: THE DETAILS

    Teamwork in healthcare has achieved major goals for many patients (although we have room for improvement): accessible, affordable, and high-quality care. In addition to the many healthcare team members, pharmacists are critical contributors to care plans. Medication expertise equips pharmacists with the knowledge to reduce drug adverse events, prevent medication errors, and provide invaluable input for decision-making.1

    In 2014, the Joint Commission of Pharmacy Practitioners (JCPP) developed a standardized process for medication management that could be used across interdisciplinary teams and dubbed it PPCP. JCPP’s members developed the approach using principles of evidence-based practice. The five steps—collect, assess, plan, implement, and follow-up—are tied together with careful communication and documentation.2 Pharmacists can remember the steps as the pneumonic “CAP-IF.”

    SOAP Notes

    The subjective, objective, assessment, and plan (SOAP) note provides a method of documentation for the collect, assess, and plan steps of the PPCP. SOAP notes are probably familiar to most preceptors, as clinicians have used them for roughly 50 years.3 Table 1 highlights the key components of SOAP notes.

    Table 1. Components of a SOAP Note1

     

    Objective Information Subjective Information
    ·       Current medication list (prescription and nonprescription)

    ·       Medical history

    ·       Physical assessments (i.e., blood pressure, heart rate, weight, height, respiratory rate, etc.)

    ·       Laboratory results

    ·       Chief complaint

    ·       Symptoms

    ·       Patient lifestyle habits, preferences, and beliefs

    ·       Patient goals for care

    ·       Socioeconomic factors

    Assessment
    ·       Problem: statement highlighting the chief complaint or main medication-related problem

    ·       Rationale: the reasoning for the intervention cited from guidelines and supporting evidence from the collected information

    ·       Goals of care: possible barriers to adherence, socioeconomic considerations, and desired outcome of intervention

    Plan
    ·       Specific recommendation or intervention based on practice guidelines (i.e., initiation of drug therapy, referral to another provider, or non-pharmacologic lifestyle modifications)

    ·       Plan for upcoming sessions, specific monitoring parameters, and progress indicators

     

    Collect

    Thorough collection of the right information supplies pharmacists with tools to make safe, effective decisions. A combination of objective and subjective information paints a more complete picture of a patient’s clinical status. If possible, pharmacists should obtain and verify their information across multiple sources. Past medical records, active medication lists, and laboratory results are great places to start.

    When soliciting subjective information, pharmacists should use open-ended questions. Prompting patients with questions formatted to avoid “yes” or “no” answers allow providers to obtain more information in less time, prioritize chief complaints better, and minimize implicit assumptions.4

    Back to the Case

    Your head is spinning trying to sort all the “P’s” in PPCP, CPP, and JCPP, but your student assures you that she will start with collecting relevant clinical information. First, you and your student perform a physical assessment of JM including taking his height and weight. JM takes no medication except an occasional antihistamine, but if he took other chronic medications, this would be the time to direct your student to perform a medication reconciliation. Next, you prompt JM’s parents with open ended questions, and they recall JM’s past medical history. You should ask your student if JM needs to be involved in the discussion (see SIDEBAR). After meeting with JM and his parents, here is the relevant information your student jots down:

    Subjective information

    • At age 5, JM frequently soaked through his underarm clothing with pungent perspiration, so since then, he uses a strong deodorant
    • He is starting to develop pubic and underarm hair
    • He has some acne on his face and upper back
    • JM occasionally tells his parents he feels “different” than his classmates because he is so much bigger and taller
    • He has no past surgeries or hospitalizations
    • Takes OTC multivitamins daily and loratadine for allergies in the spring

    Objective Information

    • Height = 4’8” inches
    • Weight = 102 pounds
    • DHEA Sulfate = Tanner stage III - 60 ug/dL (N = < 28 ug/dL)
    • Clinical exam findings = testicle size indicates puberty
    • X-ray bone age hand and wrist = greater than 2 standard deviations, 156 months (expected = 108.9 months)
    • Luteinizing hormone (LH) = 0.4 units/L (N = < 0.3 units/L)

    SIDEBAR: Pediatric Involvement in Healthcare Decisions5,6

    In pediatric cases, clinicians may choose to consult only parents when making decisions regarding their child’s medical care. However, this practice, which is rooted in legal precedence, should shift to involve affected children to some extent. The American Academy of Pediatrics advocates that adolescents actively participate in decisions based on their ability and maturity. 5 While research is lacking on how exactly to assess a child’s aptitude to participate in decision making, some studies show that children can participate as young as age 5.6 Regardless, it doesn’t hurt to ask children if they have questions or concerns. In the case, JM is 8 and has voiced his concern previously about his height and size. Therefore, including him in the conversation is a possibility if his parents agree.

    Preceptors can and should provide tangential learning when working with special populations. Reminding students that adolescents, older adults, people who have cognitive decline or dementia, and people for whom English is a second language will need careful counseling. Pharmacists and pharmacy staff will also need to select their words carefully and accommodate these patients’ needs. Assigning students to do some research on the various needs in these populations is an excellent way to help them develop skills and a professional identity.

    Upon looking at your student’s notes so far, you assure her she has done well. However, you still have some questions. You remind her that sometimes information like height and weight requires additional evaluation and ask her to calculate JM’s BMI; she finds that it’s 22.9. You ask your student, “How does JM’s height and weight compare to the expected height and weight of boys his age?” To which she replies, “Pediatric growth charts will give us a better idea!” After consulting the growth charts, she determined and documented that JM falls within the 112th percentile for both measurements.

    To make learning comprehensive, you could ask the student if the only kind of precocious puberty is central in nature. This will help your student learn to differentiate among different forms of similar diagnoses.

    Assessment

    An assessment of comprehensive patient information helps prioritize the problems that require attention. Pharmacists should consider all information when identifying the problem, the rationale, and the goals of therapy. Some example questions pharmacists can consider include1

    Medication appropriateness

    • What is the indication for each medication?
    • What is the correct dosing?
    • What are the common adverse effects?
    • What are the possible drug interactions?

    Factors that impact access to care

    • What cultural factors create barriers to care?
    • What socioeconomic factors impact the patient?
    • What is the patient’s level of healthcare literacy?
    • What goals does the patient or his parents have?
    • What barriers impact patient adherence?

    Additional services

    • What preventive care measures does the patient qualify for?
    • Which immunizations has the patient received?
    • What other concerns does the patient have?

    THE CASE RESUMED...

    After compiling the objective and subjective information on JM, the student finds guidelines in the Journal of Clinical Endocrinology for the management of CPP.7 Due to JM’s symptoms and lab values showing consistencies with CPP, the guidelines recommend initiating a gonadotropin releasing hormone (GnRH) analog. Depending on JM’s and his parents' preferences, the endocrinologist can choose either an injectable (leuprolide) or long-acting implantable device (histrelin) provided the insurance covers it or the cost is manageable.

    Once again, you should have some questions for your student. For example, asking the student to list the search terms and search engines she employed can shed light on her process. Another question might be, “Are these the only guidelines available?” You can show her that you used PubMed, as she did, but when you used Google Scholar, you found an excellent review article that lists five other publications. You suggest she look at them since expert recommendations can vary. She might also contact the endocrinologist and ask if he plans to follow the guidelines she identified, and if not, why not.

    The endocrinologist messages back saying he agrees leuprolide and histrelin are both reasonable options to consider for first-line therapy. However, he also cites a 2019 update published on Hormone Research in Paediatrics. These guidelines recommend a third U.S. Food and Drug Administration (FDA)-approved option for the treatment of CPP, triptorelin.8 He says the student should consider this choice as a potential treatment for JM as well.

    After reading the endocrinologist’s note, you emphasize to your student the importance of citing multiple guidelines when drafting an assessment. In this case, the FDA approved an additional treatment, triptorelin, in 2022. You walk through your student’s process of finding clinical information to identify more ways she can improve next time. Furthermore, you point out how the endocrinologist’s insight exemplifies the importance of interdisciplinary care.

    Simultaneously, you and your student read through all three monographs and discuss the major differences you’d like to share with his parents. You ask the student to practice her delivery of the information, and she says, “Leuprolide is a long acting injectable administered intramuscularly (IM) or subcutaneously. Your doctor will administer the IM formulation every month, three months, or six months. “Triptorelin is similar to leuprolide, but is only available as a six month IM formulation. The other option is for your doctor to administer the subcutaneous formulation every six-months.9 On the other hand, histrelin comes as a long-acting 1¼ inch implant surgically placed into the upper arm every 12 to 24 months. For the first 24 hours after the surgery, JM should avoid swimming or bathing. As long as JM avoids heavy play or exercise for the first week, he will not have to worry about any further restrictions after that. The implant also requires surgical removal.”10

    Now, you prompt the student to recall that JM’s parents expressed concern about what would happen if JM experienced an adverse reaction to the long-acting implantable device. They asked, “What is the procedure like?” and “If JM has a reaction to the implant, must he continue to wear it for 12 months or can the doctor remove it easily before then?”

    The student does more research and says she will assure JM’s parents that this outpatient procedure lasts only 10 minutes, though the appointment may last 60 to 90 minutes. Most surgeons will just numb the area; however, children may undergo sedation if necessary. The surgeon will insert the narrow implant into a small approximately 5 mm opening made in the skin on the inner surface of the arm. With this option, JM can return to school the same day. The student plans to mention that complications don’t commonly occur, but minor discomfort and bruising may.11 The student plans to continue, “The implant may be removed immediately if JM presents at any time a severe allergic reaction or adverse effect. However, this is not common.”

    Before you and the student document the assessment section of your SOAP note, the student indicates she will ask JM if he has questions. He shares that he “HATES needles” but is also scared of the surgery hurting.” The student plans to tell him not to worry because he won’t feel any pain during the operation. He can also choose to sleep during the surgery if he prefers.

    Here, the preceptor should step in with gentle corrections about patient-appropriate language. First, most Americans have no idea what a 5 mm incision will look like. You ask her to calculate its length in inches and explain it by comparing it to something the child will recognize, like the size of small dice or a stack of 20 playing cards. Next, it’s critical to remind the student that we must never tell patients that something won’t hurt. This is a lesson students should learn during immunization training and creates an opportunity for cross training (applying this principle to other areas of pharmacy) that applies regardless of patient age. Healthcare professionals should never say, “This will not hurt a bit!” or anything similar. People have different pain thresholds making it impossible to predict whether it will hurt. Student pharmacists need to develop language they are comfortable with and use it. A good response if people ask if it will hurt is, “It may hurt or sting a little but just for a minute or two.” In this case, the preceptor suggests saying, “The doctor will numb the area.”

    Finally, the preceptor may point out that “operation” can be a scary word for children. The student needs to use a word like “procedure” or find a way to avoid either of those words.

    The preceptor should also point out that JM’s parents had also said they were worried about two things: (1) potential side effects and (2) the cost of care. They heard on the news that expenses associated with these medications can add up quickly. The cost of care and determining what the patient’s insurance will cover is probably foremost in the endocrinologist’s mind, too.

    In terms of potential side effects, your student says that both GnRH analogs have similar side effect profiles. From the pediatric studies she read on GnRH adverse effects, she shares that signs of puberty may increase transiently with therapy before growth velocity eventually slows down. Some children experience weight gain, changes in appetite, body aches, headaches, gastrointestinal (GI) symptoms, or signs of a common cold. Parameters like physical growth and bone mass density may decrease during treatment but usually return to normal one year after treatment discontinuation.9, 10

    Before selecting JM’s treatment option, it’s critical to evaluate insurance coverage since it’s on the forefront of everyone’s concerns. The student needs to determine if they have insurance and what the plan covers. She starts by finding information on ballpark cost. She reports a histrelin implant costs around $40,000. If the patient requires mild sedation when the doctor inserts the implant, the cost may increase. However, in some cases, the implant may be used for up to two years. Leuprolide’s median annual cost ranges from $20,000-$40,000 depending on the formulation.12 A single injection of triptorelin costs roughly $19,000, making the annual cost nearly $40,000 as well. Then says she will remind JM’s parents that while this may give them an idea, the cost may vary outside of that range.

    Plan

    Following the assessment, pharmacists work to develop a personalized patient care plan in collaboration with other healthcare professionals. The plan should reflect recommendations from the most recent evidence-based clinical practice guidelines. Pharmacists should focus on optimization of care in a safe, effective, and cost-effective manner.

    1. Address medication-related problems and optimize medication therapy
    2. Set specific, measurable, achievable, realistic, and timed (SMART) goals in the context of the patient’s healthcare goals and access to care
    3. Involve patients to engage in education, empowerment, and self-management
    4. Support non-pharmacologic interventions as appropriate

    SMART Goals. When creating an action plan for patients, pharmacists should aim to set goals that are SMART.

    • Specific instructions provide other clinicians with accurate information about the patient.
    • Measurable outcomes provide clinicians the ability to evaluate the patient’s progress and whether the plan requires adjustments
    • Achievable and realistic goals
    • A timeline for the plan ensures healthcare providers routinely follow up with their patient

    A PLAN FOR JM

    After you document JM’s main problem, rationale, and goals for care in the assessment section, you move on to create his plan. Following careful consideration of the assessment, you and your student decide to recommend starting histrelin to treat his CPP since his insurance will cover it once the endocrinologist completes prior authorization forms. (Here, you suggest that the student find the prior authorization forms and volunteer to complete as many sections as she can for the endocrinologist. You explain that she can expedite the process and this is a skill she can apply to many different pharmacy practice locations.) Choosing histrelin is also a needle-free option, which may make JM happy. You remind your student that the plan should also include scheduling necessary appointments and follow-ups with JM’s other providers in addition to counseling on the specific adverse effects of the medication detailed in Table 2.

    Table 2. Example SOAP note for JM 7

    Name: JM

    Age: 8    

    DOB: 10/02/14

    Allergies: Seasonal allergies, NKDA

    Chief Complaint: Patient referred to clinic by endocrinologist for medication therapy; patient was recently diagnosed with central precocious puberty (CPP)
    Subjective Information

    JM is an 8-year old white male presenting to the clinic. He recently met with his endocrinologist on 6/28/23 and has been referred to the clinic for drug therapy to treat CPP. His parents confirm JM’s use of deodorant to combat excessive perspiration and body odor since the age of 5. He has also developed pubic and underarm hair in addition to acne on his face and upper back. His parents are concerned regarding JM’s reported insecurities at school due to his larger size.

    PMH: no surgeries or hospitalizations Medications: daily multivitamin, OTC loratadine (prn for allergies)
    Objective Information

    Clinical exam findings = testicle size indicates puberty

    112th percentile for weight and height

    Relevant Labs: Bone age of 13, LH 0.4 units/L, DHEA sulfate 60 ug/dL

    Height: 55 in Weight: 102 lbs BMI: 22.9 BP: 110/61 mmHg HR: 75 bpm Temp: 98.6 ℉ RR: 15
    Assessment

    Problem: Patient requires medication therapy for untreated indication.

    Rationale: According to the Journal of Clinical Endocrinology Practice Guidelines for Central Precocious Puberty, JM requires hormone suppression therapy. Symptoms of rapid linear growth, advanced skeletal maturation, and basal LH levels > 0.3 units/L require treatment with GnRH analogs until the normal age of puberty.

    Goals of Care: The goal of treatment is to reduce signs of premature pubertal progression while ensuring therapy is well tolerated and medication side effects are minimized. Patient’s parents would like to choose an option that is cost effective and safe.

    Plan

    Initiate histrelin 50mg SQ implant to be administered by JM’s surgeon every 12-24 months depending on safety and efficacy parameters evaluated at follow up appointments

    Schedule surgery appointment with JM’s surgeon at earliest convenience

    Schedule follow up in 3 months to evaluate pubertal progression, growth velocity, skeletal maturation, and tolerability

    Counsel JM/JM’s parents on possible adverse effects including weight gain, changes in appetite, initial flare of puberty symptoms, GI symptoms, body aches/pains, and signs of common cold

    Counsel JM’s parents on providing support to make JM feel good about himself. Children who are undergoing rapid development at this age may feel different when comparing themselves to other children their age.

    Implement

    During the implementation phase, pharmacists set the action plan into motion. This may include the administration of vaccines, initiating or discontinuing a medication, or scheduling the next follow-up appointment. Pharmacists, primary care physicians, or caregivers work together to provide care based on the goals made in the planning step.1

    Follow-up and Monitor

    The pharmacist in collaboration with other health care providers should follow-up with the patient as recommended in practice guidelines and referring back to the SOAP note. Continuous monitoring of medication appropriateness, adherence, safety, laboratory results, and patient concerns will indicate if the plan requires revision. Routine medication reconciliations, check-ups, or conversations with patients improve outcomes and help to achieve goals of therapy.

    Putting it All Together

    Upon completion of the SOAP note, you send the endocrinologist your recommendations. You contact JM’s parents to discuss scheduling a follow-up appointment in three months with the endocrinologist and counsel on histrelin.

    IMPLICATIONS FOR PRECEPTORS

    The Benefits. The PPCP model creates a reproducible framework that demonstrates clinical pharmacists’ contributions to medication-related outcomes.13 In addition to improving the quality and completeness of patient medical records, SOAP notes give pharmacists a place to start when working up a new patient. As students practice developing SOAP notes, preceptors should emphasize how the lessons they learn in one case can apply to future cases.

    The Drawbacks. As more pharmacy programs integrate PPCP into their curriculum, new students will have access to courses that teach the model. But because the PPCP model is relatively new, many licensed pharmacists have not yet familiarized themselves with the process. Extracting the necessary information to write quality SOAP notes can also be time consuming. Depending on the setting, pharmacists may not have enough time to walk through every step with students. Finally, the PPCP method does not encompass all clinical situations. The framework relies on pharmacists to exercise clinical judgment and reasoning to modify the model as needed.

    Uncomfortable Topics. Students often have little exposure to difficult topics. These may include end-of-life issues, psychiatric diagnoses, cultural or ethnic differences, drug abuse/misuse, and gender-related topics. In this case, students may feel strong discomfort in discussing matters related to sex and sexual development. Preceptors need to help students reduce their hesitancy when communicating with you and the patient because improper communication can lead to poor collection of relevant information. Keep in mind strong note-writing skills facilitate good care. Two things help: (1) practice, and (2) finding resources designed to help with difficult topics. The Conversation Project (https://theconversationproject.org/resources/healthcare/) is one such resource that can help students become more comfortable with difficult topics.

    In addition, students may have implicit and explicit biases for uncomfortable topics such as the use of hormone blockers, which may bring to mind their use in transgender children. Creating a safe place for your student to share opinions provides a great opportunity for you to teach students how to avoid these biases. Preceptors need to remember that learning—especially if it changes a student's perspective or points out a student's mistake—can be threatening, and students can feel vulnerable while learning. It’s an emotional experience.6

    To help guide students through these experiences, the SIDEBAR provides 10 additional tips preceptors can use when supervising the PPCP.

    SIDEBAR: PRO TIPS for Preceptors Who Supervise the PPCP

    (1) Don't let the acronym scare you! This is a new name for a process you've probably used knowingly or unknowingly for years.

    (2) Encourage independence. Hand over the problem to the student once you've described the problem and fielded the student's questions. Establish a time for the student to be prepared to discuss it but check in periodically to see if the student is having trouble.

    (3) Rescue when necessary. Some students will need more support than others. If a student is clearly flummoxed, spend more time and provide more direction.

    (4) Promote interdisciplinary communication. Having students discuss a clinical problem with another clinician, either with you or on their own, fosters interdisciplinary care. Students will also learn from the other clinicians, which will lighten your load!

    (5) When students present findings, always ask them to describe things like the search terms and search engines they used or the obstacles they encountered. Help them refine their processes to reduce barriers or find more appropriate resources.

    (6) Consistently prompt students to determine if the case is typical or unusual. Asking questions based on a modification of the case can help students learn more globally.

    (7) Don't "stay in your lane"! In this CE, the practice site is an ambulatory care location specific to pediatrics. The lessons a student learns in this rotation, if they go beyond pediatrics, will be invaluable. Helping students develop communication skills or analyze how disease states present or are treated in adults or other special populations will increase their clinical acumen in future rotations.

    (8) Address implicit biases or misconceptions. Students may not know that an attitude or opinion is biased, incorrect, or simply rude.

    (9) Debrief. After the PPCP is done, provide feedback, ask others who may have been involved to provide feedback, and ask the student to perform a self-assessment.

    (10) Appreciate reverse mentoring. Remember that students often teach us new things!

     

    Common Sources of Error

    Collecting too little information. Not all the information pharmacists need to collect will be obvious. In the patient case, the student collected important objective information like height and weight. However, without something like growth charts to evaluate JM’s height/weight compared to other kids his age, the information does not help in the assessment. Preceptors can aid students who are new to documenting SOAP notes when they are required to dive deeper into collected information. Students should not make assumptions as to what other clinicians know off the top of their heads. In this case, other areas where the preceptor helped the student included directing her to seek other expert opinions like the endocrinologist. That puts the “inter” in “interdisciplinary” care!

    Collecting too much information. Pharmacists and students should collect information worthy of appraisal. In other words, only collect the necessary information that will contribute to the identification, prevention, and resolution of either the chief complaint or medication-related problems. If pharmacists/students do not actively use collected information to make the assessment or plan, they should omit it in the note. Documenting more information does not equate to better information. This leads to overly lengthy or confusing SOAP notes. Here, as in the previous error, preceptors should ask students to examine and explain their processes.

    Not verifying information. All information should be verified across multiple sources like when performing traditional medication reconciliations. This prevents possible errors in note-taking that may arise from outdated documentation.

    Sourcing one guideline. Depending on the disease state, the frequency in which guidelines are updated can vary. Preceptors should emphasize the importance of looking for multiple guidelines and paying attention to their publication dates. Occasionally, the FDA may approve new treatment options after the release of clinical guidelines or updates. In this case, the student completely missed an additional treatment option as a result of sourcing a single guideline from 2013. Similar to how preceptors should encourage students to verify collected information across multiple sources, preceptors should also encourage students to cross-check sources that aid in their assessment.

    The assessment lacks evidence. As mentioned above, the assessment should communicate the assessor’s thought process. The information collected by the pharmacist/student should justify why the problem is a problem. If there is no subjective or objective information to back up the assessment, the assessment has no basis.

    Forgetting recommendations on current medications. Pharmacists/students should not forget to include instructions for the patient’s current medications, not just the newly prescribed medications.

    Forgetting non-pharmacologic recommendations. The plan section also encompasses non-pharmacologic interventions such as referral to another provider, ordering additional laboratory tests, education, or counseling on lifestyle interventions. Pharmacists/students should remember that not all patients require initiation of a new medication.

    Being vague. When initiating new therapy appropriately, pharmacists/students should always provide specific recommendations with the drug name, dose, and frequency. Vague instructions such as “Initiate hormone blocker therapy” are unhelpful. Similarly, instead of “monitor for side effects,” pharmacists/students can list the specific symptoms that present most commonly.

    Poor communication. Errors due to poor communication directly hinder the PPCP. Furthermore, clinicians with experience are not necessarily better communicators. Therefore, pharmacists should engage in education/training to constantly improve communication skills. SOAP notes should effectively communicate the pertinent information used to create a plan and document important details for the patient’s medical record.

    Setting it and forgetting it. The PPCP is not a linear process. While this framework provides clinicians a place to start and a checklist of sections to complete in order, pharmacists should remember to review and revise all sections at any given time. For example, pharmacists may identify new information they should go back to collect as they work on their assessments. Preceptors should encourage their students to occasionally step back and evaluate the completeness and coherence of the SOAP note. Sometimes patient cases will require students to revise sections of the SOAP note they already completed.

    And a New Case

    Just before the end of the month, the endocrinologist sends yet another patient with precocious puberty to you. The patient LD is a 9-year old Hispanic female. Her endocrinologist recently diagnosed her with idiopathic precocious puberty and wants to know which treatment you recommend. Her parents also want to know why this is happening to their daughter. Before taking LD’s family from the clinic waiting room, you decide to let your student take charge of this case while you supervise. You ask your student “Now that you have practiced writing SOAP notes and know a little about this disease state, how will you approach the PPCP this time?”

    The student says to you...

    “I stored all my notes from the last case on precocious puberty from earlier this month. I have a document containing the guidelines from the Journal of Clinical Endocrinology along with several updated publications that cite all additional first-line medications approved after the original guideline’s release. I will start with the collection of subjective information such as LD’s symptoms and medical history followed by objective information, specifically pertaining to her growth statistics. I should calculate BMI and her height/weight percentiles since precocious puberty is usually associated with accelerated growth. Next, I will examine her relevant lab values. Since the patient is female, I will be looking out for progesterone levels this time. If possible, I shall cross-reference all of the information I collect across multiple sources.”

    “Before I move onto making an assessment, I understand LD’s parents may feel very concerned about their daughter's condition. I don’t want to forget to address their question. I will explain that idiopathic precocious puberty does not have a definitive cause. To help them better understand, I’ll mention that idiopathic cases may result from anything ranging from a head injury in childhood to exposure to certain chemicals. Regardless of the cause, I will assure them there are several treatment options that may be appropriate for LD at this time. I can walk them through the pros and cons of all the available options.”

    “Next, I would prompt LD’s parents with open-ended questions to learn more about their major concerns, potential barriers to medication therapy, and insurance eligibility. I know these are important considerations for my assessment. It would also be appropriate for me to engage with LD using appropriate language for a 9-year-old girl. I realize the topic may be uncomfortable to discuss, but without taking initiative of the discussion I may forget to include pertinent details in my SOAP note.”

    “Finally, using the information I collected about the family’s preferences and LD’s medical history, I will draft the chief complaint, rationale for treatment, goals of therapy, and eventually a completed plan. The plan will include which treatment I recommend along with the dose, frequency, and which adverse effects are most common. I will write when I recommend a follow-up with her endocrinologist and make note of which lifestyle modifications may support her specific treatment. If the endocrinologist is on board, then we can collaboratively implement and follow-up with the patient as appropriate.”

    You are overjoyed to hear that your student has taken what she learned from the previous case and applied it to this case as well. Although some of the parameters were different, such as the patient’s sex, she was able to anticipate how the changes may impact her SOAP note this time. While you identify a few areas in which she can improve, you are happy that she is continuing to expand her clinical pharmacy knowledge.

    Conclusion

    The PPCP model can be applied to any healthcare setting in which pharmacists practice. This comprehensive approach to patient-centered care has established a streamlined method of documenting patient information to be shared among healthcare teams. As the PPCP continues to grow in clinical settings, practicing pharmacists should become familiar with its methods and applications.

    Pharmacist Post Test (for viewing only)

    Prepping Pharmacist Preceptors on the Pharmacists’ Patient Care Process (PPCP)
    Post-test
    Learning Objectives
    After completing this continuing education activity, preceptor-pharmacist will be able to
    • Describe the PPCP model and its uses
    • Apply the PPCP when students address clinical problems in the workplace
    • Identify areas where pharmacy students need the most guidance when using the PPCP
    POST TEST
    1. Which of the following correctly lists the steps of the PPCP process in order?
    A. Collect, plan, assess, follow-up, implement
    B. Collect, assess, plan, implement, follow-up
    C. Plan, collect, assess, follow-up, implement
    2. Which of the following best describes the JCPP’s reason for developing the PPCP?
    A. To establish a more efficient method of medical documentation
    B. To provide an opportunity for pharmacists to expand their clinical role
    C. To create a reproducible method of managing patient medications

    3. Which of the following examples is a common error pharmacy students make when using the PPCP?
    A. Avoiding discussion involving uncomfortable topics such as those sexual in nature
    B. Spending too long counseling the patient as opposed to documenting the SOAP note
    C. Omitting recommendations to follow up with the patient’s primary care provider
    4. Which of the following is a common source of error with the PPCP?
    A. Using a single clinical guideline for recommendations
    B. Spending the most time documenting the assessment section
    C. Cross-referencing medication lists against too many sources
    5. A nurse practitioner calls your clinic and would like you and your student to work up a patient with stage II hypertension. The patient is a 64-year-old African American male who is currently taking amlodipine 2.5 mg and chlorthalidone 6.25 mg. His blood pressure was 150/90 mmHg at his last doctors appointment. Which of the following would be an appropriate first step?
    A. Increase the dose of his medications. The SOAP note does not need to be performed as his blood pressure remains elevated due to subtherapeutic dosing.
    B. Ask the patient about his/her medication adherence recently. This information will dictate how you decide to approach the patient.
    C. Contact the patient’s local pharmacy for a complete list of active medications. This will be valuable information to collect prior to assessing the patient.
    6. A student working on a SOAP note cites a 2012 guideline from Europe. The preceptor notices the student forgets to consider a first-line treatment option that was approved in 2022. What should the preceptor do at this point?
    A. Call the physician to get his/her opinion on the newly approved medication
    B. Discuss the importance of citing multiple sources with the student
    C. When the student finishes the note, add in the missing information
    7. Laboratory values belong under which of the following sections of the PPCP?
    A. Assessment
    B. Objective information
    C. Subjective information
    8. Your student is counseling a patient who has dementia. When you ask him to practice how he would counsel the patient, he looks puzzled and asks “What for? He has dementia and he won’t understand anyway.” How do you proceed?
    A. Ask the student to find guidelines on how to determine when and how dementia patients should be counseled.
    B. Tell him it was a trick question and that he is correct that dementia patients should never be counseled.
    C. Explain pharmacists are legally required to offer counseling and he should be prepared if the patient requests it.
    9. A preceptor and student are working in an ambulatory care clinic. A patient presents to the counter and says she has been experiencing terrible adverse effects from one of her medications. The patient places a bottle of sertraline on the counter. She believes this is the medication causing her persistent insomnia. After talking with the doctor, she has switched to taking it in the morning, but she claims it does not help. How should the preceptor advise the student to continue?
    A. Advise the student to counsel the patient on ways to manage this adverse effect of sertraline. The student may consult the monograph or other recent guidelines.
    B. Remind the student that persistent insomnia is a flag to contact the provider. The psychiatrist can handle this as it isn’t in the scope of the preceptor’s practice.
    C. Advise the student to start by evaluating the patient’s past medical history and evaluating her medications before sending her back to see her doctor.
    10. A general practitioner refers a patient with mild asthma to your clinic. He has recommended the patient to start SMART therapy and would like you to supply your recommendations through a SOAP note. Under your supervision, the student finishes collecting the necessary objective and subjective information and has begun a draft of the assessment as follows:
    “The patient needs medication therapy for an untreated indication. According to the GINA guidelines, the patient should initiate a low dose inhaled corticosteroid plus a long-acting beta agonist combination in low doses as needed.”
    Which of the following best describes the feedback the preceptor should give the student when applying the PPCP model?
    A. The student has done a good job so far. However, the assessment should also consider patient concerns such as insurance coverage.
    B. The student has done a good job so far. The student should provide specific doses and monitoring parameters for completeness.
    C. The student has done a good job so far. The student should call the provider to check if they follow the GINA guidelines, and if not, why.

    References

    Full List of References

    References

       
      REFERENCES
      1. Joint Commission of Pharmacy Practitioners. Pharmacists’ Patient Care Process. Published May 29, 2014. Accessed June 21, 2023. https://jcpp.net/patient-care-process/
      2. Cooley J, Lee J. Implementing the Pharmacists' Patient Care Process at a Public Pharmacy School. Am J Pharm Educ. 2018;82(2):6301. doi:10.5688/ajpe6301
      3. Podder V, Lew V, Ghassemzadeh S. SOAP Notes. [Updated 2022 Aug 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 January. https://www.ncbi.nlm.nih.gov/books/NBK482263/
      4. Takemura Y, Sakurai Y, Yokoya S, et al. Open-ended questions: are they really beneficial for gathering medical information from patients?. Tohoku J Exp Med. 2005;206(2):151-154. doi:10.1620/tjem.206.151
      5. Taub S. Learning to Decide: Involving Children in their Health Care Decisions. Virtual Mentor. 2003;5(8): virtualmentor.2003.5.8. pfor3-0308. Published 2003 Aug 1. doi: 10.1001/virtualmentor.2003.5.8.pfor3-0308
      6. Elnicki DM. Learning with emotion: which emotions and learning what?. Acad Med. 2010;85(7):1111. doi:10.1097/ACM.0b013e3181e20205
      7. Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab. 2013;98(6):2198-2207. doi:10.1210/jc.2013-1024
      8. Bangalore Krishna K, Fuqua JS, Rogol AD, et al. Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium. Horm Res Paediatr. 2019;91(6):357-372. doi:10.1159/000501336
      9. Lexicomp. Wolters Kluwer Health, Inc. Updated June 20, 2023. Accessed June 21, 2023. https://online-lexi-com.ezproxy.lib.uconn.edu/lco/action/doc/retrieve/docid/pdh_f/129683?cesid=afdPrd0aazi&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dleuprolide%26t%3Dname%26acs%3Dfalse%26acq%3Dleuprolide#rfs
      10. Lexicomp. Wolters Kluwer Health, Inc. Updated June 6, 2023. Accessed June 21, 2023. https://online-lexi-com.ezproxy.lib.uconn.edu/lco/action/doc/retrieve/docid/pdh_f/128793?cesid=4Ds6TlNfgKm&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dhistrelin%26t%3Dname%26acs%3Dfalse%26acq%3Dhistrelin
      11. Supprelin LA (Histrelin) Subcutaneous Implant Procedure. Children’s Hospital of Philidelphia. Published May 4, 2021. Accessed June 21, 2023. https://www.chop.edu/treatments/supprelin-la-histrelin-subcutaneous-implant-procedure
      12. Kaplowitz P, Hoffman, R. Precocious Puberty Medication. Medscape. Updated January 24, 2022. Accessed June 21, 2023. https://emedicine.medscape.com/article/924002-medication
      13. Harris IM, Phillips B, Boyce E, et al. Clinical pharmacy should adopt a consistent process of direct patient care. Pharmacotherapy. 2014;34(8):e133-e148. doi:10.1002/phar.1459
      14. Silverman LA, Han X, Huang H, Near AM, Hu Y. Clinical characteristics and treatment patterns with histrelin acetate subcutaneous implants vs. leuprolide injections in children with precocious puberty: a real-world study using a US claims database. J Pediatr Endocrinol Metab. 2021;34(8):961-969. Published 2021 Jun 21. doi:10.1515/jpem-2020-0721

      Patient Safety: Fad Diets: Do They Deserve the Hype?

      Learning Objectives

       

      After completing this application-based continuing education activity, pharmacists will be able to

      1. Describe the prevalence of fad diets in society
      2. Outline the components of different types of fad diets
      3. Explain the effect different fad diets can have on the body
      4. Recognize situations in which fad diets present safety concerns for patients

        After completing this application-based continuing education activity, pharmacy technicians will be able to

        1. Describe the prevalence of fad diets in society
        2. Outline the components of different types of fad diets
        3. Explain the effect different fad diets can have on the body
        4. Recognize situations in which fad diets present safety concerns for patients

        Obese individual standing in front of words relating to food.

         

        Release Date: July 15, 2023

        Expiration Date: July 15, 2026

        Course Fee

        Pharmacists: $7

        Pharmacy Technicians: $4

        There is no grant funding for this CE activity

        ACPE UANs

        Pharmacist: 0009-0000-23-022-H05-P

        Pharmacy Technician: 0009-0000-23-022-H05-T

        Session Codes

        Pharmacist:  23YC22-XPK68

        Pharmacy Technician:  23YC22-KPX83

        Accreditation Hours

        2.0 hours of CE

        Accreditation Statements

        The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-022-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

         

        Disclosure of Discussions of Off-label and Investigational Drug Use

        The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

        Faculty

        Abigail R. Johnson, BS
        Senior US FDA Regulatory Affairs/Medical Writing Intern
        Arciel LLC, Stratford, CT

                   

        Faculty Disclosure

        In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

        Ms. Johnson has no financial relationships with ineligibile companies.

         

        ABSTRACT

        In the United States, being overweight or having obesity are two leading causes of health issues, and these rates have increased in recent years. Enter the concept of fad diets. People often turn to diets or tools advertised as promoting quick weight loss without considering the diet’s sustainability and their bodies’ reaction. Fad diets’ one-size-fits-all approach is usually not the cure-all solution people hope it will be. Overall healthy nutrition and lifestyle choices are more beneficial. Due to fad diets’ popularity, it is essential to understand their components and their affect within the body to reduce health risks. This continuing education activity discusses intermittent fasting, ketogenic (“keto”) diets, pay-for-food systems, paleolithic (“paleo”) diets, and the Atkins diet. It identifies patients for whom fad dieting can be dangerous.

        CONTENT

        Content

        INTRODUCTION

        Fad diets have always existed but have been on the rise in recent years due to the explosion of social media in the 21st Century. A fad diet is a popular diet followed to achieve fast results or fix long-term problems associated with eating, specifically weight.1 Fad diets are labeled as fads for a reason. These short-lived trends with wide popularity disregard for the rationale behind or quality of the approach itself.3,4

        People who choose fad diets are often trying to fix ongoing problems including overweight or obesity, inadequate nutrition, sedentary behaviors, and failure to maintain overall healthy habits.2 Individuals who follow fad diets adhere to a mainstream concept of dieting without acknowledging individual health needs and restrictions. Health consequences may arise as a result of adhering to a diet ill-suited to an individual's nutritional needs and ability to sustain the associated effort. In addition, certain diets may influence medication interactions and disease outcomes. For this reason, fad diets can undermine patient safety.

         

        This continuing education activity summarizes popular fad diets to inform pharmacy teams of their benefits and risks. It will allow teams to make recommendations for patients, understand how medications interact with the diets, and help prevent health complications.

         

        The History of Fad Diets

        Fad diets have existed throughout history in different forms. For example, in the 1920s, the Cigarette Diet was popular. Lucky Strike, a cigarette company, promoted the cigarette diet. They claimed that cigarettes would suppress appetite to boost sales using the tagline “Reach for a Lucky instead of a sweet.” Promoters advertised that people would lose weight successfully while following the diet.6 The 1940s saw the rise of the Master Cleanse. This juice cleanse consisted of a meal replacement drink consisting of hot water, lemon juice, maple syrup, and cayenne pepper. Its popularity stemmed from promises of cleansing the body of toxins while providing very few calories. It reached new levels of popularity in 2006, when superstar Beyoncé claimed to lose 20 pounds in two weeks using this method 6 In the 1960s, The Drinking Man’s Diet made an appearance. The recommendation was to consume high-protein and low-carbohydrate foods while drinking as much alcohol as desired. An example meal may have included a large serving of steak, salad or vegetables, and several alcoholic beverages. The Drinking Man’s Diet’s supporters considered alcohol a good carbohydrate and allowed indulgence. This diet was marketed toward the male population.6

         

        People have always been interested in quick fixes for weight loss and appearance without considering how they will feel or how to keep the weight off indefinitely.1 This approach to choosing a diet or making nutrition decisions ignores tactics that sustain weight loss. Fad diets are inherently unsustainable options that often lead to weight regain. These outcomes prove many fad diets are unreliable (if not dangerous).

         

        With the creation and explosion of modern social media in the early 2000s, fad diets surged in popularity. Social media often fosters a community of misinformation regarding fad diet composition, how to follow the specific diet, and the diet’s benefits.5 Much of the information on social media regarding fad diets lacks reputable, verifiable sources. Fad diet promoters use scientific jargon loosely and inappropriately to make information convincing when describing seemingly miraculous diets. However, the information could just be the opinion of an individual or a promotional company sponsorship.5 Unless diet information is published by a credible source, it should be regarded as untrustworthy.

         

        Pause and Ponder: How many times a week do you see diet-related content on social media?

         

        Fad Diet Prevalence

        Approximately 45 million Americans (about 14% of the total population) go on a diet each year.7 Of these diets, 50% are fad diets.7 According to the United States (U.S.) Weight Loss & Diet Control Market, the weight loss industry is one of the most advertised with investors spending $66 billion annually.7 More people than ever are overweight or obese and using diets as a solution. Table 1 summarizes obesity’s prevalence, which is rising each year in the U.S.

         

        Table 1. Obesity Prevalence in the U.S. Population8

        Age (years) % of Population
        Adults aged 20 and up 41.9%
        Adolescents aged 12-19 22.9%
        Children aged 6-11 20.7%
        Children aged 2-5 12.7%

         

        According to the Centers for Disease Control and Prevention (CDC), individuals who are overweight or have obesity are at elevated risk for many health issues. These include elevated cholesterol, stroke, heart disease, hypertension, cancer, type 2 diabetes, mental illness, low quality of life, and mortality, among others.9 While many factors can influence weight, individuals can adapt their diets to meet nutritional needs and make long-term differences to improve health outcomes.

         

        TYPES OF FAD DIETS

        As the definition implies, fad diets’ popularity increases and decreases with current trends. This section discusses some of the most popular current fad diets.

         

        Intermittent Fasting

        Individuals following an intermittent fasting diet alternate eating and fasting (not eating or drinking anything) on a cyclic schedule. This diet focuses more on eating during specific periods of time than restricting meal components. Various intermittent fasting schedules exist, but popular versions include alternate-day and time-restricted fasting.10,11 Alternate-day fasting means fasting every other day, while time-restricted fasting involves eating within set time windows during the day. Individuals should consult a doctor and choose the type of intermittent fasting that best fits their health needs (but most do not). Studies show following intermittent fasting schedules leads to decreased body weight, body mass index (BMI), and waist circumference.11 Studies also show improved blood glucose and triglyceride levels following this diet.10

         

        The body uses ingested calories—specifically carbohydrates, sugars, and nutrients—as fuel.10 If people eat continuously throughout the day, the body uses ingested calories as fuel to perform necessary bodily functions. The body stores unused ingested calories in the form of fat where they become an energy reserve.10,12

         

        When the period between meals lengthens and the body lacks a constant supply of calories for fuel, it turns to the fat reserve to burn fat stored in the body. The theory is that the longer a person goes without eating, the more the body will use its fuel reserve. The more reserve is used, the more fat is burned.10 As more of the reserve is used for energy while intermittent fasting, more weight is lost through fat burn.

         

        Intermittent fasting regulates eating times without restricting foods or food groups. Dieters must make conscious choices to include foods beneficial to health. This includes fruits, vegetables, plant proteins or lean meats, whole grains, superfoods (see Sidebar: Superfoods), and low-fat dairy options.12 Healthy choices also include limiting processed foods and sugars.

         

        Sidebar: Superfoods13

        Superfoods are nutrient-rich and high in important dietary components including antioxidants, vitamins, minerals, fiber, and healthy fats. These help keep the body functioning, reduce disease risk, and improve well-being. Some examples of superfoods are

        • Avocados → These include potassium and healthy fats to lower the risk of heart disease.
        • Chia seeds → These include fiber, protein, antioxidants, vitamins, and minerals. They are also easy to add to recipes.
        • Dark and leafy greens → All greens are good greens, but these are especially nutrient dense, including vitamins A, C, and E. They also contain vitamin K, which promotes bone health.
        • Ginger → This includes vitamin C, magnesium, and potassium. It also helps reduce pain and aid nausea.
        • Salmon → Fish is high in omega-3 fatty acids, which can help reduce heart disease.
        • Yogurt → This includes calcium and protein to help with bone health, cancer prevention, and immune health. It is also a good source of probiotics to support gut health.

         

        Pause and Ponder: Do patients ask about superfoods when discussing dietary information or supplements? Do you know which to recommend?

         

        Pros and Cons

        Like most diets, intermittent fasting has benefits and drawbacks. Following intermittent fasting correctly boosts memory, improves blood pressure, induces fat loss while maintaining muscle mass, helps prevent obesity, improves type 2 diabetes by reducing insulin resistance, and improves tissue health.12,14 Intermittent fasting also regulates the body’s 24-hour cycle to improve physiological functioning and metabolic health. As a result, gastrointestinal (GI) microbiomes, energy levels, and sleep may improve.15

         

        Drawbacks of this diet include issues with long-term maintenance/adherence, leading to regaining weight.10 It is difficult and tiring for individuals to maintain fasting for extended periods. In addition, until the body is accustomed to fasting periods, symptoms such as headaches, nausea, or dizziness may occur. Some individuals may feel an initial decrease in energy levels when starting this diet.10

         

        Keto Diet

        The keto diet, also known as the ketogenic diet, is centered around depriving the body of carbohydrates.16 Researchers originally developed the ketogenic or keto diet in the 1920s as an epilepsy treatment, especially for resistant pediatric cases.17 The rise of effective antiepileptic drugs and treatments decreased use of the ketogenic diet for this purpose. As originally designed, total daily calories were composed of high fat intake (70% to 80%), moderate amounts of protein (10% to 20%), and low carbohydrate intake (5% to 10%).16 An iteration of this diet has gained more traction since the 1990s, as people realized its effectiveness for quick weight loss.16

         

        The keto diet helps with weight loss through the processes of gluconeogenesis and ketogenesis. Under normal circumstances, carbohydrates produce energy for the body.16 When insufficient carbohydrates are available, insulin secretion is reduced and glucose is less available. The body then exploits gluconeogenesis, using lactic acid, glycerol, and amino acids to produce glucose as an energy source.16

         

        If carbohydrate levels drop further, the body enters ketogenesis and secretes ketone bodies as an alternative energy source.16 As insulin secretion levels remain low and ketone bodies are used for energy, fat and glucose storage falls significantly. This can cause other fats to break down, leading to bodily fat loss.16

         

        To remain in ketogenesis, the body needs constant carbohydrate deprivation.16 The longer it is deprived of carbohydrates, the more fat is burned in the ketotic state. This is known as nutritional ketosis and is considered safe, as opposed to the metabolic state of ketoacidosis (an accumulation of ketones that increases the blood’s acidity), which can be life-threatening.16

         

        During ketoacidosis, ketone bodies are produced in large amounts and can acidify the blood pH.16 Acidic blood pH reduces the amount of oxygen blood delivers to cells leading to cell death and life-threatening complications. Insulin keeps the production of ketone bodies at bay, so sometimes people with type 1 diabetes develop ketoacidosis due to decreased insulin production. Taking diabetes-related medication correctly reduces the risk of ketoacidosis in people with diabetes. Following a low carbohydrate diet for a prolonged amount of time can also lead to ketoacidosis.17 To reiterate, ketogenesis is the production of ketone bodies in response to carbohydrate and glucose depletion. Low concentrations of ketone bodies are generally regarded as a safe, as opposed to high concentrations caused by ketoacidosis (which is a medical emergency).16

         

        What to Eat and Avoid

        Given the strong emphasis on high-fat foods, healthy fats comprise the largest part of this diet.16 Foods such as seeds and nuts, coconut, avocados, poultry fat, and plant fats (e.g., olive or coconut oils) are encouraged. In addition, some dairy products—including butter, hard cheese, and yogurt—are allowed, but people on a ketogenic diet should avoid cream, ice cream, and full-fat milk given their natural sugar content.17 Individuals following this diet should consume a moderate amount of protein, ideally meats high in omega-3 fats.16 This includes grass-fed beef, free-range poultry, wild-caught fish, and pork. Nuts, seeds, tofu, and eggs are also acceptable protein sources.17

         

        Adhering to a diet with less than 10% of calories from carbohydrates can be challenging, especially since this diet requires individuals to calculate “net carbs” (See Sidebar: What are “Net Carbs”?).16 Vegetables lacking high starch contents (e.g., cauliflower, broccoli, onions, leafy greens, bell peppers, garlic, mushrooms, cucumber, summer squash) are encouraged. Small portions of fruit are also allowed, and fruits with a lower net carb content (e.g., berries) are preferred. Other acceptable carbohydrates include dark chocolate, herbs, spices, unsweetened tea, coffee, vinegars, and mustards.17

         

         

        Sidebar: What are “Net Carbs”? 17

        The body cannot digest or metabolize some carbohydrates because of their molecular structures. For example, fruits, vegetables, whole grains, and sugar alcohols contain insoluble fibers that are indigestible. Insoluble carbs have no energy value or blood sugar impact, so they are allowed when following the keto diet. The keto diet requires dieters to calculate “net carbs,” the amount of carbohydrates taken in by the body that are digested and metabolized and thus contribute to calories. However, it is important to note that the total calorie level does not change even when “net carbs” are calculated.

         

        Individuals calculate net carbs by subtracting the number of ingestible carbohydrates from the food’s total amount of carbohydrates. For example, food containing 24 total carbohydrates and 21 ingestible carbohydrates equals 3 net carbs. Ingestible carbohydrates can typically be found by subtracting the amount of fiber from the amount of carbohydrates in the food item, but it can be more complicated. A number on online net carb calculators are available to help.

         

        Net carbs are also known as “impact carbs.” Food manufacturers use both terms as marketing strategies, but governing bodies do not regulate use of these phrases.

         

        Foods containing added sugar, whole or refined grains, and flour products are restricted.17 Starchy foods are also not allowed, including some high-starch vegetables such as corn, potatoes, and winter squash. Fruits with a high net carb content and fruit juices are restricted. Most keto programs also advise against alcoholic beverages due to their carbohydrate content and added sweeteners.17

         

        Pros and Cons

        The keto diet may be beneficial for weight loss, as it uses ketone bodies for energy to deplete glucose and fat storage abilities. Decreasing sugar intake lowers the risk of developing diabetes, obesity, and metabolic syndrome.16 Following this diet may reduce cholesterol, blood sugar, and blood pressure, and decrease insulin resistance.17

         

        Diet restrictions may cause short-term adverse effects such as nausea and vomiting, fatigue, headaches, dizziness, and insomnia.16 This is known as the “keto flu.” Symptoms usually resolve once the body adjusts to the diet after a few weeks. Fluids and electrolyte replenishment can help alleviate discomfort during this period.16

         

        Documented long-term adverse effects include increased uric acid levels in the blood, increased risk of kidney stones, and osteoporosis.17 This is due to the diet’s restrictive nature and omission of necessary components to sustain a healthy diet. Nutrient deficiencies can occur as a result of following this diet.17

         

        People struggle to adhere to the ketogenic diet due to strict regulation of fat, protein, and carbohydrates.17 Dieters must carefully monitor their adherence to intake limits and meet target levels. This can be difficult for individuals to maintain long-term and lead to low adherence to the diet.17

         

        Pay-for-Food Systems

        Pay-for-food diets are meal prep services or meal delivery services with pre-portioned ingredients, pre-cooked meals, or meal replacement options. Diets focus on weight loss and are designed for convenience. These options take the guesswork out of planning meals and make it easier to track eating.

         

        Nutrisystem

        The Nutrisystem meal service claims its diets help with weight loss through a high-protein and low glycemic approach.18 Nutrisystem expects users to lose one to two pounds a week by managing blood sugar and controlling hunger to avoid overindulgence. Dietitians design meals to include healthy options and relieve the stress of planning.18

         

        Meals are pre-portioned to fit an individual’s needs and tastes.18 The meals’ composition of lean protein, healthy fat, and smart carbohydrate ingredients is supposed to curb hunger. Protein shakes and bars are options to supplement plans. Nutrisystem claims deprivation is too restrictive and allows for some deviation from the plan or healthy alternatives to “bad foods.” In addition, dieters can track their progress and calories using Nutrisystem’s app. This system promotes prizes and special offers to keep individuals motivated.18

         

        Prices vary by plan type but can range from $9.99 to $15.18 a day. Nutrisystem has plans designed specifically for men, women, partners, and people with diabetes.18

         

        SlimFast

        When SlimFast originated, the system promoted meal replacement shakes to lose weight.19 The company has since expanded to include drink mixes, snacks, and meal replacement bars. The products are grouped into categories such as calorie control, high protein, keto, and intermittent fasting. The website also contains a recipe section for dieters to use in their meal planning.19

         

        SlimFast plans are based on individuals’ goals and preferences, including the Favorite Foods Plan, Keto Plan, High Protein/Low Carb Plan, Original Plan, and Intermittent Fasting.19 Dieters purchase SlimFast products to supplement or replace parts of their current diet. Plans themselves are not priced because individuals buy their own groceries and supplement with SlimFast products associated with the plan of their choice. The company also has an app to use for weight management tracking and a private Facebook group to communicate with other individuals on the diet to offer support or guidance.19 SlimFast claims their plans and products promote and maintain weight loss and encourage people to make better food choices.19

         

        Jenny Craig

        The Jenny Craig company has recently gone out of business after 40 years in the industry. Some experts indicates that one reason has been the availability of weight loss medications and increased competition in this market space. This system emphasized one-on-one coaching mixed with healthy foods to lose weight quickly.20 The company claimed dieters could lose up to 18 pounds in the first four weeks. Coaches designed meal plans to be unrestrictive and included an individual’s favorite foods. Meals focused on low-fat foods with high fiber and protein. This program also emphasized physical activity and occasional intermittent fasting to aid the weight loss process.20

         

        Plans consisted of meals from the program, two snacks, and supplemental grocery items daily to promote weight loss and increase metabolism.20 One snack included Jenny Craig’s Recharge Bar, used when intermittent fasting. The program claimed the Recharge Bar helped dieters lose weight faster, feel less hungry, and maintain fasting. Jenny Craig coaches designed plans and provided guidance for the duration of the program.20

         

        Food was delivered weekly or biweekly. Depending on the type of plan, individuals paid $13.99 to $21.99 per day. Prices were based on the number of meals, membership length, and amount of coaching support included. Promotional offers and meal bundles were available.20

         

        Pros and Cons

        Pay-for-food diets can be intriguing as they promote healthy choices, weight loss, and convenience.18-20  They reduce mental load and stress surrounding dieting by making the choices easier or eliminating the need to choose altogether. Some services also provide support groups or coaches for accountability and guidance. In addition, if dieters can adhere to these plans, meal kits promote portion control and reduce overeating.18-20

         

        A major con associated with these diets and meal kits is adherence. As people lose weight on these diets, they may stop using them, gain weight back, and become discouraged about trying again. This can reverse improved health outcomes.18-20 Another con is cost. Individuals may be discouraged by the prices associated with pay-for-food systems. The cost may not be viable or sustainable options for all individuals.18-20  

         

        Studies have shown these diets to be ineffective. Attrition rates (percentages of people leaving a program) are 30% or greater, and 37% of dieters who complete programs lose less than 5% of their initial body weight.21 Other studies failed to produce significant results for how these pay-for-food diets affect weight loss when compared to educating or counseling individuals on weight.22 High attrition rates and insignificant weight loss results suggest these diets are unsustainable and unreliable.21

         

        Paleo Diet

        The paleo diet goes by many names, including the Paleolithic, caveman, or Stone-Age diet. It consists of (allegedly) eating like humans of the Paleolithic era did, mixed with modern components to supplement the diet. The Paleolithic era occurred from roughly 2.5 million years ago to 1,200 B.C. Diet supporters believe current body function is similar to how it functioned during this era and eating foods available or comparable to this time will improve health.23 Introduced in 2002 by Dr. Loren Cordain, a scientist specializing in nutrition, this diet has surged in popularity in recent years due to weight loss claims.24

         

        Due to disagreements about which foods were available in the Paleolithic era compared with today, many diet plans are dubbed “paleo.” They differ in specific foods allowed. All plans emphasize high protein, healthy fats, low or moderate carbohydrates, low sugar and sodium, and high fiber to meet weight loss goals.23 The term “paleo” will be used to describe this model. The paleo diet consists of consuming mostly lean meats, fruits, vegetables, nuts, seeds, and fish, in line with what researchers believe was consumed during the Paleolithic age.23 It also emphasizes reducing intake of dairy, grains, and carbohydrates.25

         

        Weight loss can occur through several pathways using the paleo diet. 23 Like the keto diet, ingesting fewer carbohydrates forces the body to use fat for fuel. In addition, replacing highly processed foods, added sugars, and large amounts of carbohydrates with healthier options can aid weight loss. Eating more protein and less calorically dense food (i.e., few calories in a large volume of food) also helps curb hunger and leave individuals more satisfied.23

         

        Less calorically dense foods—including vegetables, fruits, low-fat or fat-free dairy, and egg whites—can be eaten in larger quantities. These foods help with weight loss as they allow individuals to eat a larger volume and feel full, without ingesting large numbers of calories.26 This reduces snacking and overall food intake.23

         

        Conversely, calorically dense foods are high in calories and eaten in small amounts. These contribute weight gain as individuals who eat a small volume consume high numbers of calories.27 Examples of calorically dense foods include27

        • Proteins: fish, beans, eggs, cheese, yogurt, fats including nuts, avocados, nut butters
        • Carbohydrates: potatoes, brown rice, whole grains

         

        Overall, the paleo diet works by breaking down the diet into basic components and making healthier choices. Cutting out foods leading to high glucose or carbohydrate storage also aids in eating healthier and inducing weight loss.28

         

        What to Eat and Avoid

        Allowed foods emphasize fresh and healthy choices to remain consistent with foods found in the Paleolithic age.23 This includes lean meats, fish or shellfish, fruit, vegetables, honey, nuts or seeds, and olive or coconut oils. Frozen fruits and vegetables are allowed as they contain the same nutrients as the fresh variety and may be more convenient. Omega-3 fats are important for the body and can be found in fish, grass-fed beef, avocado, olive oil, some nuts (e.g., walnuts, almonds, pistachios), and seeds. Root vegetables such as cassava and sweet potatoes are highly nutritious and are allowed in moderation.23

         

        Restricted foods have little nutritional value or a high glycemic index unsuitable for the paleo diet.23 For example, white potatoes and processed foods are off limits. Other restricted foods include whole or refined grains, cereals, refined sugar, refined vegetable oil, legumes, dairy products, alcohol, coffee, and salt. Canola is a refined vegetable oil and is not allowed. Restricted legumes include peanuts, beans, and lentils.23

         

        This diet emphasizes eating healthy and portioning fats, proteins, and carbohydrates to enhance health.23 Calorie counting and general portion control are deemphasized in this diet. Some plans also allow for “cheat meals” (those consisting of food not beneficial to health) in the early stages of the diet to increase adherence.23

         

        Pros and Cons

        Components of this diet including fiber, potassium, and antioxidants aid bodily functions and reduce disease risk. Reducing the intake of highly processed foods with little nutritional value also helps improve overall health.25 Short-term benefits may include weight loss, improved blood pressure and cholesterol levels, and increased insulin sensitivity.23 One study documented improvements in metabolic levels, specifically glucose control and lipids, in people with diabetes.28

         

        Unfortunately, restricting or excluding foods altogether for long periods of time can lead to nutritional deficiencies and health complications. For example, limiting dairy intake leads to deficiencies of calcium, vitamin D, and B vitamins.23 These deficiencies can increase risk of osteoporosis and bone injuries.24 Dairy-related nutrient deficiencies are not specific to the paleo diet, but can occur due to its food restrictions. Restricting grains in the diet also deprives the body of nutrients, which increases risks of diabetes and heart disease. In addition, increased meat consumption (especially red meat) contributes to saturated fat intake and increases risks of cardiovascular problems and diabetes.23 It may also be difficult for people to adhere to a diet that restricts certain categories of foods.

         

        Atkins Diet

        The Atkins diet promotes low carbohydrate intake while allowing as much protein and fat as desired. Robert C. Atkins, a heart specialist, developed this diet in the 1960s as a method for weight loss and maintenance.30 Although it is a low-carb diet, the Atkins program acknowledges that eating right is always better than eating less.31 This diet is ever evolving to be current with updated nutritional expertise.30

         

        Like the keto diet, Atkins emphasizes low carbohydrate intake of less than 20 g per day to start.30 Unlike the keto diet, consumption of fat and protein is less restricted. Carbohydrates are claimed as the problem without regulating the intake of other food groups. Diet supporters believe the sugars found in carbohydrates cause health issues such as blood sugar imbalances and weight gain.30

         

        Hypothetically, eating fewer carbohydrates lowers dietary sugar leading to greater satiety, increased energy, less stored fat, and higher metabolism.31 When the body lacks glucose and carbohydrates to use as energy, it turns to fat to keep the body functioning through ketogenesis. The more fat a person burns, the more weight they lose.

         

        Fat and protein comprise the remainder of the diet. As carbohydrates are viewed as the source of health issues, intake levels of fat and protein are less restricted. Calorie counting and portion control are unnecessary, besides keeping track of carbohydrate intake to stay below the allowable limit.30

         

        The Atkins diet is split into phases with specific allowable limits of carbohydrates (see Table 2). The diet’s phases adjust to reflect changes in body function and weight. As carbohydrate levels fluctuate in each phase, protein and fat levels change to achieve satiety.

         

         

        Table 2. Atkins Diet Phases31

        Phase Instructions
        Phase 1:

        Induction

        3 regular sized meals or 4-5 small meals, vitamins/supplements, 8 oz. glasses of water, 20 g net carbs per day
        Phase 2:

        Ongoing weight loss

        Can add net carbs in 5 g increments weekly, vitamins/supplements, 8 oz. glasses of water, no more than 40 g a day after adding extra carbs, introduce Atkins food products
        Phase 3:

        Pre-Maintenance

        Maintaining previous stages, can add net carbs in 10 g increments weekly to find the perfect balance until the goal weight is reached, maintain carb intake of goal weight
        Phase 4:

        Maintenance

        Maintaining Phase 3 carb level, reducing fat intake as carb intake increases, managing cravings and weight

         

         

        While phases differ in carbohydrate intake levels, they include similar food groups overall.30 Allowed foods include vegetables, oils, fats, and protein (e.g., eggs, cheese, fish, meat and poultry). Dieters can introduce berries, nuts, seeds, starchy vegetables, and whole grains in the third phase, provided they are still losing weight. Dieters can also eat Atkins’ commercial selection of products during and after phase two. Most fruits, alcohol, baked goods high in sugar, bread, pasta, and nuts are restricted in phase one. Some fruits and grains are added by phase three.30

         

        Pros and Cons

        Benefits of the Atkins diet include weight loss; decreased blood pressure; and lower incidence of heart disease, metabolic syndrome, and diabetes.30 This diet can also improve blood sugar and cholesterol levels. These benefits are attributed to low carbohydrate intake and subsequent weight loss.30

         

        Reducing carbohydrate intake may initially cause symptoms such as headache, weakness, fatigue, and dizziness.30 Unrestricted fat intake can be unhealthy. In addition, using fat as the body’s energy source for too long may lead to ketoacidosis if dieters misuse the plan.29 Nutrient deficiency can also occur on this diet as a result of restrictions.30

         

        Weight loss pursuant to this diet is difficult to maintain due to its deficiencies and restrictive nature. Following the carbohydrate limit for long periods of time is difficult and unsustainable for some people.30 Cardiologists warn this diet puts oxidative stress (disproportionate levels of oxygen reactive species overwhelming the ability of body systems to detoxify them) on organs and can cause serious heart problems or fatal complications.29 Some long-term studies have shown the Atkins diet is no more effective than other fad diets. In addition, these studies show that most people who lost weight while following the Atkins diet regained it.30

         

        IMPLICATIONS FOR PHARMACY TEAM

        Fad dieting can compromise patient safety, and certain patients are at elevated risk for problems. Pharmacy teams are responsible for advising patients about drug-diet interactions and concerns. Table 3 describes conditions and their associated medications that impact the use of fad diets.

         

        Table 3. Implications for Pharmacy Teams10,16,23,30,32-40

        Diet Patient Conditions and Associated Medications That Can Be Contraindications with Diets
        Intermittent Fasting ·       Age younger than 18 years

        ·       Pregnancy or breastfeeding

        ·       Type 1 diabetes

        o   Insulin, blood pressure medication, cholesterol-lowering medication

        ·       History of eating disorder

        Keto ·       Diabetes

        o   Insulin, blood pressure medication, cholesterol-lowering medication

        ·       Hypoglycemia

        o   Glucagon or other forms of glucose

        ·       Pancreatitis

        o   Pain medication

        ·       Liver failure

        ·       Fat metabolism disorders

        o   Cholesterol-lowering medication

        ·       Primary carnitine deficiency

        o   L-carnitine supplements

        ·       Carnitine palmitoyltransferase deficiency

        ·       Carnitine translocase deficiency

        ·       Porphyrias

        o   Hemin

        ·       Pyruvate kinase deficiency

        o   Mitapivat (Pyrukynd), folic acid supplements, iron chelators

        Pay-For-Food Systems ·       Contraindications and associated medication will depend if it is an individually designed plan or the service’s version of intermittent fasting, keto, etc.
        Paleo ·       Cardiovascular related issues

        o   Anticoagulants, ACE inhibitors, cholesterol-lowering medications, diuretics, etc.

        ·       Diabetes

        o   Insulin, blood pressure medication, cholesterol-lowering medication

        ·       Nutrient deficiency disorders

        Atkins ·       Diabetes

        o   Insulin, blood pressure medication, cholesterol-lowering medication

        ·       Taking diuretics

        o   Thiazide, loop, potassium-sparing diuretics or a mix of types

        ·       Severe kidney disease

        o   Blood pressure medication, anemia medication, cholesterol-lowering medication, supplements

        ·       Pregnancy or breastfeeding

         

        Nutritional Myths

        As mentioned, misinformation surrounding diets has always existed, and social media has magnified the problem. Some myths are more harmful than others, but knowing the facts is essential to correctly informing others.32 Examples of nutritional myths that pharmacy teams can debunk for their patients are found in Figure 1.

         

         

        Dieting is not a one-size-fits-all solution. When pharmacy teams advise patients, they must work with patients to consider health factors . Factors to consider include a patient’s medications, lifestyle choices, and known health issues.33 Pharmacy teams should advise individuals that fad diets are not necessary and following a generally healthy diet is usually sufficient to lose weight. They should make healthy swaps and find strategies that work best for them as individuals. For example, they can cut back on processed foods, consume more fruits and vegetables, and be conscious of fat or carbohydrate intake to ensure healthy sources. These choices are effective ways to achieve the long-term goals without employing fad diets that promote quick fixes.33

         

        CONCLUSION

        Fad diets are undeserving of the positive hype they receive. They are short-term solutions that sometimes work for people looking to lose weight or make changes quickly. However, benefits are outweighed by their unsustainability and poor post-diet maintenance planning. Fad dieting also starts a cycle of yoyo dieting (see Sidebar: Yoyo Dieting). The best option for health is to find strategies that work individually and stick with them. Ditch the fad diets and make long-term healthy choices for better, lasting results.33

         

        Sidebar: Yoyo Dieting

        Yoyo dieting, or weight cycling, occurs when people achieve their goal weight through dieting, stop dieting and return to unhealthy habits, gain the weight back, diet again for a period, gain the weight back, and repeat the cycle. Yoyo dieting is not only a conscious choice. Physiological mechanisms related to energy intake and expenditure, genetics affecting weight control processes, and the interaction between genes and the environment also affect the cycle.34

         

        Yoyo dieting lacks substantial or sustainable changes to lifestyle or nutrition to keep weight off and instead focuses on quick fixes.34 These quick fixes ultimately fail when weight is regained, and the cycle continues. Most weight lost is gained back within the first two to three years after dieting ceases. However, if dieters keep weight off for two years, the likelihood of gaining it back decreases.35

         

        Pause and Ponder: Do you think fad diets are helpful or harmful?

        Resources for Pharmacists and Pharmacy Technicians

         

        Pharmacist Post Test (for viewing only)

        Fad Diets: Do They Deserve the Hype?

        Pharmacist Post-test

        After completing this continuing education activity, pharmacists will be able to

        ● Describe the prevalence of fad diets in society
        ● Outline the components of different types of fad diets
        ● Explain the effect different fad diets can have on the body
        ● Recognize the value of the pharmacist/pharmacist technician’s role in understanding this information

        1. Of the 45 million Americans who go on a diet each year, what percentage are fad diets?
        A. 66%
        B. 50%
        C. 14%

        2. What makes fad diets appealing to millions of dieters?
        A. They are a good way to stop the cycle of yoyo dieting
        B. They are considered safe for individuals with health complications
        C. They promote quick weight loss results

        3. Which of the following fad diets mainly focus on low carbohydrate intake?
        A. Keto and Atkins
        B. Keto and intermittent fasting
        C. SlimFast and Atkins

        4. Which types of fad diets claim to improve blood pressure?
        A. Intermittent fasting, pay-for-food diets, and Atkins
        B. Intermittent fasting, keto, paleo, and Atkins
        C. Paleo and Atkins

        5. What causes ketoacidosis?
        A. Prolonged extreme carbohydrate restriction***
        B. Prolonged extremely high carbohydrate intake
        C. Low-level ketone body production

        6. Why should individuals taking cardiovascular-related medications such as ACE inhibitors or cholesterol-lowering drugs avoid the Paleo diet?
        A. Nutrient deficiencies caused by the composition of the diet lead to increased risk of cardiovascular issues.
        B. Reduced grain intake and high meat or fat consumption leads to increased risk of cardiovascular issues.
        C. These medications cause sensitivity to foods included in the Paleo diet.

        7. A patient with type 1 diabetes mentions that she plans to start following the keto diet because she knows that carbohydrates spike her blood sugar. Which of the following is the BEST response?
        A. It is the best way for people with diabetes to lose weight quickly and keep it off long-term
        B. It will be difficult for you to follow long-term, so the Atkins diet is more appropriate
        C. It is not a safe option for you because you are at increased risk of ketoacidosis

        8. Why is it important for pharmacy teams to understand contraindications and health implications of fad diets?
        A. To identify signs of diabetes based on how the body reacts to certain fad diets
        B. To advise patients about drug-diet interactions and how fad diets can impact their health
        C. To direct patients to an appropriate fad diet based on their current medications

        9. What general nutrition information should people follow instead of fad diets?
        A. Cut all dairy, gluten, and fat from the diet and eat only protein and carbohydrates
        B. Decrease fats and carbohydrates in the diet and increase red meat intake
        C. Limit processed foods and make overall healthy choices like eating more superfoods

        10. A patient comes to the pharmacy to pick up medication and you advise him to avoid diets involving fasting and calorie restrictions. His condition and associated medication indicate fasting and restricting calories would be harmful to his health. Which fad diets does this warning pertain to?
        A. Intermittent Fasting, Keto, Atkins
        B. Keto, Paleo, Atkins,
        C. Intermittent Fasting, Paleo, Atkins

        Pharmacy Technician Post Test (for viewing only)

        Fad Diets: Do They Deserve the Hype?

        Pharmacy Technician Post-test

        After completing this continuing education activity, pharmacy technicians will be able to

        ● Describe the prevalence of fad diets in society
        ● Outline the components of different types of fad diets
        ● Explain the effect different fad diets can have on the body
        ● Recognize the value of the pharmacist/pharmacist technician’s role in understanding this information

        1. Of the 45 million Americans who go on a diet each year, what percentage are fad diets?
        A. 66%
        B. 50%
        C. 14%

        2. What makes fad diets appealing to millions of dieters?
        A. They are a good way to stop the cycle of yoyo dieting
        B. They are considered safe for individuals with health complications
        C. They promote quick weight loss results

        3. Which of the following fad diets mainly focus on low carbohydrate intake?
        A. Keto and Atkins
        B. Keto and intermittent fasting
        C. SlimFast and Atkins

        4. Which types of fad diets claim to improve blood pressure?
        A. Intermittent fasting, pay-for-food diets, and Atkins
        B. Intermittent fasting, keto, paleo, and Atkins
        C. Paleo and Atkins

        5. What causes ketoacidosis?
        A. Prolonged extreme carbohydrate restriction
        B. Prolonged extremely high carbohydrate intake
        C. Low-level ketone body production

        6. Why should individuals taking cardiovascular-related medications such as ACE inhibitors or cholesterol-lowering drugs not follow the Paleo diet?
        A. Nutrient deficiencies caused by the composition of the diet lead to increased risk of cardiovascular issues.
        B. Reduced grain intake and high meat or fat consumption leads to increased risk of cardiovascular issues.
        C. These medications cause sensitivity to foods included in the Paleo diet.

        7. A patient with type 1 diabetes mentions that she plans to start following the keto diet because she knows that carbohydrates spike her blood sugar. Which of the following is the BEST response?
        A. It is the best way for people with diabetes to lose weight quickly and keep it off long-term
        B. It will be difficult for you to follow long-term, so the Atkins diet is more appropriate
        C. It is not a safe option for you because you are at increased risk of ketoacidosis

        8. Why is it important for pharmacy teams to understand contraindications and health implications of fad diets?
        A. To identify signs of diabetes based on how the body reacts to certain fad diets
        B. To advise patients about drug-diet interactions and how fad diets can impact their health
        C. To direct patients to an appropriate fad diet based on their current medications

        9. What general nutrition information should people follow instead of fad diets?
        A. Cut all dairy, gluten, and fat from the diet and eat only protein and carbohydrates
        B. Decrease fats and carbohydrates in the diet and increase red meat intake
        C. Limit processed foods and make overall healthy choices like eating more superfoods

        10. You are checking out a customer at the pharmacy counter and notice she is picking up some over-the-counter items along with her prescriptions. Which of the following groups of items would prompt you to refer an individual to the pharmacist?
        A. Metformin (for diabetes), Atkins snack bars, and Dramamine (for dizziness)
        B. Sertraline (for depression), SlimFast shakes, and a bottle of water
        C. Lisinopril (for blood pressure), a gallon of ice cream, and a bottle of soda

        References

        Full List of References

        References

           
          REFERENCES
          1. Wdowik M. The long, strange history of dieting fads. Colorado State University. November 13, 2017. Accessed January 14, 2023. https://source.colostate.edu/the-long-strange-history-of-dieting-fads/
          2. Tahreem A, Rakha A, Rabail R, et al. Fad Diets: Facts and Fiction. Front Nutr. 2022;9:960922. Published 2022 Jul 5. doi:10.3389/fnut.2022.960922
          3. Foxcroft L. Introduction: 'The Price of a Boyish Form'. In: Calories and Corsets: A History of Dieting over Two Thousand Years. Profile Books; 2011:1-8.
          4. British Dietetic Association (BDA). Fad diets: Food fact sheet. September 2021. Accessed January 16, 2023. https://www.bda.uk.com/resource/fad-diets.html
          5. British Dietetic Association (BDA). Fad diets and Instagram – friend or Foe? March 2019. Accessed January 16, 2023. https://www.bda.uk.com/resource/fad-diets-and-instagram-friend-or-foe.html
          6. Gans, K. Fad diets through the decades. U.S. News. December 23, 2019. Accessed January 17, 2023. https://health.usnews.com/health-news/blogs/eat-run/articles/fad-diets
          7. Johnson J. Fad diets are bad diets. American Council on Science and Health. July 2, 2018. Accessed January 20, 2023. https://www.acsh.org/news/2018/07/02/fad-diets-are-bad-diets-13134
          8. Centers for Disease Control and Prevention. Obesity and overweight. Updated January 5, 2023. Accessed January 20, 2023. https://www.cdc.gov/nchs/fastats/obesity-overweight.htm
          9. Centers for Disease Control and Prevention. Health effects of overweight and obesity. Updated September 24, 2022. Accessed January 20, 2023. https://www.cdc.gov/healthyweight/effects/index.html
          10. Johns Hopkins Medicine. Intermittent fasting: What is it, and how does it work? Accessed January 23, 2023. https://www.hopkinsmedicine.org/health/wellness-and-prevention/intermittent-fasting-what-is-it-and-how-does-it-work
          11. Chair SY, Cai H, Cao X, Qin Y, Cheng HY, Ng MT. Intermittent fasting in weight loss and cardiometabolic risk reduction: A randomized controlled trial. J Nurs Res. 2022;30(1):e185. doi:10.1097/jnr.0000000000000469
          12. UC Davis Health. Intermittent fasting: Benefits, how it works, and is it right for you? February 4, 2022. Accessed January 23, 2023. https://health.ucdavis.edu/blog/good-food/intermittent-fasting-benefits-how-it-works-and-is-it-right-for-you/2022/02
          13. Cleveland Clinic. What is a superfood, anyway? November 10, 2021. Accessed January 23, 2023. https://health.clevelandclinic.org/what-is-a-superfood/
          14. de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease [published correction appears in N Engl J Med. 2020 Jan 16;382(3):298] [published correction appears in N Engl J Med. 2020 Mar 5;382(10):978]. N Engl J Med. 2019;381(26):2541-2551. doi:10.1056/NEJMra1905136
          15. Patterson RE, Laughlin GA, LaCroix AZ, et al. Intermittent fasting and human metabolic health. J Acad Nutr Diet. 2015;115(8):1203-1212. doi:10.1016/j.jand.2015.02.018
          16. Masood W, Annamaraju P, Uppaluri KR. Ketogenic Diet. In: StatPearls. Treasure Island (FL): StatPearls Publishing; June 11, 2022. Updated June 11, 2022. Accessed January 24, 2023. https://www.ncbi.nlm.nih.gov/books/NBK499830/
          17. Harvard T.H. Chan School of Public Health. Diet Review: Ketogenic diet for weight loss. May 22, 2019. Accessed January 24, 2023. https://www.hsph.harvard.edu/nutritionsource/healthy-weight/diet-reviews/ketogenic-diet/
          18. Nutrisystem. Accessed January 25, 2023. https://www.nutrisystem.com
          19. SlimFast. Accessed March 9, 2023. https://slimfast.com
          20. Jenny Craig. Accessed January 25, 2023. https://www-prd.jennycraig.com/how-it-works
          21. McEvedy SM, Sullivan-Mort G, McLean SA, Pascoe MC, Paxton SJ. Ineffectiveness of commercial weight-loss programs for achieving modest but meaningful weight loss: Systematic review and meta-analysis. J Health Psychol. 2017;22(12):1614-1627. doi:10.1177/1359105317705983
          22. Chaudhry ZW, Doshi RS, Mehta AK, et al. A systematic review of commercial weight loss programmes' effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus. Obes Rev. 2016;17(8):758-769. doi:10.1111/obr.12423
          23. Harvard T.H. Chan School of Public Health. Diet Review: Paleo diet for weight loss. October 28, 2019. Accessed January 26, 2023. https://www.hsph.harvard.edu/nutritionsource/healthy-weight/diet-reviews/paleo-diet/
          24. The Paleo Diet. Accessed January 26, 2023. https://thepaleodiet.com/
          25. UC Davis Health. Paleo diet: What it is and why it's not for everyone. April 27, 2022. Accessed January 26, 2023. https://health.ucdavis.edu/blog/good-food/paleo-diet-what-it-is-and-why-its-not-for-everyone/2022/04
          26. Weight loss: Feel full on fewer calories. Mayo Clinic. March 22, 2022. Accessed January 26, 2023. https://www.mayoclinic.org/healthy-lifestyle/weight-loss/in-depth/weight-loss/art-20044318
          27. Cleveland Clinic. High calorie foods and snack ideas to gain weight. September 15, 2020. Accessed January 26, 2023. https://my.clevelandclinic.org/health/articles/16555-snack-ideas-for-weight-gain
          28. Masharani, U., Sherchan, P., Schloetter, M. et al. Metabolic and physiologic effects from consuming a hunter-gatherer (Paleolithic)-type diet in type 2 diabetes. Eur J Clin Nutr 69, 944–948 (2015). https://doi.org/10.1038/ejcn.2015.39
          29. Parmar RM, Can AS. Dietary Approaches To Obesity Treatment. In: StatPearls. Treasure Island (FL): StatPearls Publishing; October 3, 2022. Accessed January 27, 2023. https://www.ncbi.nlm.nih.gov/books/NBK574576/
          30. Atkins diet: What's behind the claims? Mayo Clinic. May 12, 2022. Accessed January 27, 2023. https://www.mayoclinic.org/healthy-lifestyle/weight-loss/in-depth/atkins-diet/art-20048485
          31. Atkins. Accessed January 27, 2023. https://www.atkins.com/how-it-works
          32. Type 1 diabetes. Mayo Clinic. Accessed March 10, 2023. https://www.mayoclinic.org/diseases-conditions/type-1-diabetes/diagnosis-treatment/drc-20353017
          33. American Diabetes Association. Hypoglycemia (low blood glucose). Accessed March 10, 2023. https://diabetes.org/healthy-living/medication-treatments/blood-glucose-testing-and-control/hypoglycemia
          34. Natesan V, Kim SJ. Lipid Metabolism, Disorders and Therapeutic Drugs - Review. Biomol Ther (Seoul). 2021;29(6):596-604. doi:10.4062/biomolther.2021.122
          35. Health Resources & Services Administration. Primary carnitine deficiency. Accessed March 10, 2023. https://newbornscreening.hrsa.gov/conditions/primary-carnitine-deficiency
          36. Porphyria. Mayo Clinic. Accessed March 10, 2023. https://www.mayoclinic.org/diseases-conditions/porphyria/diagnosis-treatment/drc-20356072
          37. Cleveland Clinic. Pyruvate kinase deficiency. Cleveland Clinic. Accessed March 10, 2023. https://my.clevelandclinic.org/health/diseases/23419-pyruvate-kinase-deficiency
          38. American Heart Association. Types of heart medications. Accessed March 10, 2023. https://www.heart.org/en/health-topics/heart-attack/treatment-of-a-heart-attack/cardiac-medications
          39. Cleveland Clinic. Diuretics. Accessed March 10, 2023. https://my.clevelandclinic.org/health/treatments/21826-diuretics
          40. Mayo Clinic. Chronic Kidney Disease. Accessed March 10, 2023. https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/diagnosis-treatment/drc-20354527
          41. Egan S. 10 Nutrition myths experts wish would die. The New York Times. January 19, 2023. Accessed February 3, 2023. https://www.nytimes.com/2023/01/19/well/eat/nutrition-myths.html
          42. Haspel T. Weight-loss diets boil down to one thing, and it's not science jargon. The Washington Post. January 23, 2023. Accessed February 4, 2023. https://www.washingtonpost.com/food/2023/01/23/weight-loss-diets-fasting-keto/
          43. Contreras RE, Schriever SC, Pfluger PT. Physiological and epigenetic features of yoyo dieting and weight control. Front Genet. 2019;10:1015. Published 2019 Dec 11. doi:10.3389/fgene.2019.01015
          44. Johns Hopkins Medicine. Maintaining Weight Loss. August 8, 2021. Accessed February 6, 2023. https://www.hopkinsmedicine.org/health/wellness-and-prevention/maintaining-weight-loss
          45. Centers for Disease Control and Prevention. Weight Loss and Management. March 19, 2021. Accessed February 6, 2023. https://www.cdc.gov/healthyweight/tools/index.html
          46. USDA. Healthy Living and Weight. U.S Department of Agriculture. Accessed February 6, 2023. https://www.nutrition.gov/topics/healthy-living-and-weight

          The revised USP 795 becomes official in November 2023. What’s new?

          Learning Objectives

           

          After completing this application-based continuing education activity, pharmacists and pharmacy technicians will:

          1. Describe recent changes to USP <795>
          2. Identify the designated person’s responsibility
          3. Recognize areas of nonsterile compounding that could be improved

          Image of brown vial with pink liquid splattered around it.

           

          Release Date: July 1, 2023

          Expiration Date: July 1, 2026

          Course Fee

          Pharmacists: $7

          Pharmacy Technicians: $4

          There is no grant funding for this CE activity

          ACPE UANs

          Pharmacist: 0009-0000-23-021-H07-P

          Pharmacy Technician: 0009-0000-23-021-H07-T

          Session Codes

          Pharmacist:  23YC21-MBV42

          Pharmacy Technician:  23YC21-VBM24

          Accreditation Hours

          2.0 hours of CE

          Accreditation Statements

          The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-021-H07-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

           

          Disclosure of Discussions of Off-label and Investigational Drug Use

          The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

          Faculty

          Christina Aglieco
          PharmD Candidate 2025
          UConn School of Pharmacy
          Storrs, CT

          Robin Bogner, PhD
          Professor of Pharmaceutics
          UConn School of Pharmacy
          Storrs, CT

          Laura Nolan, CSPT, CPhT
          Pharmacy Compounding Lab Coordinator
          Instructor Specialist in Sterile and Non-sterile Compounding
          UConn School of Pharmacy
          Storrs, CT

          Faculty Disclosure

          In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

          Christina Anglieco and Laura Nolan do not have any financial relationships with ineligible companies and therefore have nothing to disclose.

          Robin Bogner acts as a consultant for Biontech.  There is no conflict of interest.

           

          ABSTRACT

          Compounding of drug preparations requires training and knowledge in the science underlying pharmaceutical compounding. Altering the original drug product can change the drug’s stability and clinical efficacy. The United States Pharmacopeia (USP) is an independent non-profit organization of knowledgeable volunteers who set the standards for pharmaceutical compounding to ensure patient safety. State regulating bodies oversee and enforce these standards at compounding pharmacies to ensure compounded preparations are up to quality and purity standards. Since the field of pharmaceutical compounding is constantly changing, USP revises its standards regularly. The USP recently revised General Chapter <795> Pharmaceutical Compounding – Nonsterile Preparations with revisions enforceable on November 1, 2023. To make this transition easier, this continuing education activity outlines the most significant changes made to USP <795>. USP changed General Chapter <795> Pharmaceutical Compounding - Nonsterile preparations to mimic those of USP General Chapter <797> Pharmaceutical Compounding – Sterile Preparations. Overall, the revision elevates nonsterile compounding’s quality and sanitary standards to improve patient safety by reducing common safety errors seen across the United States.

          CONTENT

          Content

          Introduction

          The original “little blue pill” was created in the 1860s and was a popular cure for everything from toothache to tuberculosis.1 Pharmacists compounded “blue mass syrup” and “blue pills” based on their own recipes or on one of several widespread recipes. Its name probably derives from the use of blue dye or blue chalk (used as a buffer) in some formulations. Blue mass’s ingredients varied, as each pharmacist prepared it himself, but they all included elemental mercury. One recipe for blue mass syrup consisted of1

          • 33% mercury (measured by weight)
          • 5% licorice
          • 25% Althaea (a root extract, possibly from hollyhock or marshmallow)
          • 3% glycerol
          • 34% rose honey

           

          Pharmacist-compounders produced blue pills by substituting milk sugar or chalk for the glycerol and rose oil for the rose honey. Each pill contained one grain (64.8 milligrams) of mercury and was prescribed two to three times a day, which today we know causes heavy metal poisoning, since the dose is more than 100 times more than the limit set by the Environmental Protection Agency.1 Products were made without fancy definitions or regard to cleanliness. Times have changed.

           

          Pharmaceutical compounding is the act of manipulating a drug product to create a new drug formulation.2 Pharmacists and pharmacy technicians still compound drug preparations for a specific patient or group of patients when no drug product exists on the market, or as seen more recently, when the drug product is backordered with no therapeutic alternative(s). It is also interesting to note what the United States Pharmacopeia (USP; described below) does NOT consider to be compounding. Preparing a powdered antibiotic bottle with distilled water per manufacturer’s directions is not considered compounding. Splitting tablets and repackaging is also not considered compounding, nor is preparing a single dose for a single patient to be used within four hours. In other words, making one dose of blue mass syrup and giving it directly to a patient is not compounding. (OK, maybe no one makes blue mass syrup anymore, but crushing a tablet and placing it in a liquid for immediate use is still not a compounded preparation.)

           

          Pharmaceutical compounding has two categories: sterile compounding and nonsterile compounding.2

          • Sterile compounding is creating a new drug preparation that must be sterile (completely free of pathologic microorganisms) and includes preparations that are primarily infusions, injections, eye drops, and many irrigations.
          • Nonsterile compounding is creating a new drug product that is not required to be sterile (although these products should be as “clean” as possible) and are mostly used for oral or topical administration. Nonsterile compounding is often employed for pediatric and veterinary preparations where patients need very small or very large doses. Some examples are medicated creams for neuropathic pain, and anesthetic mouthwashes for oral sores and pains.

           

          The USP is an independent non-profit organization of knowledgeable volunteers who set the standards for pharmaceutical compounding to ensure patient safety.3 The USP also distinguishes guidelines for hazardous and non-hazardous compounding. Both sterile and nonsterile compounding can involve manipulation of hazardous drugs. This continuing education activity focuses on non-hazardous nonsterile compounding. More information on hazardous compounding can be found in General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings. Access to the USP Compounding Compendium costs $250.00 for a 12-month membership. There are also various plans for multiple users. Many institutions have a contract with USP. (Readers should check with their designated person or supervisor, as they may already have access to this service.)

           

          The origin of nonsterile pharmaceutical compounding in the U.S. cannot be pinned down to one exact date, but historically, the 1800s saw immense growth in not only population but also in disease states as people traveled and settled to new areas. Between 1840 and 1850, it is estimated that more than 1.5 million persons immigrated to the United States. Backyard herbalists became highly regarded apothecaries seemingly overnight.4

           

          Unfortunately, there were no established compounding standards until 1820 when a small group of physicians raised concerns about the high prevalence of poor-quality medicine across America and the USP was formed. By 1863, during the height of the Civil War, the USP had become the most trusted source for information about medicines.3.

           

          The USP continuously strives to improve the quality of drugs, including compounded preparations. Today we know that the quality of a compounded preparation depends as much on handwashing, gloving and cleaning, as checking the pH of the product itself. These steps are necessary to safeguard the preparation that a pharmacist or pharmacy technician compounds, and ultimately, safeguard the patient.

           

          The USP sets standards for pharmaceutical compounding but has no regulatory authority, so it does not enforce the standards it sets. Each state is responsible for regulating pharmaceutical compounding, but the Food and Drug Administration (FDA) is also authorized to regulate all aspects of drugs, including compounding. Both state regulating bodies and the FDA can inspect compounding in pharmacies and take legal action and can amass fines if compounders do not uphold USP standards. However, this action only applies to states that write USP standards into their laws. Depending on the situation’s severity, legal action could result in a loss of license for the pharmacy or pharmacist.

           

          The USP sets standards for sterile and nonsterile compounding through General Chapter <797> and General Chapter <795>, respectively. (Here’s a PRO TIP: chapters numbered from 1 to 1000 are enforceable by state and federal agencies). More recently, the FDA has been inspecting compounding pharmacies to ensure they meet General Chapter <797> standards, but it is only a matter of time before these agencies turn their attention to General Chapter <795>.

           

          In November 2022, the USP published a revised General Chapter <795> Pharmaceutical Compounding – Nonsterile Preparations. Going forward, we will call these standards the newly revised standards. This revision now includes a designated person (the individual assigned to be accountable and responsible for the compounding facility’s operation, performance, and personnel) requirement to mimic General Chapter <797>. With the implementation of a designated person for nonsterile compounding under proposed General Chapter <795>, when the facility is not up to code, State boards of Pharmacy and the FDA hold the designated person responsible, creating a risk of loss of license. The revised standards will be official in November 2023. Major changes include

          • garbing
          • cleaning
          • training
          • beyond-use dating and
          • a designated person requirement

           

          The focus here is on how to implement the major changes made to the currently enforceable General Chapter <795>, which was revised and reissued in 2020. Going forward, we will call these standards the current standards. Once readers are familiar with this summary of the major changes in the newly revised standards, they are encouraged to review the full text of the proposed chapter <795> to address additional minor changes.

           

          So, to repeat, the standards that were revised and reissued in 2020 and are currently enforceable will be called the current standards. The revision that will be adopted in November 2023 will be called the newly revised standards.

           

          Garbing

          The newly revised standards put greater emphasis on garbing procedures for nonsterile compounding than the current standards do. Pharmacy personnel who compound sterile preparations are well acquainted with garbing, however, garbing is a foreign concept to many who prepare nonsterile preparations. Think back to the past. How often did you go to the back of the store, push some items on the counter aside, and start mixing a magic mouthwash? You probably made it wearing a shirt and tie or more formal dress, while possibly wearing a lab coat, unless it was a really hot day. You might even have washed your hands if you just came back from lunch. Conversely, many hospital pharmacies mix magic mouthwash in so much garb, that you might think that it is a toxic preparation. The SIDEBAR explores this topic in greater detail.

           

           

          TECH TALK SIDE BAR5

          Have you noticed that many pharmacists and pharmacy technicians no longer wear white lab coats? Physicians began to wear white coats in the late 1800s as doctors started to recognize the color white’s effectiveness. It is easier to see dirt and soil that prompts the wearer to launder it, and frequent laundering helps reduce pathogens. Soon all medical professionals adopted the practice. White coats were worn not only to protect one’s clothing, but they were seen as a sign of prestige and respect.

           

          Today, white coats are rarely used, because according to Dennis Miller, “White coats cause white coat syndrome” (hypertension) and they “increase the distance between the pharmacist and the customer.” Few states regulate pharmacy technician attire. Many institutions and most large retail chains require pharmacy technicians to wear uniform “scrubs.” Restricting white coats to professional staff may reduce some customer confusion, but in certain situations, scrubs might imply the wearer is a nurse or other hospital professional, which is also confusing. One of this CE’s authors says, “I can’t even tell you how many patients and families would ask if I was a nurse.”

           

          Recently, some hospitals have banned pharmacy technicians from wearing scrubs, forcing them to wear civilian clothing. Unfortunately, that makes technicians look like pharmacists again. Of course, some pharmacists like to wear scrubs to work; are they secretly wishing they were technicians? Doubtful. Business attire has certainly gone downhill lately. So, if we can’t wear a white coat and we can’t wear scrubs, what are we to wear?

           

          THE ANSWER (which is required by law in many states): A name tag that indicates your position!

           

           

          The current standards state that personnel involved in compounding should garb “as needed for personal protection and to prevent contamination” of the compounded nonsterile product (CNSP) prior to preparation.6 For example, compounding staff don two pairs of gloves for personal protection when preparing cytotoxic CNSPs for their own safety. More information on hazardous compounding can be found in General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings. The current standards also state compounding personnel are responsible for maintaining good hand hygiene and wearing appropriate clothing to prevent contamination of the CNSP.6 These statements give compounding personnel some latitude when they make decisions. For example, currently, some compounders don gloves to make magic mouthwash, while many others prepare it with ungloved hands in their practice. Nonsterile gloves will become mandatory on November first.

           

          The newly revised standards now specify hand washing and garbing procedures and provide guidance on personnel who should NOT prepare a CNSP. Compounding personnel are to remove all “garments that cannot be easily cleaned” before entering the designated compounding area. So compounding personnel must now remove personal outer garments (such as jackets, sweaters, hats, and scarves), hand and wrist jewelry, anything that might hinder the use of gloves, and headphones must be removed before compounding something as simple as magic mouthwash. Compounding personnel must wash their hands for at least 30 seconds and dry with one-time use paper towels before compounding as well. After handwashing, personnel must don nonsterile gloves and inspect the gloves for holes, rips, or tears. Compounding personnel should wipe or replace gloves in between different preparations and must remove these gloves before leaving the designated compounding area.6 These proposed standards are analogous to the procedures required for sterile compounding. In fact, the format of and definitions within the revised <795> aligns with the revised <797> for sterile products much more closely than in the past.

           

          The current standards still require personnel to be in good health and fit for compounding, but the revisions are considerably more specific. Personnel who have new tattoos, oozing sores, open wounds, conjunctivitis, rashes, or active respiratory infections are not considered fit to compound due to risk of contamination of the CNSP. The newly revised standards hold the designated person responsible for deciding if personnel are fit for compounding or not.6

           

          Cleaning the Designated Compounding Area

          Do I need to create an area for compounding? Yes. The newly revised standards describe a designated compounding area in detail. Some readers are thinking, “My pharmacy is small. Can I use the area for tasks other than compounding?” The designated compounding area is a space with a marked perimeter that is required to be clean, orderly, sanitary, well-lit, and have low foot traffic, and no other activities can occur in this space simultaneously. You may perform other duties there if there is no compounding going on as long as someone cleans the area before compounding again. The newly revised standards suggest the designated compounding area be uncarpeted for easier cleaning, which in one of this CE’s author’s opinion should be changed to a must, since carpets tend to harbor dust and dander, and can be very difficult to clean. (Have you ever dropped and broken a bottle on the carpet in your pharmacy? It’s not pretty.)

           

          The compounding area must be used in a manner that prevents cross contamination of CNSPs from other areas of the pharmacy. For compounding to be completed in the most efficient manner possible, all equipment in the designated compounding area must be arranged in a way that prevents errors. Last, the facility’s standard operating procedures (SOPs) must always include this information and be available to staff.

           

          The current standards simply state that compounding equipment “shall be clean, properly maintained and used appropriately.”6 This statement allowed compounding personnel to decide on their own standard of clean when preparing a CNSP and their own definition of when or if they should clean. The newly revised guidelines strengthen the minimum requirements for cleaning the designated CNSP compounding area. The USP dedicates an entire section to cleaning procedures, representing a major change in the standards. The new standards indicate that personnel must clean the perimeters—walls and ceilings—when visibly soiled, after spills, and when surface contamination occurs.6 Readers will see that visible soil, spills, and surface contamination form a frequent theme in the newly revised standards!

           

          The new standards also establish a routine cleaning schedule. The section, “Cleaning and Sanitizing” states pharmacy personnel must clean work surfaces at the beginning and end of each shift at a minimum, between each CNSP, and again if spills or surface contamination occurs. The standards add that personnel must clean floors daily on days when compounding occurs, and again if spills or surface contamination occurs.6. Personnel must clean storage shelves every three months, after spills, and when surface contamination occurs. Personnel qualified to clean can be defined as any staff member who has been properly trained and observed in a facilities cleaning procedures. That means that pharmacy staff can train housekeeping staff to complete the cleaning.

           

          Personnel need to clean and sanitize, and if two separate products are used—one to clean and one to sanitize—cleaning is done first, followed by sanitizing second. Selecting appropriate cleaning products requires careful attention. They should be (1) compatible, (2) effective, and (3) leave minimal residue. Finally, daily documentation is essential on days when compounding occurs.6 An old adage applies here: cleaning is not truly done unless it is documented. High tech organizations commonly complete this documentation using an online platform integrated with other daily documentation requirements such as daily temperature monitoring, but a simple sign off sheet is also acceptable. A best practice is to include any cleaning and its documentation into the compounder’s daily workflow, so it is not forgotten. Daily and or weekly task charts can be created to include all activities that need to be performed.

           

          PAUSE AND PONDER: How were you originally trained to compound? Were you told to watch how it was done and then you were on your own?

           

          Training

          Another major area of change is the training of compounding personnel. The current standards state that compounders must be “proficient in compounding” and suggest that compounders should pursue knowledge by attending seminars or studying literature related to compounding. It also states that compounders must be conversant on General Chapter <795> and familiar with General Chapter <797>. With standards this vague, and no required number of CE credits on this subject, how often do you think compounding personnel previously searched for compounding topics? Also, the current standards simply require at a minimum compounding personnel to be trained and capable of the compounding duties assigned to them, and for someone to document the training. Compounding duties include verifying critical processes like weighing and mixing that occur frequently during compounding.

           

          The newly revised standards will require a more structured training program for compounding personnel. All compounding personnel must complete this training program initially before being allowed to compound and every 12 months thereafter. The newly revised standards require compounding personnel to repeat compounding procedures “independently while under the supervision of the designated person or assigned trainer for completion of the training program.”6 The organization’s designated person will be responsible for designing the training program, which must include

          • the required training, meaning a detailed description of the training
          • the frequency of training, and
          • the process used to evaluate competency.

           

          Table 1 lists the training program’s required topics. It is interesting to note that pharmacists who do not compound but complete in-process checks, verification, or dispensing also must complete the CNSP training program before completing checks, verification, or dispensing. A training program may include an online portion of reading or videos teaching concepts with quizzes to evaluate understanding, and a physical portion to evaluate measuring, mixing, and overall compounding. The designated person or assigned trainers can train personnel, and of course, they must document the completion of the training program.6

           

          Table 1. Proposed General Chapter <795> Required Topics for Training6

          Training programs must teach compounding personnel the following:
          ·       cleaning and sanitizing
          ·       documentation such as Master Formulation Records and Compounding Records
          ·       hand hygiene and garbing
          ·       handling and transporting CNSPs and their components
          ·       measuring and mixing
          ·       proper use of compounding equipment and devices
          ·       understanding General Chapter <795>
          ·       understanding safety data sheets
          ·       understanding procedures to complete compounding duties

           

          It is important to note this table only lists the minimum requirements, additional requirements may be necessary according to each facility’s needs.

           

          The Designated Person

          The necessity to designate a person who has oversight and full responsibility for compounding practices now in General Chapter <800> is included in proposed General Chapter <795> and <797>. The current standards again broadly describe the requirements. The chapter states that compounding personnel are responsible for adhering to the general principles of compounding outlined in the current standards. It specifies several responsibilities, which include training, selecting ingredients for compounding, labeling, and cleaning. However, since the compounding process may include many people, the ultimate accountability is unclear.

           

          To clarify accountability, the proposed General Chapter <795> requires each organization to designate one or more persons to be responsible and accountable for nonsterile compounding. The designated person’s responsibilities include ensuring the organization develops written formal quality control and quality assurance procedures and reviews them annually. The designated person must monitor and observe compounding, identify areas of error, and take corrective action if needed. The designated person has several other responsibilities. These include6

           

          • establishing, documenting, and monitoring SOPs within the CNSP compounding area to include component handling and storage
          • ensuring that all staff members follow all SOPs
          • reviewing complaints
          • determining if potential issues are likely with CNSPs
          • selecting components to be used in compounding

           

          Beyond Use Dates

          The final major difference is the establishment of beyond-use dates (BUD) for CNSPs. The current standards hold compounders responsible for establishing BUDs based on their observation of the drug during compounding. Compounders (not a designated person) are held responsible for noticing signs of instability and using their education and experience to assign a BUD to the final preparation.6 The current standards also recommend assigning BUDs based on three categories: non-aqueous, water-containing oral, or water-containing topical. The new guidelines are based on the activity of water (aw) in each product.

           

          Table 2 compares the current and proposed BUD recommendations.6

           

           

          Table 2. A Comparison of BUD Requirements6,7       

          Description Minimum BUD requirement
          Current USP <795> Proposed USP <795>
          Aqueous non-preserved 14 days in refrigerator 14 days in refrigerator

           

          Aqueous preserved 14 days in refrigerator 35 days controlled room temp or refrigerator
          Aqueous topical

          (Cream, lotion, shampoo, nasal spray, gel, rinse, foam, etc.)

          30 days 35 days if preserved

          14 days if non-preserved

          See activity of water chart

          Nonaqueous oral

          (Oil or powder filled capsule, glycol or oil based oral solution, compressed tablet, powder for inhalation, troche, lollipop, etc.)

          6 months 90 days
          Nonaqueous

          (Medicated stick, ointment, suppository, etc.)

          6 months 180 days (6 months)

           

          Proposed General Chapter <795> determines BUDs based on a preparation’s water activity (aw, see SIDEBAR), which is more clearly defined as aqueous and non-aqueous by the following distinction:

           

          • CNSPs with an aw ≥0.6, considered aqueous dosage forms
          • CNSPs with an aw <0.6, considered non-aqueous dosage forms

           

           

          SIDEBAR: Activity of Water7-10

          The water in a preparation can “participate in chemical, biochemical, or physicochemical reactions.” However, it is not the water content (such as % water in the CNSP), but rather the activity of water that determines the water’s availability to participate in degradation reactions and allow microbial growth. Therefore, compounders must determine a BUD by considering the preparation’s water activity and not the preparation’s water content.

           

          Water activity is roughly equivalent to relative humidity, except that relative humidity is expressed in terms of percent and water activity is expressed as a fraction. So, a water activity of 0.6 is roughly equivalent to 60% relative humidity. If the dosage form with a water activity of 0.6 were to be sealed in a package, any surrounding space would eventually have a relative humidity of 60%. Compounders can measure water activity for a specific preparation by the procedures outlined in General Chapter <922> Water Activity. However, the proposed General Chapter <795> provides an easy classification system (see Table 3).

           

          The aw cut-off of 0.6 established in USP comes from various studies showing no microbial growth of any kind in foods below this value. Although the water activity determination was constructed using food, it is also the basis of USP <1112> Water Activity Determination and is the foundation for the BUD rationale in the proposed <795>. A product with an aw greater than or equal to 0.6 has been shown to have increased bacterial, fungal, and other microbial growth. However, in products with an aw below the threshold of 0.6, no microbial growth was found.

           

           

          The newly revised standards recommend adding antimicrobial agents to any CNSP with an aw at or exceeding 0.6 when assigning a BUD of 35 days. Even components as simple as ascorbic acid can help extend the BUD. As always, careful research must be done to determine suitable preservatives for each product and if an extended BUD date is assigned, the preparation must be tested for antimicrobial effectiveness. Consider one formula for magic mouthwash, which might have an aw of 0.73 and contains no preservatives. With no USP monograph, one would refer to Table 3 to determine that the BUD should be limited to 14 days when stored in the refrigerator. We are sure that pharmacists compounding blue mass syrup could have cared less about the activity of water in their concoctions. We wonder if they would have viewed mercury as a preservative.

           

          Compounders can assign non-aqueous dosage forms with an aw less than 0.6 a maximum BUD of 90 days for an oral liquid and 180 days for alternative routes.

           

          While the newly revised standards provide strong guidance on determining a CNSP’s BUD, compounders should only use its tables if no other stability information is available. The designated person is responsible for searching for stability information for each CNSP and determining if a CNSP can have a BUD beyond that specified in Table 2. If the designated person finds an extended BUD appropriate, compounding staff must test it for antimicrobial effectiveness. However, if compounding staff is following a United States Pharmacopeia- National Formulary (USP-NF) monograph for CNSP preparations, the BUD must not exceed that which is indicated in the monograph. Last, the CNSP’s components should drive the overall expiration date, which is not a change from the current standards.

           

          Table 3. Proposed General Chapter <795> classification of commonly compounded dosage forms as non-aqueous or aqueous partial list.

          Nonaqueous Dosage Forms aw <0.6

           

          Aqueous Dosage Forms aw ≥0.6

           

          -       ­Animal treat, oil based

          -       Capsule: oil filled or powder filled

          -       Oral solution: glycol based or oil based.

          -       Glycol based gel

          -       Stick or lip balm

          -       Tablet compressed or triturate

          -       Sorbitol based lollipop

          -       Ointment: hydrophilic petrolatum polyethylene and mineral oil based

          -       Oral suspension: fixed oil

          -       Powder for inhalation

          -       Suppository: polyethylene glycol base or fatty acid base

          -       Troche or lozenge: gelatin based or glycol based

          -       Animal treat

          -       Foam

          -       Shampoo

          -       Cream: oil in water emulsion, emollient cream, petrolatum, and mineral oil gel: alcohol free aqueous or hydroxypropyl methylcellulose gel

          -       Lotion

          -       Nasal spray

          -       Rinse

          -       Oral solution: water based, low sucrose syrup vehicle

          -       Oral suspension

           

           

          CONCLUSION

          Compounders face many of the same challenges today as they did in the 1800s. They were faced with a limited drug list, similar to a closed formulary in today’s world. They searched for alternative therapies, and they did, as we still do, face many drug shortages. The main difference is that we have advanced knowledge to make better products to keep patients safer.

           

          The time has come to designate your area, designate your person, and train your staff, including pharmacists who may not actually be compounding! Keep the designated area clear for compounding use only, if possible, and remove any unnecessary items before entering. Set up a cleaning routine for the entire space, including floors, walls, and shelving, and incorporate the routine into the daily workflow so it is never forgotten. Train your staff well to the new standards and reevaluate every 12 months. Look into the literature to determine the best BUD for each CNSP and when information is not available, use USP guidance for assigning a BUD date. Choose a designated person wisely, as they need to be responsible and organized with taking responsibility and accountability for all nonsterile compounding occurring in the facility.

           

          Remember, improvements in non-sterile compounding standards will make for higher quality and safer compounded non-sterile products for our patients and are enforceable come November 1, 2023.

          Pharmacist Post Test (for viewing only)

          After completing this continuing education activity, pharmacists and pharmacy technicians will be able to

          1. Describe recent changes to USP <795>
          2. Identify the designated person’s responsibilities
          3. Recognize areas of nonsterile compounding that could be improved

          1. The USP made major revisions to General Chapter <795> in the newly revised standards. What topics are affected?
          a. Cleaning, training, purchasing, designated person, and verification processes.
          b. Garbing, training, sanitizing, designated person, purchasing.
          c. Garbing, cleaning, training, designated person, and BUDs.

          2. When will the proposed General Chapter <795> become enforceable?
          a. It is already enforceable
          b. July 1, 2023
          c. November 1, 2023

          3. Which of the following conditions would make compounding personnel unfit for compounding at the discretion of the designated person?
          a. Recent placement of a temporary (water-removable) tattoo
          b. Cough, runny nose, and upper respiratory congestion
          c. All of the above.

          4. Who must create and enforce a new training program under the newly revised standards?
          a. Only staff who will perform compounding
          b. All personnel involved in compounding verification and dispensing
          c. The designated person or the designated person’s designee

          5. How often must the training program and reevaluation of competency be completed?
          a. Once prior to compounding, and then every 12 months
          b. Once after November 1, 2023, and then biannually
          c. Once only, since compounding never changes

          6. Sally is about to enter the compounding area. She is wearing makeup, a set of bangle bracelets, and sterile gloves. Which item is not allowed when compounding a CNSP?
          a. Makeup
          b. Wrist jewelry
          c. Gloves

          7. Which of the following must the designated person complete personally (that is, not train or delegate to others)?
          a. Cleaning the compounding area twice daily
          b. Identifying BUDs for all compounded products
          c. Ensuring staff follow all operating procedures

          8. The FDA visits your pharmacy after several patients develop infections related to a CNSP compounded in your facility. They find that the BUD was incorrect and the product was contaminated. Who will ultimately “take the fall” for this issue?
          a. The designated person.
          b. The entire pharmacy department.
          c. The compounder who prepared the CNSP.

          9. Which of the following CNSP properties now restricts the maximum BUD?
          a. Activity of water
          b. Time till it reaches the patient
          c. Duration of treatment

          10. Your supervisor tells you it’s time to improve your organization’s compounding. You need to find the best area for compounding. Which of the following is the best option for a designated compounding area?
          a. The farthest corner of the pharmacy provided that customers cannot see it and housekeeping staff indicates it is clean
          b. A carpeted section of the pharmacy next to the employee refrigerator that has easily cleanable countertops and shelving.
          c. A well-lit, uncarpeted area with easily cleanable countertops that is segregated from countertop space used for daily activities

          Pharmacy Technician Post Test (for viewing only)

          After completing this continuing education activity, pharmacists and pharmacy technicians will be able to

          1. Describe recent changes to USP <795>
          2. Identify the designated person’s responsibilities
          3. Recognize areas of nonsterile compounding that could be improved

          1. The USP made major revisions to General Chapter <795> in the newly revised standards. What topics are affected?
          a. Cleaning, training, purchasing, designated person, and verification processes.
          b. Garbing, training, sanitizing, designated person, purchasing.
          c. Garbing, cleaning, training, designated person, and BUDs.

          2. When will the proposed General Chapter <795> become enforceable?
          a. It is already enforceable
          b. July 1, 2023
          c. November 1, 2023

          3. Which of the following conditions would make compounding personnel unfit for compounding at the discretion of the designated person?
          a. Recent placement of a temporary (water-removable) tattoo
          b. Cough, runny nose, and upper respiratory congestion
          c. All of the above.

          4. Who must create and enforce a new training program under the newly revised standards?
          a. Only staff who will perform compounding
          b. All personnel involved in compounding verification and dispensing
          c. The designated person or the designated person’s designee

          5. How often must the training program and reevaluation of competency be completed?
          a. Once prior to compounding, and then every 12 months
          b. Once after November 1, 2023, and then biannually
          c. Once only, since compounding never changes

          6. Sally is about to enter the compounding area. She is wearing makeup, a set of bangle bracelets, and sterile gloves. Which item is not allowed when compounding a CNSP?
          a. Makeup
          b. Wrist jewelry
          c. Gloves

          7. Which of the following must the designated person complete personally (that is, not train or delegate to others)?
          a. Cleaning the compounding area twice daily
          b. Identifying BUDs for all compounded products
          c. Ensuring staff follow all operating procedures

          8. The FDA visits your pharmacy after several patients develop infections related to a CNSP compounded in your facility. They find that the BUD was incorrect and the product was contaminated. Who will ultimately “take the fall” for this issue?
          a. The designated person.
          b. The entire pharmacy department.
          c. The compounder who prepared the CNSP.

          9. Which of the following CNSP properties now restricts the maximum BUD?
          a. Activity of water
          b. Time till it reaches the patient
          c. Duration of treatment

          10. Your supervisor tells you it’s time to improve your organization’s compounding. You need to find the best area for compounding. Which of the following is the best option for a designated compounding area?
          a. The farthest corner of the pharmacy provided that customers cannot see it and housekeeping staff indicates it is clean
          b. A carpeted section of the pharmacy next to the employee refrigerator that has easily cleanable countertops and shelving.
          c. A well-lit, uncarpeted area with easily cleanable countertops that is segregated from countertop space used for daily activities

          References

          Full List of References

          References

          1. Massae Pilularum—pill masses, Henriette’s Herbal Homepage. Accessed June 2, 2023. https://www.henriettes-herb.com/eclectic/kings/massae-pilu.html
          2. Watson, C.J., Whitledge, J.D., Siani, A.M. et al. Pharmaceutical Compounding: a History, Regulatory Overview, and Systematic Review of Compounding Errors. J. Med. Toxicol. 17, 197–217 (2021). https://doi.org/10.1007/s13181-020-00814-3
          3. USP Timeline. www.usp.org. Accessed March 21, 2023. https://www.usp.org/200-anniversary/usp-timeline#:~:text=1820&text=Concerned%20about%20the%20dangers%20of
          4. Sprowls, Joseph Barnett, Lewis W. Dittert, and Rufus Ashley Lyman. Sprowls' American Pharmacy: An Introduction to Pharmaceutical Techniques and Dosage Forms. Lippincott Williams & Wilkins, 1974. page 3.
          5. Miller D. Are those white coats really necessary? Accessed June 3, 2023. https://www.drugtopics.com/view/dear-pharmacists-are-those-white-coats-really-necessary
          6. USP. Pharmaceutical Compounding - Nonsterile Preparations <795>. In: USP-NF. Rockville, MD: USP; May 1, 2020.

          DOI: https://doi.org/10.31003/USPNF_M99595_05_01

          1. USP. Pharmaceutical Compounding - Nonsterile Preparations <795>. In: USP-NF. Rockville, MD: USP; November 1, 2023.

          DOI: https://doi.org/10.31003/USPNF_M99595_06_01

          1. USP. Applications of Water Activity Determination to Non-sterile Pharmaceutical Dosage Products <1112>. In: USP-NF. Rockville, MD: USP; 2013

          DOI: https://doi.org/10.31003/USPNF_M402_01_01

          1. USP. Water Activity <922>. In: USP-NF. Rockville, MD: USP; May 1, 2021.

          DOI: https://doi.org/10.31003/USPNF_M12475_02_01

           

          1. Sikorski ZE. Fennema's food chemistry (fifth edition) edited by SrinivasanDamodaranKirk L.parkin CRC press, Boca Raton, Florida, 2017. 1107 pp. ISBN 9781482208122. J Food Biochem. 2018;42(2):e12483-n/a. doi: 10.1111/jfbc.12483.

           

          Patient Safety: Social Media Sensation: Semaglutide

          Learning Objectives

           

          After completing this application-based continuing education activity, pharmacists will be able to

          ·       Recall the mechanism of action and dosing schedule of GLP-1 receptor agonists
          ·       Classify adverse reactions most commonly associated with GLP-1 receptor agonists
          ·       Discuss GLP-1 receptor agonists indications for use

          After completing this application-based continuing education activity, pharmacy technicians will be able to

          ·       Identify the different formulations of GLP-1 receptor agonists
          ·       Classify storage requirements for GLP-1 receptor agonists
          ·       Review GLP-1 receptor agonists indications for use

          Cartoon person scratching head while looking at a scale

           

          Release Date: June 17, 2023

          Expiration Date: June 17, 2026

          Course Fee

          Pharmacists: $5

          Pharmacy Technicians: $2

          There is no grant funding for this CE activity

          ACPE UANs

          Pharmacist: 0009-0000-23-020-H05-P

          Pharmacy Technician: 0009-0000-23-020-H05-T

          Session Codes

          Pharmacist:  23YC20-XFT68

          Pharmacy Technician:  23YC20-TXF84

          Accreditation Hours

          1.5 hours of CE

          Accreditation Statements

          The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-020-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

           

          Disclosure of Discussions of Off-label and Investigational Drug Use

          The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

          Faculty

          Jennifer Kuivinen, RPh, CIP
          Pharmacist
          Meijer Pharmacy
          Petoskey, MI

          Faculty Disclosure

          In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

          Jennifer Kuivinen does not have any financial relationships with ineligible companies and therefore has nothing to disclose.

           

          ABSTRACT

          Recently, it’s a rare day when the national news outlets and social media platforms don’t discuss medication-assisted weight loss. Semaglutide has become a social media sensation for its ability to help people–even people who do not have diabetes (its approved indication) lose weight. With celebrities reporting significant weight loss with off-label use of glucagon-like peptide-1 (GLP-1) receptor agonists, pharmacy teams are fielding questions and juggling prescriptions to deal with drug shortages. This continuing education activity provides basic facts about using GLP-1 receptor agonists for weight loss.

          CONTENT

          Content

          INTRODUCTION

          Lifestyle modifications have been the mainstay of weight management for years. We’ve all heard the advice: Exercise more, eat less, limit fried foods and sugary drinks, and the weight should slowly disappear. As the weight comes off, you might have some setbacks but just keep tracking your foods and your success is right around the corner.

           

          If only it was that easy!

           

          Scroll any social media platform today and search the term, “#ozempicweightloss” and a plethora of joyful testimonials appear. Some videos have reports of people losing 17 pounds in 3 months or 64 pounds in a year with no cravings for food. “I can eat whatever I want!!” cried a satisfied user. It is as if the golden ticket has been found in all the candy bars ever produced and everyone is going to the candy factory!

           

          Although the recent media emphasis has been on semaglutide, and the Ozempic product primarily, other glucagon-like peptide-1 (GLP-1) receptor agonists have also been associated with weight loss to varying degrees. This continuing education activity’s primary focus is to clarify misinformation, highlight specific GLP-1s’ risks and benefits when used for weight loss, and answer frequently asked questions.

           

          WHAT ARE GLP-1 RECEPTOR AGONISTS?

           

          Major breakthroughs in the physiology of the pancreas occurred in the early 1900s.1 At that time, physiologists thought the nervous system had exclusive control of all bodily functions. That idea changed when two scientists, William Bayliss and Ernest Starling, discovered a chemical compound they named secretin. Released from intestinal mucosa, secretin stimulated the pancreas.2 Shortly after the discovery of the hormone insulin in 1921, research being conducted at the time primarily stimulated the pancreas to produce insulin by administering glucose via the intravenous route. However, when glucose was administered orally (allowing nutrients to travel to gastrointestinal areas), insulin levels improved substantially. This observation was known as the incretin effect. As a result, two insulinotropic hormones were later identified as incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) discovered in 1971 and glucagon-like peptide-1 (GLP-1) discovered in 1985.1,2

           

          Analyzing the venom of the Gila monster (Heloderma suspectum) in 1990, endocrinologist Dr. John Eng discovered a peptide that stimulated insulin release from the pancreas.3 Named exendin-4, this peptide was similar in structure and function to GLP-1 found in humans. One problem with GLP-1 was that when it is released into the body, dipeptidyl peptidase-4 (DPP-4). quickly inactivated it. Researchers then developed the DPP-4 inhibitors to allow GLP-1 to remain active for a longer period of time. However, synthetically producing GLP-1 receptor agonists (GLP-1RA) directly has extended the peptide’s life. Initial development resulted in twice daily and then daily administration (half-life of 13 hours) of GLP-1RAs. However, when researchers combined semaglutide with a free fatty acid side chain that was tightly bound to albumin, its half-life was increased substantially. The resultant half-life of 165 hours led to an advantageous injection administration schedule for semaglutide: once weekly.3,4,5

           

          Mechanism of Action

          As a class of medications, all GLP-1RAs share common mechanisms of action in the treatment of diabetes: stimulate the pancreas to secrete insulin, suppress the action of glucagon, and decrease gastric emptying.4 Scientists previously studied the effects of GLP-1 and noticed that the protein, when injected in rats, decreased appetite quickly.5 Once clinicians began using GLP-1RAs to treat diabetes in humans, they also observed weight loss due to decreased appetite, increased feelings of fullness, and reduced caloric consumption.4

           

          Researchers determined that the brain contained GLP-1 receptors. Weight loss was due to GLP-1RAs ability to travel to these receptors and influence specific areas of the hypothalamus that are key to controlling appetite, calorie consumption, satiety, and body weight.4 Among GLP-1RAs, semaglutide and liraglutide stimulate the highest amount of weight loss success.

           

           

          Comparison of GLP-1 drugs

           

           

          Table 1. GLP-1RAs for Weight Loss

          Medication Dosing Counseling points Supplies needed for injection
          Semaglutide (Wegovy) Adult and pediatric patients aged 12 and older, starting dosage at 0.25 mg injected subcutaneously once weekly.

           

          Weeks 1-4: 0.25 mg

          Weeks 5-8: 0.5 mg

          Weeks 9-12: 1 mg

          Weeks 13-16: 1.7 mg

          Weeks 17 & forward: 2.4 mg maintenance dose once weekly.

           

          If adverse reactions occur during the upward titration period, consider delaying increase in dosage for four weeks.

           

          Consider discontinuing the drug if patients do not lose at least 5% of baseline body weight within 3 months

          1 alcohol swab or soap and water

           

          1 gauze pad or cotton ball

           

          1 sharps disposable container for used Wegovy pens

          Liraglutide

          (Saxenda)

          Adults and pediatric patients aged 12 and older, starting dosage at 0.6 mg injected subcutaneously once daily. (NOTE: This is a DAILY dose)

           

          Week 1: 0.6 mg

          Week 2: 1.2 mg

          Week 3: 1.8 mg

          Week 4: 2.4 mg

          Week 5 & forward: 3 mg maintenance dose daily.

           

           

           

           

           

           

           

           

           

          If adverse reactions occur during upward titration period, consider delaying dose increase for approximately one additional week.

           

          Patients can continue on maximally tolerated dose if goal weight loss achieved on that dose.

           

          Soap and water

           

          Pen needle: 8 mm

          (Novofine or NovoTwist)

           

          1 sharps disposable container for pen and needles

           

           

          Adverse Drug Reactions and Boxed Warning

          GLP-1 agonists all have similar and common gastrointestinal adverse effects (nausea [~15–30%], vomiting [~10-15%], diarrhea [~5-10%], abdominal pain, constipation).6,7,8 Patients can use some strategies to possibly mitigate these adverse effects6,7,8:

          • Increasing the GLP-1 agonist dose slowly
          • Staying hydrated and increasing fiber
          • Avoiding high-fat foods and alcohol
          • Stopping eating when full (and eating only when hungry)
          • Spacing meals appropriately
          • Using short-term proton pump inhibitors or H2 blockers if needed

          Patients may also experience headache, fatigue, dyspepsia (gastrointestinal upset), dizziness, abdominal distension, eructation  (burping), hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease.7 Clinicians should evaluate patients for gallbladder disease if cholelithiasis (gallstones) or cholecystitis (an inflamed gall bladder) is suspected.

           

           

          Reports of patients experiencing hair loss have surfaced recently from news and social media. Listed as an adverse reaction for Wegovy, but not for Ozempic, the Wegovy dose is much higher for treatment of weight loss.9 Some clinicians think that the rapid loss of weight triggers the body to conserve calories consumed for essential functions.9 Since patients eat less while taking the medications, their diet may consist of lower amounts of protein and minerals important for hair growth. Clinicians have seen hair growth resume once the body reaches a plateau in weight loss, therefore the loss of hair is not permanent.9

          These drugs also share a boxed warning for risks of pancreatitis and medullary thyroid carcinoma (cancer in the thyroid gland in its medulla, the calcitonin-producing area), which is rare.6 Patients with a personal history of pancreatitis or a personal or family history of medullary thyroid carcinoma must avoid these drugs.6

          These drugs also required an FDA approved Medication Guide whenever GLP-1RAs are dispensed. Pharmacy technicians can be very helpful to pharmacists if they check the patient’s bag and make sure that the Medication Guide is in it.

           

          Recent Shortages of GLP-1 Receptor Agonists

           

          The sensation of weight loss success for some has caused serious problems for other patients who have diabetes and are struggling to find medication at local pharmacies. Staff in community-based pharmacy practice are well aware of the semaglutide shortages that have occurred in the past year. Pharmacists and technicians should be able to explain the current drug shortages, adverse reactions, and FDA approved or off-label use to patients and other healthcare providers.

           

          Ozempic face”

           

          As social media and now news media have reported the success of dramatic weight loss, some users bemoan weight loss woes associated with use of GLP-1 agonists. The term, “Ozempic face,” introduced by a dermatologist in New York, describes the typical female patient who has lost a significant amount of weight on semaglutide but now needs (or wants) dermal fillers for her sagging facial structures.10 Patients complain about sagging skin and a gaunt appearance, two problems that follow the loss of facial fat after any harsh weight loss.

           

          Facial fat loss is common when patients lose weight, and when the weight loss is significant, patients will look older. Skin wrinkles and loosens—hallmarks of aging. Similar to weight loss from old-fashioned dieting, fat loss while taking GLP-1 agonists affects the entire body (not just the face). But patients on GLP-1 agonists for cosmetic weight loss fail to understand that they can’t just lose weight where they’d like to lose weight. The facial fat loss is distressing to them.10 Pharmacy teams need to know that “Ozempic face” is a slang term, and GLP-1 agonists don’t specifically target the face.11

           

           

          Weight Loss Blockbuster or Fad

           

          Over the past two years, celebrities and social media influencers have posted successful weight loss stories while using semaglutide and as a result, catapulted its popularity as a weight loss miracle.12 Questions remain as to how long the weight loss effect will last and if patients will gain the weight back once stopping the treatment. Novo Nordisk, semaglutide’s manufacturer, indicates weight loss can be sustained with long-term use. However, the data collected is limited by a time span of two to three years. Since people who pay out-of-pocket for semaglutide will pay around $1200 per month and some insurance companies may not cover the medication, pharmacists should counsel patients that once the medication is discontinued, weight gain is likely to occur and the weight gain might exceed the original amount lost.12

           

           

          FDA APPROVED AND OFF-LABEL USE

          In December of 2017, the FDA approved semaglutide (Ozempic) for the treatment of diabetes. As significant weight loss was observed, the Semaglutide Treatment Effect in People with obesity (STEP) studies produced promising weight loss data.13 As a result, the FDA approved semaglutide for an additional indication, weight loss, in June 2021 under the brand name Wegovy.

           

           

          Diabetes

          In patients with type 2 diabetes mellitus (T2DM), semaglutide is used in combination with diet and exercise to reduce blood sugar levels.14 In patients with T2DM who additionally have established cardiovascular disease, liraglutide and semaglutide are indicated to help lessen the risk of major cardiovascular incidents. Dulaglutide, liraglutide, and semaglutide also have beneficial effects on chronic and diabetic kidney disease.6 Patients who have a history of pancreatitis should avoid any member of the GLP-1RA class and they are not to be used as treatment for patients who have type 1 diabetes.

           

          Dosing semaglutide for the treatment of diabetes requires a period of time for dosage escalation to minimize adverse effects. The FDA has approved both subcutaneous and oral semaglutide (Rybelsus) dosage forms, but only the injectable version is approved for weight loss. Subcutaneously, semaglutide is initially dosed at 0.25 mg once weekly, and after four weeks the patient should increase to 0.5 mg weekly for four weeks. Doses of 1 mg and 2 mg are optional if glycemic control has not been achieved, however the 1 mg dose should also be used for a minimum of four weeks before increasing to the maximum 2 mg strength.6 Dosed on the same day of the week, injections can be dosed at any time of the day with or without regard to meals. Patients sometimes miss or forget their scheduled dosing day. If this occurs, patients should inject the dose within 5 days of the missed dose.6

           

          Patients who have diabetes and currently use metformin, sulfonylureas, thiazolidinediones, or insulin can use semaglutide in combination.  However, patients can administer semaglutide and insulin injections at the same time and in the same areas of the body, but not close together; they must never mix them together in the same syringe.14 Hypoglycemic episodes are possible when using a sulfonylurea and/or insulin with semaglutide. Pharmacists therefore should remind patients of the signs and symptoms of hypoglycemia when these drugs are used together. Prescribers may need to adjust the dose of insulin and/or a sulfonylurea when starting semaglutide.6

           

          Obesity and Weight Management

          Affecting 70% of American adults, obesity and being overweight contribute to a variety of complications and have reduced quality of life.15 Debilitating and expensive disease states associated with obesity include: T2DM, cardiovascular disease, osteoarthritis, sleep apnea and cancer.13,15 Since obesity has roughly tripled worldwide from 1975 to 2016, investigating the reasons for the rise in prevalence and finding solutions is of utmost importance to prevent and treat obesity.16

           

          The access and ease of inexpensive prepared high caloric foods, limited physical activity, and sedentary life styles are factors that have contributed to the rise of obesity.17 As mentioned, treatment typically has concentrated around the modification of these lifestyle habits.18 Although the weight reduction is usually moderate in magnitude, it is recovered over time (yes, that means that people gain the weight back!).13

           

          Anti-obesity medications have been added to lifestyle modifications. Discouraged by adverse drug reactions, contraindications, cost, and moderate weight loss results with weight that is regained over time, many patients and prescribers are hesitant to consider these treatment options.16

           

          Maintaining weight loss has proved equally difficult due to the regulatory centers in the brain that control appetite. Increased hunger and abnormal satiety signals controlled by neuroendocrine pathways have been discovered in the hypothalamus.16 Researchers have also identified levels of hormones that regulate weight in the hypothalamus. These hormones (leptin, ghrelin, peptide YY, and GIP) play a role in counteracting weight loss after dieting and lead to regain of weight.17, 16

           

          Once semaglutide was approved for the treatment of diabetes, clinical trials focused on weight loss. The STEP trials were phase 3 studies implemented to evaluate the safety and efficacy of semaglutide 2.4 mg subcutaneously once weekly injections for 68 weeks. Patients enrolled in the studies were adults with obesity or overweight, a mean age of 46.2 to 55.3 years, mean BMI of 35.7 to 38.5 kg/m², and were mostly female (mean: 74.1% to 81.0%) for five of the trials.13All studies included lifestyle interventions at varied intensities.13, 18 In one of the larger studies that compared semaglutide with placebo, semaglutide was associated with a 12.4% loss of body weight.15As a result of the  ≥ 5% in weight loss exhibited in the studies, the FDA approved semaglutide for chronic weight management.18,15 The approval came in June of 2021, and the manufacturer marketed semaglutide as Wegovy.

           

          The STEP 8 trial compared once-weekly semaglutide to once-daily liraglutide and enrolled 338 adult patients with 126 receiving semaglutide 2.4 mg, and 127 participants receiving liraglutide 3 mg. Participants were overweight or obese, without diabetes, had a mean BMI of 37.5, and most had 0-2 comorbidities with dyslipidemia and hypertension being the most frequent.19, 18 The primary results at 68 weeks reported an estimated mean change in body weight at -15.8% with semaglutide, and -6.8% with liraglutide.19 Based on data from this STEP study, the researchers concluded semaglutide is far superior to liraglutide when used for weight loss and had significantly improved cardiometabolic risk factors.19, 18

           

          The most frequent adverse side effects reported in the STEP studies were gastrointestinal disorders. Most gastrointestinal side effects were considered mild or moderate in severity and usually were most prominent during the dose titration phase.19 In the STEP 8 study, semaglutide (84.1%) reported a higher occurrence of gastrointestinal events than liraglutide (82.7%).19  Other side effects reported were hypoglycemia, acute pancreatitis, gallbladder disorders that generally resulted in cholelithiasis (gall stones), malignant neoplasms (cancer), change in pulse and injection site reactions.18, 19

           

          SIDEBAR: Alcohol use disorder potential

          As patient use of semaglutide has expanded over the past several years, a side effect has emerged that is surprising many clinicians. Patients have reported an abrupt loss in the desire to drink alcohol, almost to the point of repulsion for some patients. GLP-1RAs are known to decrease the desire, enjoyment, and consumption of fatty foods in humans, but observations that patients began to decrease alcohol consumption was unexpected. Although studies to date have observed a reduction of alcohol in rats, mice, and monkeys when receiving GLP-1RAs, reliable researchers avoid extrapolating results from animal studies directly to humans, especially since humans tend to consume more alcohol than animals.20 Since several patients have reported decreased intake of alcohol and data from animal models reflect these results, researchers are starting to investigate GLP-1RAs effect on patients who have alcohol use disorder (AUD).

           

          Existing studies on GLP-1RAs effect on AUD in humans are minimal. A recent study published from Denmark compared the use of a different GLP-1RA, exenatide 2 mg versus placebo in patients with AUD. Researchers were looking to determine if exenatide reduced the amount of heavy drinking days. At the same time, functional MRI brain scans were also completed during the study that focused on areas involved in addiction and reward centers of the brain. Administered once weekly to 127 patients along with cognitive behavior therapy for 26 weeks, exenatide failed to show a decrease in heavy drinking days.21  However, in a subgroup of obese patients (BMI > 30 kg/m2) heavy drinking days and total alcohol intake was reduced.21 Brain scans revealed weakened alcohol cue reactivity and lower dopamine transporter availability for those patients in the exenatide group.21

           

          Ongoing phase two clinical trials are studying the effects of semaglutide on patients with AUD.22 Since semaglutide usage and availability have increased with approved indications for diabetes and obesity, researchers are continuing to investigate this drug class for potential promising new therapies.

           

          Product information

          When used for chronic weight management, semaglutide (Wegovy) is approved in addition to a reduced calorie diet and increased physical activity.7, 15 Semaglutide is indicated for patients who meet one of the following criteria: BMI of 30 kg/m² or greater, or patients who have a BMI of 27 kg/m² with at least one comorbid weight related condition (cancer, cardiac disease, diabetes, dyslipidemia, obstructive sleep apnea).7, 15 Available in a prefilled pen that contains one dose, semaglutide is a clear and colorless liquid that can be injected into the upper arm, lower stomach or upper thigh.7 Semaglutide should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C).7 If the pen has been frozen, exposed to light, or heat above 86°F (30°C), the pen should be discarded. The pen remains stable and active for 28 days once removed from refrigeration. Each pen contains the exact dose to be delivered with the needle located inside each pen, therefore each pen should be disposed of in a sharps container.7

           

           

          Drug shortages, alternatives for therapy

          Shortly after marketing Wegovy, the facility hired by Novo Nordisk to fill syringes was cited by the FDA for issues with current good manufacturing processes.23, 24 As a result, deliveries and manufacturing of Wegovy was halted in December of 2021.24 At the same time, staggering demand for the drug was reported by the manufacturer mainly due to news and social media platforms announcing the success of several celebrity weight loss stories. As a result of the Wegovy shortage, prescribers started to write for Ozempic off label in an effort to treat obesity and therefore depleted the supplies of Ozempic.24 At the end of 2022 and early 2023, Novo Nordisk announced that supply issue resolution for Wegovy was on the horizon and that production of the drug was being increased. Due to residual and increasing demand though, some supply issues might continue sporadically but over time distribution centers and pharmacies should receive more drug product in the months ahead.25

           

          CONCLUSION

          Probably the first drug to be considered a social media sensation, semaglutide’s entrance into the realm of prescription weight loss treatments has been filled with anticipation, fame, demand, intrigue, and acceptance. Lifestyle management will continue to play a role in losing and maintaining weight loss, with or without a GLP-1RA used in treatment for weight management. Long term use of semaglutide seems to be necessary to maintain a healthy weight but more research is necessary. Gastrointestinal side effects are seen as the most prevalent adverse effect, leading some patients to discontinue the drug. As availability of semaglutide increases due to resolution of the issues that halted production, price, and lack of coverage by insurance plans continues to be problematic for some patients. This is an area where pharmacy technicians can help by looking for coupons or patient assistance programs.

           

          Researchers continue to investigate the various effects seen as a result of usage of semaglutide. Investigators are hopeful of finding new treatments for patients that are struggling with alcohol use disorder and addictive behaviors. GLP-1RAs will continue to be in the headlines for years to come. Pharmacists and technicians hold the golden ticket of information by helping patients and providers understand this unique class of medication’s history, mechanism of action, dosing, side effects, storage requirements, pricing and potential treatments being investigated.

           

           

          Pharmacist Post Test (for viewing only)

          Pharmacist Post-test

          After completing this continuing education activity, technicians will be able to
          • Recall the mechanism of action and dosing schedule of GLP-1 receptor agonists
          • Classify adverse reactions most commonly associated with GLP-1 receptor agonists
          • Discuss FDA approved and off-label therapeutic uses of GLP-1 receptor agonists

          1. What are the GLP-1RAs’ common mechanisms of action in the treatment of diabetes?
          A. Stimulate central glucose receptors to secrete insulin, suppress the action of glucagon, and decrease gastric emptying
          B. Stimulate the pancreas to secrete insulin, suppress the action of glucagon, and decrease gastric emptying
          C. Suppress the pancreas so insulin secretion decreases, increase the action of glucagon, and speed gastric emptying

          2. Why do patients who take GLP-1RAs eat less?
          A. GLP-1RAs influence specific areas of the hypothalamus that are key to controlling appetite
          B. GLP-1RAs influence specific areas of the medulla that are key to controlling appetite
          C. GLP-1RAs influence specific areas of the GI tract that are key to controlling appetite

          3. Which of the following is a common adverse reaction associated with GLP-1RAs?
          A. Vasovagal reaction
          B. Blurred vision
          C. Gastrointestinal upset

          4. Joey is a 44 year-old-man who comes to the pharmacy and says that he is experiencing flatulence and burping ever since he started his GLP-1RA. Which of the following do you
          suggest as a way to mitigate this adverse effect?

          A. Reschedule the dose to take it right before bedtime
          B. Recommend a probiotic with Lactobacillus
          C. Avoid high fat foods and alcoholic beverages

          5. Which of the following GLP-1RAs are approved by the Food and Drug Administration for weight loss?
          A. Semaglutide and liraglutide
          B. Dulaglutide and semaglutide
          C. Only semaglutide

          6. Which of the following would be considered an off-label use of a GLP-1RA?
          A. Weight loss in patients with T2DM, used in combination with diet and exercise to reduce blood sugar levels
          B. Weight loss in patients who need to lose 10 pounds quickly to fit into Marilyn Monroe’s size 12 dress
          C. Weight loss in patients who have a BMI greater than 27 kg/m² with at least one weight-related comorbid condition

          Pharmacy Technician Post Test (for viewing only)

          Social Media Sensation: Semaglutide

          After completing this continuing education activity, technicians will be able to
          • Identify the different formulations of GLP-1 receptor agonists
          • Classify storage requirements for GLP-1 receptor agonists
          • Review GLP-1 receptor agonists indications for use

          1. Which of the following GLP-RA is injected once daily?
          A. Semaglutide, (Ozempic)
          B. Semaglutide, (Wegovy)
          C. Liraglutide, (Saxenda)

          2. A patient presents a prescription for Wegovy 0.5 mg. Checking the refrigerator, the place for Wegovy is empty. You notice Saxenda is in stock and you have Ozempic 0.5 mg and 1 mg in stock. What is your best response?
          A. We have Ozempic 1 mg pens in stock and I can have the pharmacist check and fill today
          B. We have Ozempic 0.5 mg in stock but we need a new prescription for Ozempic from your prescriber
          C. We have Saxenda in stock, we can have that ready later today

          3. Semaglutide should be discarded when exposed to which of the following conditions?
          A. Exposed to light or the pen was frozen
          B. Refrigeration between 36-46 °F
          C. Room temperature for up to 28 days

          4. Sharon calls the pharmacy and informs you that she has used her GLP-1RA pen this morning but wants to know how she should dispose of the pen. What is the correct response?
          A. At a drug take-back event
          B. In a sharps container
          C. In the trash

          5. Semaglutide is approved for weight loss in patients who have a BMI of what level?
          A. BMI between 27-30 kg/m² with two comorbid conditions
          B. BMI less than 25 kg/m² who has depression
          C. BMI greater than 30 kg/m² alone or 27 kg/m² with one comorbid condition

          6. Which of the following would be considered an off-label use of a GLP-1RA?
          A. Weight loss in patients with T2DM, used in combination with diet and exercise to reduce blood sugar levels
          B. Weight loss in patients who need to lose 10 pounds quickly to fit into Marilyn Monroe’s size 12 dress
          C. Weight loss in patients who have a BMI greater than 27 kg/m² with at least one weight-related comorbid condition

          References

          Full List of References

          REFERENCES

          1. Creutzfeldt, W. The [pre-] history of the incretin concept. Regulatory Peptides. 2005;128:87-91.
          2. Holst JJ, Gasbjerg LS, Rosenkilde MM. The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology. 2021;162(7). doi:10.1210/endocr/bqab065
          3. Exendin-4: From lizard to laboratory...and beyond. National Institute on Aging. July 11, 2012. Accessed April 3, 2023. https://www.nia.nih.gov/news/exendin-4-lizard-laboratory-and-beyond
          4. Nauck M, Quast D, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism. 2021; 46. https://doi.org/10.1016/j.molmet.2020.101102
          5. Blakeslee, S. A Protein Tells Eaters To Stop. The New York Times Jan 4, 1996 Section A, Page 1.
          6. OZEMPIC (semaglutide) injection, for subcutaneous use. Novo Nordisk. October 2022. Accessed March 22, 2023. https://www.ozempic.com/prescribing-information.html
          7. WEGOVY (semaglutide) injection, for subcutaneous use. Novo Nordisk. June 2021. Accessed March 22, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
          8. Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14-19. doi:10.1080/00325481.2021.2002616
          9. Sullivan K, Some people taking weight loss drugs say they're experiencing hair loss. April 22, 2023. Accessed April 27, 2023. https://www.nbcnews.com/health/health-news/weight-loss-drugs-and-hair-loss-rcna79798
          10. Johnson A. ‘Ozempic Face’ Explained: Why It Happens And How To Fix It. February 1, 2023. Accessed February 22, 2023. https://www.forbes.com/sites/ariannajohnson/2023/02/01/ozempic-face-explained-why-it-happens-and-how-to-fix-it/
          11. Speckhard Pasque L. Let’s stop using the term “Ozempic face.” February 10, 2023. Accessed March 22, 2023. https://mcpress.mayoclinic.org/women-health/lets-stop-using-the-term-ozempic-face/
          12. Constantino, A. People taking obesity drugs Ozempic and Wegovy gain weight once they stop medication. March 29, 2023.  Accessed April 3, 2023. https://www.cnbc.com/2023/03/29/people-taking-obesity-drugs-ozempic-and-wegovy-gain-weight-once-they-stop-medication.html
          13. Kushner R, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the step trials 1 to 5. Obesity. 2020; (6):1050-1061. doi: 10.1002/oby.22794
          14. Drug Trial Snapshot: Ozempic. US Food & Drug Administration. Published August 20, 2020. Accessed April 12, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-ozempic
          15. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. U.S. Food and Drug Administration. Published June 4, 2021. Accessed April 18, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
          16. Obesity and overweight. World Health Organization. Published June 9, 2021. Accessed April 18, 2023. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
          17. Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Advances in Therapy. 2021;38(6):2821-2839. doi:10.1007/s12325-021-01710-0
          18. Alabduljabbar K, Al-Najim W, le Roux CW. The impact once-weekly semaglutide 2.4 mg will have on clinical practice: a focus on the STEP trials. Nutrients. 2022;14(11):2217. Published 2022 May 26. Assessed April 20, 2023. doi:10.3390/nu14112217
          19. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA.2022;327(2):138–150. doi:10.1001/jama.2021.23619
          20. Blum D, Some people on Ozempic lose the desire to drink. Scientists are asking why. February 24, 2023. Accessed May1, 2023. https://www.nytimes.com/2023/02/24/well/eat/ozempic-side-effects-alcohol.html#:~:text=Side%20Effects%3A%20Diabetes%20treatments%20like,can%20also%20take%20a%20toll.
          21. Klausen MK, Jensen ME, Moller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022. 7(19). doi: 10.1172/jci.insight.159863.
          22. Hendershot C, Semaglutide for alcohol use disorder. NIH Clinical Trials.gov. Indentifier:NCT05520775
          23. Wegovy® supply update, investor conference call. Novo Nordisk. Dec 2021. Accessed: April 25, 2023. https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2021/conference-call-supply-update-20Dec2021.pdf
          24. Goodman B, As the market for new weight loss drugs soars, people with diabetes pay the price. December 28, 2022. Accessed April 25, 2023. https://www.cnn.com/2022/12/28/health/weight-loss-diabetes-drug-shortages/index.html
          25. Lovelace Jr B, Supply of weight loss drug Wegovy expected to improve in next few months, company says. February 1, 2023. Accessed April 25, 2023. https://www.nbcnews.com/health/health-news/supply-weight-loss-drug-wegovy-expected-improve-months-company-says-rcna68572

           

           

          The Gall of it All: Gallbladder Disease

          Learning Objectives

            After completing this application-based continuing education activity, pharmacists will be able to
          1. DESCRIBE the functions of the gallbladder and how it aids digestion
          2. RECOGNIZE gallbladder disease based on various presentations
          3. EXPLAIN gallstone prevalence, risk factors, and pathogenesis
          4. DISCUSS treatment approaches for gallbladder disease and post-cholecystectomy management
          After completing this application-based continuing education activity, pharmacy technicians will be able to:
          1. DESCRIBE the functions of the gallbladder and how it aids digestion
          2.EXPLAIN gallstone prevalence, risk factors, and pathogenesis
          3. LIST over-the-counter medications used by patients with gallbladder disease and post-cholecystectomy
          4. IDENTIFY when to refer patients with questions about gallbladder disease to a pharmacist

          Cartoon image of gallbladder filled with stones

          Release Date:

          Release Date:  June 15, 2023

          Expiration Date: June 15, 2026

          Course Fee

          FREE

          There is no funding for this CPE activity.

          ACPE UANs

          Pharmacist: 0009-0000-23-019-H01-P

          Pharmacy Technician: 0009-0000-23-019-H01-T

          Session Codes

          Pharmacist:  23YC19-ABC92

          Pharmacy Technician:  23YC19-BCA36

          Accreditation Hours

          2.0 hours of CE

          Accreditation Statements

          The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-019-H01-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

           

          Disclosure of Discussions of Off-label and Investigational Drug Use

          The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

          Faculty

          Sara L. Tolliday, PharmD
          Pharmacy Team Lead
          Wentworth-Douglass Hospital
          Outpatient Pharmacy
          Dover, NH


           

          Faculty Disclosure

          In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

          Dr. Tolliday has no financial relationships with ineligible companies.

          ABSTRACT

          The gallbladder—a member of the biliary system—is responsible for bile secretion into the digestive tract. It was more useful centuries ago when the human diet was allegedly carnivorous and high in fat, its role in digestion today is less essential. This makes removal of the organ to treat gallbladder disease (GBD) quite commonplace. Although surgery is first line GBD treatment, pharmacy teams should remain involved in care for patients with this condition. Pharmacy involvement is especially important post-gallbladder removal. This continuing education activity describes the function of the gallbladder, risk factors for and pathogenesis of GBD, treatment approaches for GBD, and how to optimize care for patients with the disease and post-gallbladder removal.

          CONTENT

          Content

          INTRODUCTION

          Gallbladder disease (GBD; see Sidebar: Types of Gallbladder Disease) is the most common surgical emergency, responsible for 600,000 surgeries per year in the United States.1 Cholelithiasis, or gallstones, is one of the most common and costly gastrointestinal diseases, affecting more than 20 million Americans annually.2 An estimated 115 of every 100,000 of the world’s population will undergo gallbladder removal surgery every year.3

          GBD is influenced by genetic and environmental factors, diet, physical activity, and nutrition. The healthcare team should encourage patients to incorporate healthy habits into their lifestyles to reduce the risk of GBD. This continuing education activity will discuss GBD pathology, risk factors, treatment, considerations post-cholecystectomy, and the pharmacy team’s role.

           

          GALLBLADDER DISEASE

          The Gallbladder

          The gallbladder is the small pear-shaped organ located in the right upper quadrant (RUQ) of the abdomen beneath the liver. It is part of the biliary system, which is a series of ducts in the liver, gallbladder, and pancreas that drain into the small intestine.4 The gallbladder acts as a storage pouch for up to 50 mL of bile, also known as “gall.”5 Gall became a synonym for bile in the Middle Ages and also meant “embittered spirit.”5 In the late 19th century, gall was used to describe a person having boldness or insolence.4

          Bile is a yellowish-brown alkaline surfactant (substance that decreases surface tension) continuously produced by the liver.1,2 It is composed of cholesterol, bilirubin, water, bile salts, phospholipids, and ions. The common bile duct carries bile from the liver to the gallbladder. Fatty foods and proteins released from the stomach into the small intestine stimulate the gallbladder to empty bile into the duodenum via the sphincter of Oddi, which facilitates digestion. Bile salts emulsify lipids in the intestines allowing absorption of dietary fats such as cholesterol and fat-soluble vitamins. Unused bile salts return to the gallbladder through the distal ileum and portal circulation.1,2

          The gallbladder was probably more valuable centuries ago.5 Some scientists believe that primitive humans were carnivorous hunters; meals were large, few, and far between.5 The gallbladder would have been crucial for digestion of large, high fat meals. The organ wasn’t considered nonessential until the late 1600s, after two Italian doctors discovered that animals could thrive without it.1 This discovery was forgotten until a German physician successfully performed the first cholecystectomy (surgical removal of the gallbladder) in a human in 1878.1,6 Figure 1 describes a brief history of the gallbladder, gallstones, and cholecystectomy beginning in the 15th century.

          Today, the gallbladder assists in digestion of fat-soluble vitamins, proving important even for vegetarians.5 People can still live a healthy life after gallbladder removal; however, the risk of hepatic problems increases due to impaired fat digestion.5

           

          Timeline of gall bladder surgical history from the 1400's to 1992

          Sidebar: Types of Gallbladder Disease2,8

          • Biliary dyskinesia: gallbladder motility disorder caused by scarring or spasm of sphincter of Oddi, the valve that controls the flow of biliary and pancreatic secretions into the duodenum
          • Cholangitis: inflammation of the biliary system
          • Cholecystitis: inflammation of the gallbladder
          • Choledocholithiasis: common bile duct stones
          • Cholelithiasis: gallstones
          • Gallbladder empyma: severe acute cholecystitis, a surgical emergency
          • Gallbladder pancreatitis: inflammation of the pancreas caused by pancreatic duct obstruction by a gallstone
          • Gallbladder perforation: a hole in the gallbladder wall
            • Acute: generalized biliary peritonitis
            • Subacute: acute plus pericholecystic abscess
            • Chronic: cholecystoenteric fistula
          • Gallbladder polyps: overgrowths or lesions in the gallbladder wall

          This continuing education activity will focus on gallstones and their complications, which may include cholecystitis, choledocholithiasis, and cholangitis. Cholecystectomy (gallbladder removal) is the treatment mainstay for gallstones and pharmacist intervention is most valuable post-cholecystectomy.

           

          Gallstones and Acute Cholecystitis

          The most common gallbladder disease is gallstones.7 Gallstones commonly form from imbalances in bile constituents and biliary sludge (solids precipitated from bile) caused by slowed gallbladder motility or altered hepatic cholesterol metabolism. Hardened cholesterol or bilirubin become saturated in bile and crystalize, like rock candy, and can lodge in the common bile duct.7 Gallbladder hypomotility leads to delayed emptying, resulting in the formation of biliary sludge and consequently, gallstones.7

          Bilirubin is a substance found in bile resulting from red blood cell breakdown in the liver. It is normally eliminated through the feces. Gallstones caused by bilirubin, or “pigment stones”, are rare and only account for approximately 10% of all gallstones.8 Pigment stones are commonly seen in individuals with blood disorders, such as sickle-cell anemia.8 Approximately 75% of gallstones in Western countries contain cholesterol as their major component.9

          The presence of stones in the gallbladder is called cholelithiasis. Most patients with gallstones are asymptomatic and may not have any attributable symptoms during their lifetime.8 Asymptomatic cholelithiasis does not require treatment as the risk of symptom development is only about 10% at five years.8

          Cholelithiasis becomes acute cholecystitis when gallstones block the cystic duct, causing the gallbladder to become inflamed and patients to become symptomatic. Biliary pain—also known as biliary colic—is the most common symptom of cholecystitis. Epigastric (upper-middle abdomen) pain lasting from 30 minutes to several hours radiates around or through the back and may be accompanied by heartburn, bloating, nausea, and/or vomiting. The sharp, stabbing pain generally follows food intake and peaks after the first hour. It is characteristically steady and is severe enough to interfere with activities of daily living. The pain is not relieved with a bowel movement. Women often describe biliary pain as being worse than childbirth.2,8

          Cholecystitis pain from an acute episode usually subsides over one to five hours as the stone dislodges.3,10 The likelihood that patients experience repeated symptomatic episodes from their gallstones is approximately 38% to 50% annually.8 More than 90% of patients presenting with a single episode of biliary colic have recurrent pain within 10 years.13

          Ultrasound is the best test for diagnosing gallstones and finds most patients with an average of two to 20 stones. The record-setting number of stones was found in England in 1987; a female patient had 23,530 stones removed.5 Computerized tomography (CT) can also be used for diagnosis, but it is less accurate than other imaging methods, detecting approximately 75% of gallstones.2 Providers can also diagnose by the presence of Murphy’s sign, or pain upon inhalation when the inflamed gallbladder meets the examiner’s hand.8 Other diagnostic markers include elevated liver function tests, white cell count, erythrocyte sedimentation rate, and C-reactive protein.8 Patients presenting with acute cholecystitis may have experienced several bouts of biliary colic before diagnosis.

          Acute cholecystitis diagnosis typically requires admission for pain management and intravenous (IV) fluid rehydration. Nonsteroidal anti-inflammatory drugs (NSAIDS) like ketorolac, diclofenac or indomethacin combat inflammation and promote speedy recovery.8 NSAIDS are generally preferred to narcotic analgesics as they are equally effective with fewer adverse effects.2 A study of 324 patients given IV ketorolac or meperidine showed both drugs offered similar pain relief but patients in the NSAID group reported fewer adverse effects.2 Patients receive broad-spectrum antibiotics (e.g., ciprofloxacin, cefuroxime) to prevent or treat bacterial infection.8

          Failure to properly treat cholecystitis can lead to severe inflammation, gangrene, sepsis, and life-threatening gallbladder perforation. Cholecystitis can also lead to gallstone pancreatitis if stones in the sphincter of Oddi are not cleared and block the pancreatic duct.2

          Chronic Cholecystitis

          Repeated episodes of cholecystitis or chronic irritation from gallstones can lead to chronic cholecystitis.11 Chronic cholecystitis more often presents with cholelithiasis (calculous) but can also exist without gallstones (acalculous). Symptomatic patients usually present with dull RUQ pain that radiates around the waist to the middle back. Most patients are afebrile.11

          While acute cholecystitis symptoms are sharp and abrupt, chronic cholecystitis symptoms usually develop and worsen over weeks to months.11 Lab values normally elevated in acute disease may not be in chronic disease and therefore cannot be used in diagnosis. Ultrasound of the RUQ is the best diagnostic tool to evaluate the gallbladder for wall thickening and inflammation. Elective cholecystectomy is the preferred treatment for chronic cholecystitis. Patients who are not eligible for or who prefer not to undergo surgery should be closely monitored. A low-fat diet and other lifestyle modifications can help reduce symptom frequency.11

          Pharmacists should recognize the differences between presentations of acute versus chronic cholecystitis and refer patients to the nearest emergency department if symptoms are severe.

          Choledocholithiasis and Cholangitis

          Choledocholithiasis, or common duct stones, are gallstones that have migrated from the gallbladder to the common bile duct via the cystic duct. Approximately 8% to 16% of patients with symptomatic gallstones will also have common bile duct stones.8 Common duct stones can be asymptomatic or may lead to complications such as gallstone pancreatitis or acute cholangitis. Cholangitis is inflammation of the biliary system that causes fever, jaundice, and abdominal pain (Charcot triad).8 Charcot triad becomes Reynolds pentad when hypotension and altered mental state are also present.8 These symptoms develop due to bile stasis and bacterial infection in the biliary tract.

          Cholangitis is most commonly caused by gram-negative (Escherichia coli [25% to 50%], Klebsiella spp. [15% to 20%], Enterobacter spp. [5% to 10%]) intestinal bacteria, and less often by gram-positive bacteria (Enterococcus spp. [10% to 20%]).8 Patients require prompt treatment with IV antibiotics such as a broad-spectrum cephalosporin or ciprofloxacin.8 Pharmaceutical intervention should be followed by stone removal to prevent septicemia (systemic blood infection), which can be fatal.  Most clinicians recommend that common bile duct stones be removed once discovered, even when asymptomatic.8

          Risk Factors

          Several genetic and environmental factors contribute to gallstone development. Patients with first-degree relatives with history of cholelithiasis are at a three times higher risk of gallstones.8 Approximately 60% of patients with acute cholecystitis are female, but the illness is generally more severe in males.2 Women experience a higher prevalence because of estrogen’s effects on cholesterol metabolism.12 Estrogen increases cholesterol synthesis and decreases bile acid production.12 Progesterone in pregnancy decreases gallbladder contractility leading to stasis, making gallstones 10 to 15 times more common in women who have been pregnant.8,12 Women with history of biliary colic, gallstones, and the like should be aware of how hormones may affect their risk for recurrence. This is valuable information for pharmacists to consider and an appropriate place to intervene and educate.

          European and American populations are more likely to develop gallstones, and Black people of African descent are least likely. Prevalence is highest in Native American populations, with 60% incidence in the Pima Indian populace of southern Arizona.8 Table 1 summarizes risk factors for GBD.2,8,13

           

          Table 1. Risk Factors for Developing Gallbladder Disease2,8,14-16
          Demographics

          ·       Ethnicity (American Indians, Chilean and Mexican Hispanics)

          ·       Family history

          ·       Female gender (10:1 female:male)

          ·       Older age

           

          Diet

          ·       High fat, calorie, and refined carbohydrate intake

          ·       Low fiber and unsaturated fat intake

          ·       Total parenteral nutrition

           

          Lifestyle

          ·       Pregnancy and multiple pregnancies

          ·       Persistent fasting or very low-calorie diet

          ·       Rapid weight loss (i.e., bariatric surgery)

          ·       Sedentary

           

          Medications

          ·       Estrogen therapy or oral contraceptives

          ·       Some hypoglycemic medications (GLP-1RAs)

          ·       Chronic use of gastric acid suppressants (H2RAs, PPIs)

          ·       Ketamine abuse

           

          Heath Conditions & Other Factors

          ·       Alcoholic liver cirrhosis

          ·       Dyslipidemia (elevated triglycerides and low HDL)

          ·       Gallbladder motor dysfunction

          ·       Gastrointestinal surgery

          ·       Metabolic syndrome, gallbladder, or intestinal stasis

          ·       Short bowel syndrome

          ·       Type 2 diabetes mellitus

           

          GLP-1RAs, glucagon-like peptide 1 receptor agonists; H2RAs, histamine-2-receptor antagonists; HDL, high-density lipoprotein; PPIs, proton-pump inhibitors.

           

          Glucagon-like peptide 1 (GLP1) receptor agonists (GLP-1RAs) are notable for their glucose control and cardiovascular risk reduction for patients with type 2 diabetes mellitus and more recently, for weight loss. Their link to GBD is controversial as GLP1 inhibits gallbladder motility and delays gallbladder emptying.14 A recent systematic review and meta-analysis of 76 randomized clinical trials shows an association between GLP-1RA use and elevated GBD risk. The risk for gallbladder or biliary diseases were more prominent with higher doses, longer duration, and when used for weight loss.14 Clinicians should discuss the benefits of using these hypoglycemics for type 2 diabetes or weight loss and whether they outweigh the risk for GBD. Pharmacists can educate patients initiating GLP-1RAs about their benefits, risks, and implications with past medical history of or additional risk factors for GBD. Multiple GLP-1RAs are available in varying doses and pharmacists should continue to counsel patients as doses are increased over time.

          Chronic use of gastric acid suppressants may cause cholelithiasis.15 These drugs impact gut microbiome and may slow gallbladder motility leading to delayed gallbladder emptying. A recent prospective cohort of 0.47 million participants found that regular use of proton-pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) resulted in increased cholelithiasis risk.15 Physicians should be aware of this association when prescribing these medications, especially for patients requiring long-term use or those already at high risk for gallstones. Pharmacists should keep these risks in mind when filling prescriptions for their patients on long-term or high-dose H2RAs and PPIs.

          Ketamine abuse has been associated with chronic biliary colic. Ketamine was developed in 1962 as an anesthetic.16 “Street ketamine”, a close analogue of ketamine, is commonly used for its euphoric effects. Ketamine’s onset of action after oral ingestion is about ten minutes and its hallucinogenic effects are short acting, lasting up to two hours. The most common signs of ketamine abuse are hypertension, tachycardia, and abdominal tenderness. Ketamine abuse is also associated with impaired consciousness, dizziness, abdominal pain, and lower urinary tract symptoms.16 Case reports have shown ketamine abusers presenting with severe bladder dysfunction and recurrent episodes of epigastric pain due to a dilated common bile duct not associated with gallstones.16 Clinicians should collect detailed drug histories for patients presenting with recurrent abdominal pain, namely biliary colic.

          Diets characterized by increased caloric intake with highly refined sugars, high fructose, low fiber, high fat, and consumption of fast food increase the risk of gallstone formation.9 Nutrition and lifestyle changes may be beneficial in the prevention of gallstones. Increased physical activity, consuming smaller more frequent meals, and “heart healthy” diets low in cholesterol and fat and high in fiber can reduce risk of cholelithiasis.7 Fat should not be completely cut out of the diet as too little fat can also precipitate gallstone formation.

          Weight loss can reduce gallstone risk, but rapid weight loss achieved by low-calorie diets (less than 800 kcal/day) or bariatric surgery can cause gallstones.2,9 Patients should seek professional advice before starting diets promoting very low caloric or high fat intake to achieve rapid weight loss (i.e., Atkins, ketogenic). Pharmacists should be aware of patients who have recently undergone bariatric surgery or are taking drugs or supplements for weight loss. These patients may be at a higher risk for gallstones, especially those with past medical histories of GBD or abdominal colic symptoms.

          Some foods and medications seem to be associated with a reduced risk of gallstones:

          • Statins alter bile cholesterol and thus affect gallstone formation, suggesting a role in prevention. While the relationship between statins and gallstone formation is conflicting, studies report reduction in symptomatic gallstone disease with statin use.17
          • Ezetimibe, a selective NPC1L1 inhibitor, has been associated with a reduced incidence of cholesterol gallstones in animal studies. The mechanism involves reduced amounts of absorbed cholesterol, decreasing biliary cholesterol saturation, and in turn, reduced rate of cholesterol gallstone formation.12
          • Vitamin C supplementation has been shown to reduce gallstone prevalence. Researchers have studied vitamin C supplementation’s effects in gallstone formation in guinea pigs; those deficient in vitamin C more often develop gallstones. An observational study of a randomly selected population in Germany (n = 2129) showed a positive correlation between regular vitamin C intake and a reduced gallstone incidence.18
          • Coffee consumption may also offer a protective effect against gallstone formation. Studies suggest coffee stimulates cholecystokinin release, enhancing gallbladder contractility, thereby reducing bile cholesterol crystallization. A 2019 observational analysis published in the Journal of Internal Medicine found a 23% decrease in gallstone formation in subjects consuming six or more cups of coffee daily.19
          • A small study conducted in Spain shows that regular consumption of olive oil containing monounsaturated and polyunsaturated omega-6 fatty acids may prevent gallstones. Similarly, fish (omega-3 fatty acids) and fish oil may reduce triglycerides and prevent gallstones. A group of participants with hypertriglyceridemia taking fish oil supplements for a seven-week study in the Netherlands experienced improved gallbladder motility and a decrease in triglycerides.10

          TREATING GALLBLADDER DISEASE

          Endoscopic retrograde cholangiopancreatography (ERCP) is the most common way to identify and remove common duct stones. ERCP is minimally invasive and carries the risk of acute pancreatitis.8 This diagnostic tool may also identify duct strictures at which time stents are placed to reduce obstruction and improve biliary flow.8,10 Timely stent removal (within three to six months) is crucial to prevent occlusion, stent migration, or cholangitis.22 Cholecystectomy is the definitive treatment for symptomatic gallstones and should commence within 48 hours of symptom onset during the acute inflammatory process, before tissue thickening or scarring develops.8,10

          Surgical Intervention: Cholecystectomy

          The first gallstone removal surgery was a coincidence. In the mid-19th century, a physician was performing investigative surgery on a female patient, and when he cut into her gallbladder, several bullet-like objects spilled out.5 The first planned gallbladder removal was performed 15 years later.5 Before the early 1900s, the surgery was performed through an incision in the RUQ (Kocher’s incision, named after Emil Theodor Kocher, a Swiss physician and medical researcher who performed the first successful cholecystectomy in 1878).6,8 This invasive procedure was outmoded a few years after Erich Muhe, a German surgeon, performed the first laparoscopic cholecystectomy in 1985.8 Today, surgeons perform more than 98% of cholecystectomies laparoscopically, over 70% of which are outpatient day surgeries.8

          Cholecystectomy is associated with fewer gallbladder-specific complications and shorter length of hospital stay when surgery is elective or performed as a single emergency visit without previous surgical admissions.3 A population-based cohort study of outcomes following surgery for benign GBD showed poorer outcomes and risk of readmissions with delayed cholecystectomy. Many studies define emergency or early surgical intervention as operations performed within 48 to 72 hours of symptom onset. A study of 14,200 patients in Canada discovered patients experienced fewer complications when surgery was performed within seven days of hospital admission.3 These studies show value in offering emergency surgery over delaying cholecystectomy for patients presenting with benign GBD.3

          Antibiotic prophylaxis is not routinely recommended for low-risk patients undergoing elective laparoscopic cholecystectomy.13 High-risk patients (age older than 60, type 2 diabetes, acute colic within 30 days of surgery, jaundice, acute cholecystitis, or cholangitis) may benefit. Providers should limit prophylaxis to IV cefazolin 1 g as a single dose one hour prior to surgery.13

          Several studies suggest that pain management before or during, and after laparoscopic cholecystectomy can reduce post-operative pain. A 2018 review of 258 randomized control trials recommended a basic analgesia technique: acetaminophen plus an NSAID or cyclooxygenase-2 inhibitor with local anesthetic infiltration.21 Opioids are reserved for breakthrough pain.21

          Patients are generally discharged a few hours after surgery. Surgeons should be on alert for early signs of complications if there is divergence from the usual course of rapid recovery post-op. Extreme pain shortly after surgery may indicate intra-peritoneal leakage of bile or bowel contents.8 Persistent hypotension (low blood pressure) and pain can suggest bleeding. Re-laparoscopy may be necessary to identify and repair these problems and is preferred to diagnostic imaging.8

          Removal of the gallbladder will not cause weight loss/gain or vitamin deficiencies. Patients should be able to tolerate foods they couldn’t before surgery, but providers should advise them to add those foods back into their diet very slowly. Following gallbladder removal, the liver will continue to make bile, but instead of storing it in the gallbladder, it will drain into the stomach and small intestines. Patients might experience three to five days of soreness post-op and are expected to fully heal within four to six weeks.7

          Diarrhea and bloating due to alternation of biliary flow are common short-term occurrences after surgery.22 A small percentage (1% to 2%) of patients will have loose stools each time they eat greasy or high-fat meals.7 A cystic duct remnant is also possible, potentially leading to stone formation, causing Mirizzi syndrome. Mirizzi syndrome is characterized by fever, jaundice, and RUQ pain due to common hepatic duct obstruction caused by compression from the impacted stone in the remnant cystic duct.22 Endoscopic removal of the stone may be adequate. In rarer cases, surgical excision of the remnant duct may be necessary to prevent further complications.22

          Pharmacologic and Other Non-Surgical Interventions

          Nonoperative methods exist for patients unwilling or unable to undergo surgical intervention. Contraindications for laparoscopic cholecystectomy include10,13

          • Absolute: gallbladder cancer (see Sidebar: Gallbladder Cancer), general anesthesia intolerance, giant gallstones, morbid obesity, uncontrolled bleeding disorder
          • Relative: advanced cirrhosis/liver failure, bleeding disorder, peritonitis, previous upper abdominal surgeries, septic shock

          Gallbladder Cancer20

          Gallbladder cancer is a rare malignancy but accounts for almost 50% of biliary cancers. Biliary cancers have a poor five-year survival rate and a high recurrence rate. Factors affecting prognosis are stage at discovery, tumor location, operability, response to chemotherapy, and presence and location of metastases. Early-stage gallbladder cancer may be curable with surgical resection.

           

          Oral bile acid dissolution drugs include ursodeoxycholic acid (ursodiol) and chenodeoxycholic acid (chenodiol).23 Table 2 lists dosing and adverse effects of these medications. Smaller gallstones (0.5 to 1 cm) may be better suited for pharmaceutical intervention but may take up to 24 months to dissolve.2 Ursodiol is preferred over chenodiol due to its safer adverse effect profile. Use-limiting adverse effects of chenodiol include dose-dependent diarrhea, hypercholesterolemia, hepatotoxicity, and leukopenia.2 Recurrence rate is more than 50% and fewer than 10% of patients with symptomatic gallstones are candidates for this treatment.13

           

          Table 2. Oral Bile Acids2,23,24

          Drug Dosage Duration Adverse Effects
          Ursodiol

          (Actigall)

          8-10 mg/kg/day given in 2-3 divided doses Symptom relief after 3-6 weeks, results may take 6-24 months, continue for 3 months after documented dissolution Dyspepsia (>10%), nausea, vomiting, pruritis, headache, diarrhea, dizziness, constipation
          Chenodiol (Chenodal) 250 mg twice daily for 2 weeks, increase dose by 250 mg/day weekly until maximum tolerable dose reached (13-16 mg/kg/day in 2 divided doses) Discontinue if no response by 18 months, safety not established beyond 24 months Dose-dependent diarrhea* (>10%), hypercholesterolemia, leukopenia, increased serum aminotransferase

          * If diarrhea occurs, reduce dose and restart at previous dose when symptoms resolve.

           

          Extracorporeal shock wave lithotripsy is a noninvasive option for symptomatic patients.13 Complications such as biliary pancreatitis and liver hematoma are rare, however stone recurrence is common. Recent studies show this procedure is beneficial for large pancreatic and common bile duct stones with similar pain relief and duct clearance outcomes compared to surgery.13

          The initial approach for pregnant women with symptomatic gallstones is supportive care.13 Meperidine is the choice agent for pain control as NSAIDs are not recommended in pregnancy.13 Chenodiol is contraindicated in pregnancy.24 Ursodiol has been used in pregnant patients for intrahepatic cholestasis; safety and efficacy of use for gallstones has not been studied.13,23 Laparoscopic cholecystectomy, when indicated, is safe in all trimesters.13

          POST-OPERATIVE CONSIDERATIONS AND THE PHARMACY TEAM

          Post-Cholecystectomy Syndrome

          Persistent or delayed onset abdominal pain after laparoscopic cholecystectomy may indicate post-cholecystectomy syndrome (PCS).22 Additional PCS symptoms include fatty food intolerance, nausea, vomiting, diarrhea, heartburn, indigestion, flatulence, and jaundice. PCS often occurs in the post-operative period but can present months or years after surgery.22 Cholecystectomy carries a low mortality risk, but approximately 10% of patients undergoing cholecystectomy each year develop PCS.22 The risk increases with urgent surgeries and 20% of patients will develop PCS regardless of choledochotomy (surgical incision of common bile duct).22

          PCS etiologies can be extra-biliary (pancreatitis, pancreatic tumors, hepatitis, esophageal diseases, mesenteric ischemia, diverticulitis, peptic ulcer disease) or biliary (bile salt induced diarrhea, retained calculi, bile leak, biliary strictures, stenosis, sphincter dyskinesia) in nature.22 Pathophysiology is related to alterations in bile flow and bile is the main trigger for patients with gastroduodenal symptoms or diarrhea.

          The likelihood of diarrhea post-cholecystectomy ranges from 2% to 50% according to various studies.25 Diarrhea usually improves or resolves over the course of weeks to months. As discussed, in the gallbladder’s absence, bile flows straight from the liver into the small intestine continuously. This redirection of bile flow can overwhelm the ileum’s capacity for reabsorption, leading to increased bile acids in the colon and subsequently cholerheic diarrhea (also known as bile acid diarrhea).25 Patients may respond to treatment with bile acid sequestrants, including cholestyramine and colestipol.25

          Bile acid sequestrants release chloride and bind bile acid in the intestines, preventing bile acid reabsorption. The drugs do not leave the gastrointestinal tract and are eliminated in the feces. They are indicated for hypercholesterolemia but patients use them off-label for chronic diarrhea due to malabsorption (Table 3). The most common adverse effect of bile acid sequestrants is constipation, which occurs in more than 10% of patients.26,27 Clinicians should instruct patients to drink plenty of fluid and increase dietary fiber. Most adverse effects are gastrointestinal-related (e.g., abdominal pain, flatulence, bloating, anorexia, nausea, vomiting, dysphagia), and others include26,27

          • Cholestasis and cholecystitis (with colestipol only)
          • Dental bleeding and caries
          • Diuresis, dysuria, and burnt odor to urine
          • Edema
          • Worsened hemorrhoids

          Bile acid sequestrants bind vitamin K and folate so prescribers should monitor for deficiencies of both. Patients should supplement with folate. Patients may supplement with vitamin K; however preexisting coagulopathy is a contraindication. These drugs should be used with caution in patients with renal insufficiency.26,27

           

          Table 3. Bile Acid Sequestrants26,27

          Drug Dosage Administration
          Cholestyramine

          (Prevalite, Questran)

          2-4 g daily as a single dose or divided, increase by 4 g weekly based on response and tolerability, maximum 24 g/day Mix dose in 60-180 mL of any beverage, soup, or pulpy fruit, should not be sipped or held in mouth for long periods*

           

          Take with meals, administer oral medications ≥1 hour before or 4-6 hours after dose

          Colestipol (Colestid) Granules: 5 g once or twice daily, increase by 5 g in 1-2 month intervals, maintenance dose 5-30 g once daily or in divided doses

           

          Tablets: 2 g once or twice daily, increase by 2 g in 1-2 month intervals, maintenance dose 2-16 g once daily or in divided doses

          Administer other medications ≥1 hour before or 4 hours after dose

           

          Granules: do not administer in dry form to avoid GI distress or accidental inhalation, should be added to at least 90 mL of any beverage, soup, or pulpy fruit

           

          Tablets: administer one at a time; swallow whole; do not cut, crush, or chew

          *May cause tooth discoloration or enamel decay. GI, gastrointestinal.

           

          PCS is a temporary diagnosis until further investigation establishes organic or functional diagnosis.22 Misdiagnosis of preexisting conditions is possible. The healthcare team should order a complete blood count and consider patients re-presenting with ongoing or new-onset abdominal pain post-cholecystectomy for CT scan.8 Presence of gas and fluid in the gallbladder bed may be normal but fluid or gas build-up elsewhere may indicate a bile leak. Elevated liver function tests may also suggest a bile leak or retained common bile duct stone. The most common cause of PCS is the presence of stones in the biliary tree.10 ERCP, both diagnostic and therapeutic, is the most common procedural approach to PCS.22

          Medication: Treatment Goals

          Pharmacologic treatment goals in GBD are to prevent complications and reduce morbidity.22 Administration of bulking agents like psyllium fiber can help patients with symptoms of irritable bowel syndrome (IBS) and/or diarrhea. Psyllium husk (Metamucil, Benefiber) is an over-the-counter (OTC) option for patients looking to increase fiber intake. It is usually used to treat constipation and works by stimulating intestinal contractility, speeding up the movement of stool through the colon.28 Psyllium can also treat diarrhea by soaking up excess water from the intestines, bulking stool, and promoting regularity.28 Psyllium may reduce absorption and effectiveness of many medications; it is important that patients seek pharmacist counseling before initiating a psyllium fiber regimen.

          Antispasmodics (e.g., loperamide) may help patients with IBS symptoms like cramping. Cholestyramine may help symptoms of diarrhea alone. Antacids (Maalox, Mylanta, Tums), H2RAs (e.g., famotidine), and PPIs (e.g., esomeprazole, lansoprazole, omeprazole) can improve gastritis or gastric reflux symptoms by reducing acid production.22 One study showed a correlation between dyspeptic symptoms and gastric bile salt; these patients may benefit from bile acid sequestrants.22 Patients should consult their gastroenterologist for recommended dosing of these drugs, as they may vary depending on clinical presentation and severity of symptoms.

          The Pharmacy Team’s Role

          Pharmacists and pharmacy technicians are integral members of the healthcare team. Pharmacists can educate patients about GBDs, the risk factors for their development, and how to mitigate them with a proper diet and exercise.

          Pharmacy technicians can help by directing patients in the right direction when looking for OTC antacids, fiber supplements, or anti-diarrheal agents. Many patients may not ask questions about OTC products before purchase. Pharmacy technicians are often the patients’ first point of contact in the pharmacy and should ask open-ended questions at the register before or during the transaction.

          Patients should use the products as directed by their gastroenterologists. Pharmacy technicians should refer patient questions relating to administration, dosing, adverse effects, and drug interactions to the pharmacist on duty. Consider possible scenarios that may arise in the pharmacy and how pharmacy technicians and pharmacists should approach them:

          • Mark is a pharmacy technician at XYZ Pharmacy. Jaclyn enters the pharmacy, approaches the pick-up window, and places several OTC items on the counter. She states she would like to pick up a prescription her doctor called in today. Mark retrieves Jaclyn’s prescription and notices it is for omeprazole 40mg. The items on the counter include Tums, famotidine 20mg, docusate sodium 100mg, and lansoprazole 30mg. Mark knows that omeprazole and lansoprazole are in the same drug class. What questions can Mark ask Jaclyn? Should Mark involve the pharmacist?
          • Jaclyn comes back to the pharmacy a week later to pick up a prescription for cholestyramine. She wants to know if she can take this with omeprazole and famotidine. Mark refers Jaclyn’s question to the pharmacist. How should the pharmacist respond to Jaclyn’s question and what counseling points are important to include?

          CONCLUSION

          Gallbladder diseases typically occur secondary to cholelithiasis. Most gallstone cases are asymptomatic, but some develop into symptomatic disease. Factors that may increase GBD risk include gender, age, family history, ethnicity, diet, and medical conditions. Surgical gallbladder removal is the most common treatment, but many nonsurgical alternatives exist when surgery is nonpreferred or contraindicated. Additionally, PCS can occur months to years after surgery and treatment should be directed based on specific diagnosis post-examination. Healthcare providers should collaborate to develop the best procedural and/or pharmaceutical treatment plan as each patient’s clinical presentation and symptoms will vary.

          The pharmacy team should take an active role in GBD management, especially following cholecystectomy. Pharmacy technicians should be wary when patients complain of abdominal pain or attempt to purchase multiple OTC products to treat their symptoms; they should relay specific disease- and drug-related questions to the pharmacist on duty. GBD is a common and highly manageable condition, and patients can live normal and healthy lives once symptoms are properly controlled and treated.

           

           

          Pharmacist Post Test (for viewing only)

          After completing this continuing education activity, pharmacists will be able to
          • DESCRIBE the functions of the gallbladder and how it aids digestion
          • RECOGNIZE gallbladder disease based on various presentations
          • EXPLAIN gallstone prevalence, risk factors, and pathogenesis
          • DISCUSS treatment approaches for gallbladder disease and post-cholecystectomy management

          1. How do gallstones form?
          A. Fat soluble vitamin deficiency
          B. Gallbladder hypermotility
          C. Imbalances in bile components

          2. Which of the following are risk factors for GBD?
          A. Female gender; high fat, high calorie, low fiber diet; and type 2 diabetes
          B. Female gender; low fat, high calorie, high fiber diet; and rapid weight loss
          C. Male gender; high fat, high calorie, low fiber diet; and type 2 diabetes

          3. MB is a 44-year-old female who presents to the emergency department with severe RUQ pain and nausea. She states this is the third time this year that she has presented to the ED with these symptoms. MB is admitted and the hospitalist starts her on IV fluids, acetaminophen, and ketorolac. Which of the following interventions is most appropriate?
          A. MB should also receive meperidine to manage her pain
          B. MB should undergo cholecystectomy within 72 hours of admission
          C. MB is at high risk for infection and should be given IV cefazolin for prophylaxis

          4. Gallstone recurrence is common with which of the following?
          A. Oral bile acid dissolution drugs
          B. Endoscopic retrograde cholangiopancreatography
          C. Asymptomatic cholelithiasis

          5. Which of the following is FALSE about gallbladder removal surgery?
          A. Patients should have higher tolerability for foods they could not tolerate before surgery
          B. Patients should supplement with fat soluble vitamins post-cholecystectomy
          C. Up to 50% of patients may experience diarrhea following cholecystectomy

          6. Why is diarrhea a common complication post-cholecystectomy?
          A. Overproduction of bile
          B. Vitamin deficiencies
          C. Altered biliary flow

          7. Which of the following statements is TRUE regarding the use of oral bile acid dissolution agents?
          A. They can cause vitamin K and folate deficiencies
          B. Chenodiol is preferred in pregnant women due to its safer adverse effect profile
          C. Fewer than 10% of symptomatic patients are candidates for treatment

          8. AP is a 37-year-old female, weighing 80 kg with symptomatic gallstones. She is not a candidate for laparoscopic cholecystectomy due to previous anesthesia intolerance. AP brings a prescription to the pharmacy for ursodiol 250 mg TID. How long will AP most likely need to take this medication?
          A. 3 to 6 weeks
          B. 6 months to 2 years
          C. 1 to 3 years

          9. KM is a 42-year-old female whose gastroenterologist recommends she try psyllium husk twice daily for her chronic diarrhea post-cholecystectomy. She seems confused when you hand her Metamucil because she thought it was used for constipation. What should you tell KM?
          A. Psyllium husk treats diarrhea by binding bile acids in the gut and excreting them in the stool
          B. Psyllium husk treats diarrhea by soaking up excess water in the intestines to bulk the stool
          C. Psyllium husk treats diarrhea by increasing intestinal contractility

          10. Which of the following is an appropriate counseling point for bile acid sequestrants?
          A. Their most common adverse effects are diarrhea and edema
          B. They are contraindicated in patients with uncontrolled bleeding disorders
          C. Take other oral medications at least 1 hour before or 4 hours after dose

          Pharmacy Technician Post Test (for viewing only)

          After completing this continuing education activity, pharmacy technicians will be able to
          • DESCRIBE the functions of the gallbladder and how it aids digestion.
          • EXPLAIN gallstone prevalence, risk factors, and pathogenesis.
          • LIST over the counter medications used often by patients with gallbladder disease and post-cholecystectomy.
          • IDENTIFY patient questions that need to be referred to a pharmacist.

          1. How do gallstones form?
          A. Fat soluble vitamin deficiency
          B. Gallbladder hypermotility
          C. Imbalances in bile components

          2. Which of the following are risk factors for GBD?
          A. Female gender; high fat, high calorie, low fiber diet; and type 2 diabetes
          B. Female gender; low fat, high calorie, high fiber diet; and rapid weight loss
          C. Male gender; high fat, high calorie, low fiber diet; and type 2 diabetes

          3. Gallstone recurrence is common with which of the following?
          A. Oral bile acid dissolution agents
          B. Endoscopic retrograde cholangiopancreatography
          C. Asymptomatic cholelithiasis

          4. Which of the following may reduce the risk of developing gallstones?
          A. Statins
          B. Oral contraceptives
          C. Ketogenic diet

          5. Why was the gallbladder more essential centuries ago?
          A. Humans consumed smaller meals containing less fat
          B. Humans consumed larger meals containing more fat
          C. Humans consumed meals containing more protein

          6. What is cholelithiasis?
          A. Gallstones caused by bilirubin
          B. The presence of stones in the gallbladder
          C. The presence of gallstones in the cystic duct

          7. Which of the following statements is TRUE regarding the use of oral bile acid dissolution agents?
          A. They can cause vitamin K and folate deficiencies
          B. Chenodiol is preferred in pregnant women due to its safer adverse effect profile
          C. Fewer than 10% of symptomatic patients are candidates for treatment

          8. How does psyllium husk help patients with diarrhea?
          A. Psyllium husk treats diarrhea by binding bile acids in the gut and excreting them in the stool
          B. Psyllium husk treats diarrhea by soaking up excess water in the intestines to bulk the stool
          C. Psyllium husk treats diarrhea by increasing intestinal contractility

          9. Which of the following patients should pharmacy technicians refer to a pharmacist?
          A. A patient holding a container of Metamucil and Fibercon fiber capsules and wants to know which contains psyllium
          B. A patient asking for help locating famotidine, which their gastroenterologist recommended for acid indigestion
          C. A patient who has failed several OTC therapies wants to know what to try for persistent diarrhea post-cholecystectomy

          10. Which of the following statements is TRUE regarding OTC products for patients with GBD and/or PCS?
          A. Antispasmodics like loperamide may help patients’ gastritis symptoms
          B. Famotidine can relieve gastritis symptoms by reducing acid production
          C. Patients can take an antacid like omeprazole to calm IBS symptoms

          References

          Full List of References

          1. Division of General Surgery. History of Medicine: The Galling Gallbladder. Columbia University Irving Medical Center, New York, NY; 1999-2022. Accessed April 26, 2022. https://columbiasurgery.org/news/2015/06/11/history-medicine-galling-gallbladder
          2. Afamefuna S, Allen SN. Gallbladder disease: Pathophysiology, diagnosis, and treatment. US Pharm.2013;38(3):33-41. https://www.uspharmacist.com/article/gallbladder-disease-pathophysiology-diagnosis-and-treatment
          3. CholeS Study Group, West Midlands Research Collaborative, et al. Population‐based cohort study of outcomes following cholecystectomy for benign gallbladder diseases. [published correction appears in Br J Surg. 2018 Aug;105(9):1222]. Br J Surg. 2016;103(12):1704-1715. doi:10.1002/bjs.10287
          4. Jones MW, Small K, Kashyap S, Deppen JG. Physiology, Gallbladder. In: StatPearls. Treasure Island (FL): StatPearls Publishing; May 8, 2022.
          5. 5 surprising truths about the gallbladder. Surgical Consultants of Northern Virginia; Reston, VA. 2023. PatientPopInc. Accessed September 21, 2022. https://www.scnv.com/blog/5-surprising-truths-about-the-gallbladder
          6. De U. Evolution of cholecystectomy: A tribute to Carl August Langenbuch. Indian J Surg. 2004;66(2):97-100.
          7. Haelle T. 10 essential facts about your gallbladder. Everyday Health. August 15, 2015. Accessed September 21, 2022. https://www.everydayhealth.com/news/essential-facts-about-your-gallbladder/
          8. Beckingham IJ. Gallstones. Surgery (Oxford). 2020;38(8):453-462. doi:10.1016/j.mpsur.2020.06.002
          9. Di Ciaula A, Garruti G, Frühbeck G, et al. The role of diet in the pathogenesis of cholesterol gallstones. Curr Med Chem. 2019;26(19):3620-3638. doi:10.2174/0929867324666170530080636
          10. Ahmed A, Cheung RC, Keeffe EB. Management of gallstones and their complications. Am Fam Physician. 2000;61(6):1673-1688.
          11. Jones MW, Gnanapandithan K, Panneerselvam D, Ferguson T. Chronic Cholecystitis. In: StatPearls. Treasure Island, FL: StatPearls Publishing; October 24, 2022. Accessed March 29, 2023. https://www.ncbi.nlm.nih.gov/books/NBK470236/
          12. Di Ciaula A, Portincasa P. Recent advances in understanding and managing cholesterol gallstones. F1000Res. 2018;7:F1000 Faculty Rev-1529. doi:10.12688/f1000research.15505.1
          13. Abraham S, Rivero HG, Erlikh IV, Griffith LF, Kondamudi VK. Surgical and nonsurgical management of gallstones. Am Fam Physician. 2014;89(10):795-802.
          14. He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseasesA systematic review and meta-analysis of randomized clinical trialsJAMA Intern Med.2022;182(5):513–519. doi:10.1001/jamainternmed.2022.0338
          15. Yang M, Xia B, Lu Y, et al. Association between regular use of gastric acid suppressants and subsequent risk of cholelithiasis: A prospective cohort study of 0.47 million participants. Front Pharmacol. 2022;12:813587. Published 2022 Jan 28. doi:10.3389/fphar.2021.813587
          16. Al-Nowfal A, Al-Abed YA. Chronic biliary colic associated with ketamine abuse. Int Med Case Rep J. 2016;9:135-137. Published 2016 Jun 2. doi:10.2147/IMCRJ.S100648
          17. Pulkkinen J, Eskelinen M, Kiviniemi V, et al. Effect of statin use on outcome of symptomatic cholelithiasis: a case-control study. BMC Gastroenterol. 2014;14:119. Published 2014 Jul 3. doi:10.1186/1471-230X-14-119
          18. Walcher T, Haenle MM, Kron, M, et al. Vitamin C supplement use may protect against gallstones: An observational study on a randomly selected population. BMC Gastroenterol. 2009;9:74. doi:10.1186/1471-230X-9-74
          19. Nordestgaard AT, Stender S, Nordestgaard BG, et al. Coffee intake protects against symptomatic gallstone disease in the general population: a Mendelian randomization study. J Intern Med. 2020;287(1):42-53. doi:10.1111/joim.12970
          20. Mukkamalla SKR, Kashyap S, Recio-Boiles A, et al. Gallbladder Cancer. In: StatPearls. Treasure Island, FL: StatPearls Publishing; July 10, 2022. Accessed December 20, 2022. https://www.ncbi.nlm.nih.gov/books/NBK442002/
          21. Barazanchi AWH, MacFater WS, Rahiri JL, et al. Evidence-based management of pain after laparoscopic cholecystectomy: a PROSPECT review update. Br J Anaesth. 2018;121(4):787-803. doi:10.1016/j.bja.2018.06.023
          22. Zackria R, Lopez RA. Postcholecystectomy Syndrome. In: StatPearls. Treasure Island, FL: StatPearls Publishing; August 29, 2022. Accessed November 21, 2022. https://www.ncbi.nlm.nih.gov/books/NBK539902/
          23. Ursodeoxycholic Acid, Ursodiol. Clinical Pharmacology. New York, NY: Elsevier Inc.; 1960. Updated August 6, 2018. Accessed October 25, 2022. Available from: http://www.clinicalkey.com
          24. Chenodiol. Clinical Pharmacology. New York, NY: Elsevier Inc; 1960. Updated September, 29 2015. Accessed October 25, 2022. Available from: http://www.clinicalkey.com
          25. Bonis PA, Lamont JT. Approach to the adult with chronic diarrhea in resource-abundant settings. UpToDate. UpToDate Inc.; 1978-2022. Last Updated May 2, 2022. Accessed November 28, 2022. https://www.uptodate.com/contents/approach-to-the-adult-with-chronic-diarrhea-in-resource-abundant-settings
          26. Cholestyramine Resin. Lexicomp. UpToDate Inc.; 1978-2022. Updated November 25, 2022. Accessed November 29, 2022. Available from: https://online.lexi.com
          27. Colestipol. Lexicomp. UpToDate Inc., 1978-2022. Updated October 22, 2022. Accessed November 29, 2022. Available from: https://online.lexi.com
          28. Sruthi M. What does psyllium husk do? MedicineNet. Updated October 7, 2021. Accessed November 29, 2022. https://www.medicinenet.com/what_does_psyllium_husk_do/article.htm

           

           

          Patient Safety: Medication Refusal: Understanding the Why “They Just Say No”

          Learning Objectives

           

          After completing this application-based continuing education activity, pharmacists will be able to

          Recognize and define types and leading causes of treatment/medication refusal
          Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
          Determine treatment alternatives for patients with dietary, religious, or other restrictions
          Identify and implement key components of a medication refusal protocol

            After completing this application-based continuing education activity, pharmacy technicians will be able to

            Recognize and define types and leading causes of treatment/medication refusal
            Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
            Determine treatment alternatives for patients with dietary, religious, or other restrictions
            Identify and implement key components of a medication refusal protocol

             

            Release Date: October 17, 2023

            Expiration Date: October 15, 2026

            Course Fee

            Pharmacists: $7

            Pharmacy Technicians: $4

            There is no grant funding for this CE activity

            ACPE UANs

            Pharmacist: 0009-0000-23-047-H05-P

            Pharmacy Technician: 0009-0000-23-047-H05-T

            Session Codes

            Pharmacist:  20YC80-TRX39

            Pharmacy Technician:  20YC80-XRT42

            Accreditation Hours

            2.0 hours of CE

            Accreditation Statements

            The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-047-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

             

            Disclosure of Discussions of Off-label and Investigational Drug Use

            The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

            Faculty

            Danielle Haskins, PharmD
            CVS Pharmacy Manager
            Santee, CA

             

            Ming May Zhang, PharmD Candidate 2022
            University of Connecticut School of Pharmacy
            Storrs, CT

            Faculty Disclosure

            In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

            Danielle Haskins and Ming May Zhang  do not have any financial relationships with ineligibile companies.

             

            ABSTRACT

            Based on the principle of informed consent, competent patients always
            have the right to refuse medical treatment. Patients may refuse treatment
            for a variety of reasons, including dietary restrictions, religious reasons, medical
            misconceptions, a desire to avoid adverse effects, and mistrust of the medical
            team. Patient refusals can create serious dilemmas in the healthcare setting. On
            the one hand, clinicians have an ethical and legal obligation to honor patient autonomy.
            On the other hand, a patient’s refusal of treatment often leads to adverse
            medical outcomes, resulting in harm to the patient. Healthcare
            professionals should search for acceptable treatment alternatives that honor patients’
            wishes while meeting their medical needs. Every institution—whether in
            the community, long-term care, or inpatient setting—should have a protocol to
            guide and standardize the approach to managing treatment refusals. In complex
            cases, it may be beneficial to use expert ethics consultations.

            CONTENT

            Content

            ONLY PDF version is Available for this CE

             

             

            Pharmacist Post Test (for viewing only)

            Medication Refusal: Understanding the Why "They Just Say No"
            After participating in this activity, pharmacists and pharmacy technicians will be able to
            1. Recognize and define types and leading causes of treatment/medication refusal
            2. Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
            3. Determine treatment alternatives for patients with dietary, religious, or other restrictions
            4. Identify and implement key components of a medication refusal protocol

            1. Which of the following is an example of ACTIVE medication refusal?
            a. A patient ingests her medication when the caregiver administers it, but secretly spits it out half an hour later.
            b. A patient states that she does not wish to take her oral medication, then refuses to open her mouth to ingest the medication.
            c. A patient initially refuses to take her medication, but concedes when the caregiver repeatedly asks her to.

            2. A patient states that he is vegetarian and wishes to avoid animal products. Which of the following excipients is INAPPROPRIATE for this patient?
            a. Gelatin
            b. Peanut oil
            c. Mannitol

            3. Which of the following best describes motivational interviewing?
            a. An interviewing style that involves the use of ethics counselors, who help healthcare professionals navigate complicated cases
            b. The process by which patients are educated about a treatment’s risks, benefits, and alternatives
            c. A behavioral technique that motivates patients to change by empowering them and motivating them with their own values

            4. Which of the following statements is FALSE about the practice of covert medication?
            a. It refers to administering medications without a patient’s knowledge, such as by concealing medications in food or drink.
            b. It is justifiable in mentally competent patients who refuse treatment against medical advice.
            c. It may be better received than more aggressive methods, such as forced injections.

            5. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which of the following best describes her reasons for refusing Medication X?
            a. Dietary restriction
            b. Medical misconception
            c. Mistrust of the medical team

            6. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which is the best resource to refer her to?
            a. Pillbox, so she can research medications’ ingredients and avoid those containing animal products
            b. The primary literature and PubMed or GoogleScholar, so she can find the most recent data
            c. The patient should not be referred; Medication X is the most effective option for her illness, and she should take it regardless of her beliefs

            7. Why might an ethics consultation be useful in certain instances of treatment refusal?
            a. Ethics counselors are authorized to make healthcare decisions on behalf of incompetent patients.
            b. Ethics counselors are compensated based on patient outcomes, so they persuade patients to choose the most medically effective option.
            c. Ethics counselors are trained in core ethics and healthcare competencies and can help navigate difficult situations.

            8. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. This is an example of:
            a. Beneficence
            b. Primum non nocere
            c. Autonomy

            9. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. Which of the following is the LEAST appropriate response to BT?
            a. Inform BT of the risks and benefits of OTC products, and show him how to interpret the Drug Facts labels.
            b. Identify BT’s reason for refusal—ask about his beliefs, perceptions, and concerns. Counsel him accordingly.
            c. Inform BT that you will request an ethics consultation to advise in this situation, which in your opinion is untenable.

            10. Patient WG is prescribed a new medication and told to take one capsule twice a day. WG misunderstands—he takes two capsules once a day, instead. Which of the following best describes WG’s behavior?
            a. Intentional non-adherence
            b. Unintentional non-adherence
            c. Passive refusal

            11. Patient AU tells you, “Dr. S prescribed five different pills for me, but I’m not taking any of them. I’m a regular churchgoer and I know I should love and respect all people, but I don’t have a good feeling about Dr. S. I think she has it out for me. I’m going to get the meds from Dr. G instead.” Based on this statement, AU’s primary reason for refusal is:
            a. Religious refusal
            b. Lack of belief in the medications’ effect
            c. Mistrust of the medical provider

            12. Patient LG is a 5-year-old female who requires a life-saving blood transfusion. Her caretaker refuses to consent to the procedure since it goes against her religious beliefs. Which of the following statements is TRUE of this situation?
            a. The attending physician must request an ethics consultation, since this is legally required for all cases involving a minor.
            b. LG’s caretaker has the ultimate say in her medical decisions but LG’s doctors are ethically obligated do what is beneficial for the patient.
            c. Since LG does not suffer from any brain disorders, she can make her own medical decisions. The medical team only needs LG’s consent, not the caretaker’s.

            Pharmacy Technician Post Test (for viewing only)

            Medication Refusal: Understanding the Why "They Just Say No"
            After participating in this activity, pharmacists and pharmacy technicians will be able to
            1. Recognize and define types and leading causes of treatment/medication refusal
            2. Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
            3. Determine treatment alternatives for patients with dietary, religious, or other restrictions
            4. Identify and implement key components of a medication refusal protocol

            1. Which of the following is an example of ACTIVE medication refusal?
            a. A patient ingests her medication when the caregiver administers it, but secretly spits it out half an hour later.
            b. A patient states that she does not wish to take her oral medication, then refuses to open her mouth to ingest the medication.
            c. A patient initially refuses to take her medication, but concedes when the caregiver repeatedly asks her to.

            2. A patient states that he is vegetarian and wishes to avoid animal products. Which of the following excipients is INAPPROPRIATE for this patient?
            a. Gelatin
            b. Peanut oil
            c. Mannitol

            3. Which of the following best describes motivational interviewing?
            a. An interviewing style that involves the use of ethics counselors, who help healthcare professionals navigate complicated cases
            b. The process by which patients are educated about a treatment’s risks, benefits, and alternatives
            c. A behavioral technique that motivates patients to change by empowering them and motivating them with their own values

            4. Which of the following statements is FALSE about the practice of covert medication?
            a. It refers to administering medications without a patient’s knowledge, such as by concealing medications in food or drink.
            b. It is justifiable in mentally competent patients who refuse treatment against medical advice.
            c. It may be better received than more aggressive methods, such as forced injections.

            5. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which of the following best describes her reasons for refusing Medication X?
            a. Dietary restriction
            b. Medical misconception
            c. Mistrust of the medical team

            6. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which is the best resource to refer her to?
            a. Pillbox, so she can research medications’ ingredients and avoid those containing animal products
            b. The primary literature and PubMed or GoogleScholar, so she can find the most recent data
            c. The patient should not be referred; Medication X is the most effective option for her illness, and she should take it regardless of her beliefs

            7. Why might an ethics consultation be useful in certain instances of treatment refusal?
            a. Ethics counselors are authorized to make healthcare decisions on behalf of incompetent patients.
            b. Ethics counselors are compensated based on patient outcomes, so they persuade patients to choose the most medically effective option.
            c. Ethics counselors are trained in core ethics and healthcare competencies and can help navigate difficult situations.

            8. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. This is an example of:
            a. Beneficence
            b. Primum non nocere
            c. Autonomy

            9. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. Which of the following is the LEAST appropriate response to BT?
            a. Inform BT of the risks and benefits of OTC products, and show him how to interpret the Drug Facts labels.
            b. Identify BT’s reason for refusal—ask about his beliefs, perceptions, and concerns. Counsel him accordingly.
            c. Inform BT that you will request an ethics consultation to advise in this situation, which in your opinion is untenable.

            10. Patient WG is prescribed a new medication and told to take one capsule twice a day. WG misunderstands—he takes two capsules once a day, instead. Which of the following best describes WG’s behavior?
            a. Intentional non-adherence
            b. Unintentional non-adherence
            c. Passive refusal

            11. Patient AU tells you, “Dr. S prescribed five different pills for me, but I’m not taking any of them. I’m a regular churchgoer and I know I should love and respect all people, but I don’t have a good feeling about Dr. S. I think she has it out for me. I’m going to get the meds from Dr. G instead.” Based on this statement, AU’s primary reason for refusal is:
            a. Religious refusal
            b. Lack of belief in the medications’ effect
            c. Mistrust of the medical provider

            12. Patient LG is a 5-year-old female who requires a life-saving blood transfusion. Her caretaker refuses to consent to the procedure since it goes against her religious beliefs. Which of the following statements is TRUE of this situation?
            a. The attending physician must request an ethics consultation, since this is legally required for all cases involving a minor.
            b. LG’s caretaker has the ultimate say in her medical decisions but LG’s doctors are ethically obligated do what is beneficial for the patient.
            c. Since LG does not suffer from any brain disorders, she can make her own medical decisions. The medical team only needs LG’s consent, not the caretaker’s.

            References

            Full List of References

            References

               

              These can be found on the pdf version of the CE

              Patient Safety: Seven Secrets for Patient Safety with Dietary Supplements

              Learning Objectives

               

              After completing this application-based continuing education activity, pharmacists will be able to

              ·       Discuss the importance of knowing about a patient’s dietary supplement usage
              ·       Identify commonly used dietary supplements, their regulation, and the value of certification
              ·       Recognize potential medication-dietary supplement interactions
              ·       Demonstrate the ability to locate different sources of information about dietary supplements

              After completing this application-based continuing education activity, pharmacy technicians will be able to

              ·       Discuss the importance of knowing about a patient’s dietary supplement usage
              ·       Identify commonly used dietary supplements, their regulation, and the value of certification
              ·       Recognize potential medication-dietary supplement interactions
              ·       Recognize the need for pharmacist counseling when a patient is taking a dietary supplement

              a dinner plate with a variety of colorful capsules with a fork and spoon on the table

               

              Release Date: January 16, 2026

              Expiration Date: January 16, 2029

              Course Fee

              Pharmacists: $7

              Pharmacy Technicians: $4

              There is no grant funding for this CE activity

              ACPE UANs

              Pharmacist: 0009-0000-26-002-H05-P

              Pharmacy Technician: 0009-0000-26-002-H05-T

              Session Codes

              Pharmacist:  23YC01-FKE24

              Pharmacy Technician:  23YC01-EFK68

              Accreditation Hours

              2.0 hours of CE

              Accreditation Statements

              The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-26-002-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

               

              Disclosure of Discussions of Off-label and Investigational Drug Use

              The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

              Faculty

              Jennifer Salvon, RPh
              Clinical Pharmacist
              Mercy Medical Center

              Springfield, MA

              Adjunct Faculty Member
              University of Connecticut School of Pharmacy
              Storrs, CT

              Faculty Disclosure

              In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

              Jennifer Salvon does not have any relationships with ineligible companies and therefore has nothing to disclose.

               

              ABSTRACT

              Consumer consumption of dietary supplements is at an all-time high. Available products number in the tens of thousands, generating millions in annual spending. Increasing interest in overall health and wellness, preventive medicine, and immune function contribute to the rise in usage. It is a common misconception that dietary supplements are safe because they are “natural.”
              Ingestion of dietary supplements poses serious health risks including adverse reactions, drug interactions, and toxicity. Adulterated, mislabeled, and contaminated products exist in the marketplace, further increasing consumer risk. Existing federal regulation and oversight for supplements differs from prescription and over-the-counter medications, occurring primarily on a post-marketing basis. Self-reporting by consumers, healthcare professionals, and industry personnel identifies these issues. Patients often omit dietary supplements from medication histories, leaving healthcare professionals unaware that patients are using them. While misinformation abounds on the Internet, many online clinically-backed sources exist.

              CONTENT

              Content

              Introduction

               

              Consuming natural substances to produce a desired effect on the body dates back thousands of years to ancient Egypt, Rome, China, and many other cultures. Records from early Mesopotamia include written formulas using many oils still in use today, including cedar, cypress, and licorice. Around 300 B.C., the Greek philosopher Theophrastus described the medicinal benefits of natural substances in his History of Plants. Throughout the centuries, many philosophers, scientists, and physicians continued collecting, combining, and documenting the use of natural products to treat different illnesses.1

               

              As the science of medicine developed, so did the science of pharmacology. Isolation of the active ingredients found in herbal substances lead to the development of synthetic compounds with similar properties. The first synthetic medication, chloral hydrate, derived from chloroform and discovered in the 1800s by German chemist Justus von Lieberg, is still in use today.2

               

              Fast forward to modern day, and the interest and use of prescription medications, over-the-counter (OTC) products, and dietary supplements are at an all-time high. In 2020, consumers filled 6.3 billion prescriptions in the United States3 (U.S.) and purchased more than 6 billion OTC products.4 The dietary supplement market reached an unprecedented level in 2020 with a global spend of $61.2 billion. Experts predict it will reach $128.64 billion by 2028.5

               

              The COVID-19 pandemic, caused by the SARS-CoV-2 acute respiratory coronavirus, significantly impacted our perception and approach to healthcare.6 More and more people use complementary and alternative approaches to healthcare than ever before.7 For example, sales of elderberry supplements more than doubled and zinc products quadrupled shortly after the pandemic's start.8

               

              Pharmacists, widely recognized as drug information experts, and pharmacy technicians routinely field consumers' questions about dietary supplements. Many pharmacists lack the necessary knowledge or don't know where to look to answer these questions. Pharmacy schools educate future pharmacists on prescription and OTC medications with courses about nutrition and dietary supplementation, if offered, available as electives. This continuing education activity presents information about dietary supplements through a series of seven common pharmacy situations and lets learners in on seven secrets they can apply to their practices.

               

               

               

              Situation: Continuing education is a professional requirement many pharmacists find tedious. Looking through the UCONN online CE library and seeing a new continuing education activity entitled ‘Seven Secrets of Patient Safety with Dietary Supplements,’ a pharmacist remarks to the pharmacy team, "What a waste, no one even takes dietary supplements."

               

              Secret #1: Almost 60% of people in the United States used a dietary supplement in the last 30 days.11,12

               

              Dietary supplements crowd the aisles in drug stores, supermarkets, warehouse clubs, and even corner convenience stores. The sheer number of products is staggering. The Dietary Supplement Database (DSLD) is an online, searchable database developed by the Office of Dietary Supplements (ODS) at the National Institutes of Health (NIH). The database contains product labeling information on dietary supplements sold in the United States, including both on and off-market products. DSLD currently lists more than 140,000 labels.9

               

              In the early 1960s, the National Center for Health Statistics began a program named the National Health and Nutrition Examination Survey (NHANES). NHANES is a continuous program focusing on various health and nutritional measurements and assesses adults' and children's health and nutritional status in the U.S.10 Scientific and technical journals publish the study results.

               

              One section of the program assesses dietary supplement use among adults. Results from the 2017-2018 NHANES show that11,12

              • 57.6% of adults 20 years or older used a dietary supplement in the past 30 days
              • Women (63.8%) had a higher utilization than men (50.8%)
              • Use of dietary supplements increased with age, with women 60 years or older reporting the highest usage at 80.2%
              • Use of multiple dietary supplements increased with age
              • Most common dietary supplements used by all age groups include multivitamin-mineral supplements, vitamin D, and omega-3 fatty acids

               

              The Council for Responsible Nutrition (CRN) is a trade association for the dietary supplement and functional food industry. Annually, the CRN performs a survey gathering data on consumer use of dietary supplements. The 2019 survey conducted by the CRN underscored dietary supplement usage with the following results13:

              • 77% of US adults take dietary supplements, including 79% of American women and 74% of males
              • Top reasons for taking supplements included:
                • Energy
                • Immune health
                • Filling nutrient gaps
                • Healthy aging
                • Heart health

               

              The COVID-19 pandemic significantly impacted our perception and approach to healthcare.6 As of August 5, 2022, SARS-CoV-2 has infected more than 580 million people worldwide.14 Interest in boosting our overall immunity and protecting ourselves from viral infections has dramatically increased as a result.7 Many vitamins and minerals play essential roles in proper immune function.7,15 Sales of supplements associated with boosting immunity increased over the last two years, including vitamins C and D, zinc, omega-3, garlic, ginger, and turmeric.16

               

              Table 1. Common Dietary Supplements and Potential Uses7,17,18

               

              Dietary Supplement Potential Use
              Black Cohosh Menopausal symptoms
              Calcium Dyspepsia

              Osteoporosis

              Premenstrual syndrome

              Echinacea Prevention and treatment of the common cold

              Promotion of wound healing

              Elderberry Prevention of upper respiratory tract infections

              Reduction in duration and severity of symptoms of the common cold

              Folic acid Folate deficiency

              Kidney failure

              Neural tube defects

              Ginkgo Anxiety

              Dementia

              Memory improvement

              Premenstrual syndrome

              Ginger Dysmenorrhea

              Nausea and vomiting

              Osteoarthritis

              Ginseng Cognitive function

              Erectile dysfunction

              Iron Anemia

              Restless leg syndrome

              Magnesium Constipation

              Dyspepsia

              Melatonin Sleep disorders
              Multivitamin with minerals General supplementation
              Omega-3 fatty acids

               

               

              Alzheimer’s disease

              Cardiovascular disease

              Dementia

              Depression

              Reduction of triglycerides

              Potassium Hypokalemia

              Hypertension

              Kidney stones

              Probiotics

               

               

              Atopic dermatitis

              Antibiotic-associated diarrhea

              Irritable bowel syndrome

              St. John’s Wort Anti-depressant

              Menopausal symptoms

              Turmeric Allergic rhinitis

              Osteoarthritis

              Pruritis

              Valerian Insomnia
              Vitamin A Aging skin

              Healthy vision

              Vitamin B-12 Vitamin B-12 deficiency
              Vitamin C Anemia

              Antioxidant effects

              Prevention of the common cold

              Vitamin C deficiency

              Vitamin D Osteomalacia

              Osteoporosis

              Vitamin D deficiency

              Vitamin E Alzheimer's disease

              Dysmenorrhea

              Premenstrual syndrome

              Zinc Acne

              Depression

              Diabetes

              Diarrhea

              Treatment of common cold

               

               

              Eating a healthy diet is essential for good health and nutrition. The Dietary Guidelines for Americans advise professionals, including policymakers, health care providers, and nutrition educators, about what to eat to meet the body’s nutritional needs. It emphasizes eating a diet rich in nutrient-dense foods, such as fruits and vegetables, as the best way to meet the body’s nutritional needs. The guideline identifies specific populations in which dietary supplementation may be necessary, such as women who are pregnant or lactating and adults older than 50.19

               

              In addition to these defined special populations, many pharmacy patients may find it necessary to take specific vitamins or minerals due to medication-induced nutrient deficiencies.

               

              Table 2. Examples of Nutrient Depletion Induced by Medications7,17

               

              Nutrient Medication(s) Mechanism
              Vitamin D Anticonvulsants

               

              Increase hepatic metabolism
              Bile acid sequestrants

               

              Decrease absorption
              Orlistat

               

              Decrease absorption
              Magnesium

               

              Estrogens

               

              Decrease serum levels by increasing uptake into tissues
              Loop diuretics

               

              Increase excretion
              Proton pump inhibitors

               

              Decrease absorption
              Vitamin B12

               

               

              Biguanides

               

              Decrease absorption
              Proton pump inhibitors

               

              Decrease absorption
              H-2 blockers

               

              Decrease absorption
              Potassium Loop diuretics

               

              Increase excretion
              Thiazide diuretics

               

              Increase excretion
              Corticosteroids

               

              Increase excretion

               

              The pharmacist's dismissal of dietary supplement education is understandable. No one wants to waste precious time on irrelevant continuing education. However, the facts presented here illustrate the need for pharmacist education on dietary supplements.

              Pause and ponder: A patient presents information about taking lemon and baking soda tea to prevent COVID-19 infection and asks you if it really works. How would you approach this conversation?

               

              Situation: Sunday afternoons sometimes (but not often!) present the opportunity to catch up on administrative activities. While completing an inventory reconciliation of the vitamin section, a technician inquires, "Why does the FDA approve so many different products?" Looking up distractedly from the CII safe count, the pharmacist pauses, then replies in a weary voice, "You know, I’m not sure, probably just to make it more confusing for us."

               

              Secret #2: Regulatory oversight of dietary supplements differs from prescription and OTC medications.

               

              What is a Dietary Supplement?

               

              On the most basic level, a dietary supplement is a substance consumed to add nutrients to a diet or to lower the risk of certain health problems. The use of natural substances has been around for millennia, but it is only within the last five decades that countries worldwide have formalized language and regulations around dietary supplements. Terminology, quality control, and safety assessment differ depending on the country and governing legislative body.20

               

              In 1994, the United States Congress passed the Dietary Supplement Health and Education Act (DSHEA), an amendment to the Food, Drug, and Cosmetic Act. DSHEA defines the term dietary supplement as a product intended for ingestion and containing an ingredient that supplements the diet. Dietary supplement labeling must include the term ‘dietary supplement’ or an equivalent term such as ‘herbal supplement’ or ‘magnesium supplement.’ DSHEA also stipulates that a dietary supplement must be free of contamination, adulteration, and properly labeled.21 We will discuss dietary supplement product integrity and labeling later in this activity.

               

              According to DSHEA, dietary supplements include vitamins, minerals, herbs, other botanicals, amino acids, and live microbials (probiotics). Dietary supplements are available in many different formulations including tablets, capsules, soft gels, gel caps, powders, and liquids.21

               

              DSHEA defined the term ‘new dietary ingredient’ as an ingredient that meets the above criteria and was unavailable in the U.S. before October 15, 1994. If manufacturers want to market a product containing a new dietary ingredient, they must notify the U.S. Food and Drug Administration (FDA) before marketing. The FDA then reviews the product for safety but not effectiveness.21

               

              Regulation of Dietary Supplements

               

              The FDA and the Federal Trade Commission (FTC) share regulation and oversight of dietary supplements. The FDA is responsible for the information provided on dietary supplement product labeling, including the package labeling, product inserts, and information available at the point of sale. The FTC monitors dietary supplement advertising, ensuring advertisements are truthful, substantiated, and not misleading. Both agencies have the authority to address violations and work together to ensure their efforts are consistent with one another.22

               

              The FDA does not have the authority to approve dietary supplement products before manufacturers market, distribute, and sell them to consumers. Manufacturers are responsible for ensuring the products they produce and distribute meet all quality standards defined by federal law. Quality standards include22

              • Ensuring the safety of the dietary ingredients used in the product
              • Following current Good Manufacturing Practices (cGMP)
              • Meeting all product labeling requirements
              • Ensuring substantiation of all claims made about the product
              • Ensuring products are free of adulteration or misbranding

               

              cGMP, defined and regularly updated by the FDA, establish the minimum requirements for manufacturing, packaging, and labeling products to ensure product quality. cGMP includes guidance on obtaining quality ingredients, operating procedures, and quality controls.23 Failure to follow cGMP results in possible product contamination.

               

              While the FDA may not have the authority to approve dietary supplements before the product marketing and distribution, it can monitor products via post-marketing surveillance and auditing. The FDA routinely performs manufacturer inspections, monitors the marketplace, and investigates adverse event reports. Follow-up includes working with the manufacturer to bring the product into compliance, issuing warning letters, and recalling products.21

               

              Reporting Issues with Dietary Supplements

               

              Post-marketing surveillance is essential for documenting and monitoring any issues with dietary supplements. Information about severe reactions and product quality are important issues to report. The FDA Safety Reporting Portal is an online tool used to report safety issues on several categories of products, including pet or livestock foods, tobacco products, animal drugs, and dietary supplements.24

               

              The website address for the portal is https://safetyreporting.hhs.gov. Anyone can use the portal to report issues, including consumers, healthcare professionals, manufacturers, and researchers. Generating a new report starts on the home screen. The reporter chooses to file the report as a guest or by creating an account. Creating an account streamlines data entry and allows the reporting individual to save a draft of the report, follow up on a report, and view previous submissions.24

               

              Generation of an Individual Case Safety Report ID (ICSR) occurs after report submission. The ICSR allows the reporter to identify the report for future reference including submission of a follow-up report with additional information. FDA reviewers assess the seriousness of the reported issue and assign follow-up. Submission of this information allows the FDA to identify potentially dangerous products and potentially remove them from the market.24

               

              Traditionally, insurance companies limit coverage to prescription medications. Recent trends show an expansion of coverage to include some dietary supplements. Insurance coverage of dietary supplements blurs the regulatory differences between prescription medications and dietary supplements. Understanding the differences in oversight is beneficial and allows the pharmacy staff to counsel patients effectively.

              Situation: While running back to the pharmacy after a much-needed bathroom break, a pharmacist stops when approached by a customer asking for advice about an iron supplement. Overhearing the inquiry, another customer comments, "You should buy that online; it’s cheaper, and the quality is just as good." The pharmacist nods assent, turns, and hurries back to the pharmacy amid the erupting sounds of chaos behind the counter.

               

              Secret #3: Product integrity fluctuates between manufacturers and sources of dietary supplements.

               

              Integrity of Dietary Supplements

               

              The lack of government oversight opens the door for substandard products to flood the market. Poor ingredient quality, heavy metal or microbial contamination, adulteration, and mislabeling occur regularly. In the current economy, with rising prices, consumers are turning to less expensive options, and cheaper is not necessarily better, especially with dietary supplements.

               

              In the literature, many studies exist that analyze dietary supplement product integrity. A study published in 2021 tested multiple bottles of 29 herbal supplements for consistency of ingredient activity and the presence of metal and fungal contaminants. The analysis showed inconsistent ingredient activity not only between bottles of the same product manufactured by the same company, but also between bottles manufactured by different companies. Assaying for metal contamination found zinc in 88% of bottles and nickel in 40% of bottles. In 37 of 58 bottles tested, fungal contamination was present, with 21 bottles having multiple strains.25

               

              Another study analyzed 41 dietary supplements for the presence of cadmium, lead, and mercury. Results revealed that 68.3% of samples contained contamination with cadmium and lead, and 29.3% with mercury.26 One research team evaluated 121 dietary supplements along with 49 prescription drugs for levels of toxic element contamination. A small percentage of the dietary supplement products exceeded safety levels for mercury, lead, cadmium, arsenic, or aluminum. None of the prescription products exceeded these safety levels.27

               

              Adulterated products contain substances not listed on the product labeling, substitution of inferior materials for active ingredients, or may contain a lesser amount of ingredients. Weight loss, sports enhancement, and sexual function supplements commonly contain banned substances.28

               

              The FDA created and currently maintains the Health Fraud Product Database to increase awareness. This database contains information about products cited in warning letters, advisory letters, recalls, public notifications, and press announcements for various issues. Issues cited include products claiming to cure, treat, or prevent a disease and products containing undeclared ingredients or a new dietary ingredient.29 The database is available in the consumer section of the FDA website at https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database.

               

              On January 2, 2022, the FDA issued a warning letter to the manufacturers of Nasitrol, a nasal spray based on the ingredient iota carrageenan. A review of the product’s website found claims that the product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. Federal regulations define products making these claims as drugs and subject to review by the FDA before approval and subsequent marketing. As discussed earlier, this is in direct violation of federal regulations.30

               

              In another example, on July 15, 2022, the FDA issued a public notice advising consumers to refrain from purchasing Adam’s Secret Extra Strength Amazing Black, a product promoted for sexual enhancement. Laboratory analysis found that the product contained tadalafil, a prescription medication used for erectile dysfunction.31 Due to the potential for severe side effects such as hypotension, tadalafil administration requires medical supervision by a physician.32

               

              A study published in 2018 analyzed FDA warning letters issued from 2007 through 2016, using data from the Health Fraud Product Database. During this time frame, the FDA found 776 adulterated dietary supplements from 146 different companies. A total of 157 products contained more than one unapproved ingredient. Products marketed for sexual enhancement accounted for 45.5% of letters, weight loss 40.9%, and muscle building 11.9%. Unapproved ingredients included sildenafil in sexual enhancement, sibutramine in weight loss, and synthetic steroids or steroid-like ingredients in muscle building supplements.33

               

              One way for consumers to know they are purchasing a valid product is by looking for a certified product. The certification process involves an independent, third-party company testing a company’s products, offering quality assurance for dietary supplements. Parameters tested include34

              • Product contains the ingredients stated on the label
              • Presence of harmful ingredients
              • Presence of contamination
              • Proper dissolution
              • cGMP followed during manufacture

               

              Three independent, private, third-party certifying organizations operate in the United States: the US Pharmacopeial Convention (USP), NSF International, and Consumerlabs.com. All three companies offer product certification programs for a fee. Each company allows products passing certification to display a seal on product labeling. Table 3 summarizes information about each organization.

               

              Table 3. Dietary Supplement Certification Organizations

               

              Certifying Organization US Pharmacopeial Convention NSF International Consumerlab.com
              Website www.usp.org

              www.qualitysupplements.org

               

              www.nsf.org www.consumerlab.com
              Services offered Dietary supplement verification program including GMP facility audits, product QCM process evaluation, and product testing Product and ingredient certification

              GMP Certification

              Certified for Sport

              Product reviews

              Quality Certification Program

              Information available on the website Program information, list of verified products, and educational resources Program information, product search engine, and educational resources Product reviews, health condition information
              GMP = Good Manufacturing Practice

              Source: adapted from reference 33

               

              Online product ordering is a convenient shopping option rapidly gaining popularity in recent years, especially during the pandemic. While tempting to order the least expensive product, investigating the source and quality of dietary supplements available online is essential. Proactive training of the entire pharmacy team aids in providing patients with accurate information.

              Situation: A weary technician finally finishes ringing out the last customer after two hours straight at the register. A sigh of relief quickly turns into a disgruntled groan as another customer approaches. With a bottle labeled ‘Menopausal Support’ in hand, the customer points to the bottle label and asks, "What does ‘proprietary blend’ mean?" The technician glances over her shoulder, sees the pharmacist engaged in an intense phone conversation, and replies to the customer, "The bottle label clearly lists the ingredients."

               

              Secret #4: Federal regulations define required dietary supplement label information. Unfortunately, ambiguity still exists, making it challenging to identify exactly what the product contains.

               

              Federal regulations define the information required on dietary supplement product labeling in detailed, specific terms. Product labeling must include35

              • Product name
              • The term ‘dietary supplement’ or similar term (i.e., herbal supplement)
              • Name and location of the manufacturer, along with a domestic address and phone number for reporting serious adverse events
              • Nutrition labeling in the form of a “Supplement Facts” panel with the following information (see Figure 1):
                • Serving size
                • Number of servings per container
                • Listing of each dietary ingredient in the product
                • Amount of dietary ingredient per serving (Exception: ingredients in a proprietary blend)
                • Amount per serving listed as a quantitative amount by weight, as a percentage of the Daily Value, or as both
              • A list of other ingredients not declared on the Supplement Facts label (usually excipients such as preservatives or dyes)
              • Net quantity of contentsImage of a Supplemental Facts label found on dietary products.

              Figure 1. Supplemental Facts Label (sourced from reference 36)

              One area of ambiguity in dietary supplement product labeling is the listing of a proprietary blend. The term proprietary blend refers to a blend of dietary ingredients unique to a manufacturer and product. Federal labeling regulations allow the listing of proprietary blends on dietary supplement products, however, only the total weight of the blend is required, not the weight of individual ingredients.35 There is no way for the healthcare professional or consumer to know exactly how much of a particular ingredient the proprietary blend contains.

               

              Consumerlabs.com cautions consumers about products containing proprietary blends or formulas. In many instances, the blend's name sounds like a desired, expensive ingredient that is only a small part of the formula. Marketing of products containing proprietary blends may mislead the consumer with claims meant to impress the consumer and drive sales of the product.37

               

              FDA regulations do allow structure/function claims on dietary supplement labeling. Structure/function claims describe how a nutrient or dietary ingredient may affect or act to maintain the structure or function of the body.35 Examples of structure/function claims include35

              • Calcium builds strong bones
              • Antioxidants maintain cell integrity
              • Fiber maintains bowel integrity

               

              If a dietary supplement label contains a structure/function claim it must also contain the following statement: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."35

               

              The example in this situation involved a product marketed for menopausal support. Menopausal symptoms affect more than 1 million women in the US annually and include symptoms such as hot flashes and sleep disturbances.38 A search of the DSLD using the term ‘menopausal support’ and filtering for on-market products containing the ingredient ‘proprietary blend’ returned almost 3,000 products.9 This abundance of products illustrates the ambiguity that exists on dietary supplement labeling.

               

              Pharmacy technicians are often the first line of contact at the pharmacy. Training and development of pharmacy technicians on the facts surrounding dietary supplements empower technicians, allowing them to answer factual questions and provide effective patient education.

               

              Situation: The pharmacy phone constantly rings throughout the day, and today is no exception. The new COVID vaccine is out, and everyone wants to know if the pharmacy has it in stock. Answering yet another call, the technician is surprised when a patient asks to talk to the pharmacist, complaining about dizziness. The pharmacist checks the patient’s profile, finding no underlying causative medication. Further questioning the patient, the pharmacist uncovers the recent addition of melatonin at night for sleep.

               

              Secret #5: Like prescription medications, dietary supplements have pharmacologic and physiologic effects on the body, potentially resulting in health risks and side effects.

               

              Consumers perceive dietary supplements as safe due to their source from natural substances. While generally well tolerated, dietary supplements affect the body like prescription medications, capable of producing an undesired effect. Lack of regulatory oversight allows products to reach consumers without adequate safety evaluation.

               

              Information describing adverse effects of dietary supplements is anecdotal, derived from case reports and reports submitted through the FDA Safety Reporting Portal. Most dietary supplements have not been studied in pregnant or lactating women or children.

               

              A study published in 2015 evaluated ten years of emergency room data to assess the number of annual visits resulting from dietary supplement adverse events. The authors calculated an average of more than 23,000 emergency room visits stemmed from the consumption of dietary supplements, resulting in more than 2,000 hospitalizations annually.39

               

              Events in older adults accounted for the highest percentage of visits, with 40% of visits due to difficulty swallowing. Incidence in young adults aged 20 to 34 was significant at 28% and primarily involved weight loss and energy products. Side effects reported include heart palpitations, chest pain, and tachycardia.39

               

              Unsupervised child ingestions accounted for 21% of visits. Unlike prescription medications, regulations do not require child-resistant packaging for dietary supplements, except for iron-containing products.39 The authors note the numbers evaluated in the study are likely underreported as patients do not always include dietary supplements with the current medication list.39

               

              Table 4. Adverse Effects of Common Dietary Supplements7,17

               

              Supplement Adverse Effects
              Black Cohosh

               

              Breast tenderness, diarrhea, gastrointestinal upset, nausea/vomiting
              Calcium

               

              Burping, constipation, gastrointestinal upset
              Echinacea

               

              Diarrhea, constipation, gastrointestinal upset/pain, heartburn, nausea/vomiting, skin rashes
              Ginseng Gastrointestinal side effects, headache, sleep difficulty
              Ginger

               

              Burping, diarrhea, heartburn
              Iron

               

              Abdominal pain, constipation, diarrhea, nausea/vomiting
              Magnesium

               

              Diarrhea, gastrointestinal irritation, nausea/vomiting
              Melatonin

               

              Dizziness, drowsiness, headache
              Omega-3 fatty acids Bad breath, headache, heartburn, nausea, diarrhea, unpleasant taste
              Potassium

               

              Abdominal pain, burping, diarrhea, nausea/vomiting
              St. John’s Wort

               

              Diarrhea, dizziness, dry mouth, fatigue, headache, insomnia
              Turmeric

               

              Constipation, dyspepsia, gastrointestinal reflux, nausea/vomiting
              Vitamin C

               

              Abdominal cramping, heartburn, kidney stones (if history of kidney stones)
              Zinc

               

              Abdominal cramping, diarrhea, metallic taste, nausea/vomiting

               

               

              Patients often fail to report usage of dietary supplements and most pharmacy software lacks the ability to note dietary supplement usage in the patient profile. In this situation, the pharmacist took the extra time to further question the patient about dietary supplement usage and successfully identified the causative agent.

               

              Pause and Ponder: In what ways could you incorporate activities into the daily workflow to increase awareness of patients’ use of dietary supplements?

               

              Situation: Today, the workload in the pharmacy is lighter than usual. With a grateful sigh, the pharmacist sinks onto a stool reaching for a quick snack. Then the phone rings… The caller is a triage nurse from the local hospital to verify a patient’s medication profile. Pulling up the profile, the pharmacist verifies the list of medications, including digoxin. The triage nurse confirms atrial fibrillation as the cause for admission, adding that the patient recently started taking St. John’s Wort for depression.

               

              Secret #6: Some dietary supplements affect the CYP450 liver enzymes, potentially altering the pharmacokinetics of medications, leading to treatment failure and/or toxicity.

               

              Dietary supplement-drug interactions

               

              Drug-drug interactions result in altered absorption, metabolism, or excretion. Drug-dietary supplement interactions occur through the same pathways as those used by FDA-approved drugs. The cytochrome P450 (CYP P450) enzymes in the liver are responsible for the metabolism of most medications.41,42 The ability of a drug to either induce or inhibit these enzymes is a significant factor in drug-drug interactions. The natural ingredients found in dietary supplements are capable of inhibition or induction, also having the potential to interact with medications.

               

              St. John’s Wort, an herbal commonly taken for the relief of mild to moderate depression, induces the activity of CYP3A4.43,44 This induction increases the clearance of medications metabolized by CYP3A4. Examples of medications cleared by CYP3A4 include alprazolam, atorvastatin, cyclosporine, oral contraceptives, oxycodone, and warfarin.43,44 Patients need counseling about potential drug interactions with St. John’s Wort.

               

              Limited clinical studies evaluating the impact of drug-dietary supplement interactions exist. Many interactions are theoretical, based on limited clinical evidence, animal research, and case reports.

               

              Table 5. Examples of Potential Drug-Dietary Supplement Interactions7,17

               

              Dietary Supplement Medication Interaction
              Calcium

               

               

              Quinolone and tetracycline antibiotics Decreased antibiotic efficacy

              Take antibiotic 2 hours before or 4-6 hours after calcium

              Dolutegravir

              Elvitegravir

              Reduced serum levels

              Take medication 2 hours before or 2 hours after calcium

              Ginseng Diabetes medications Increase risk of hypoglycemia
              Immunosuppressants Decreased effectiveness of immunosuppressant
              Ginkgo

               

              Anticoagulants Increased risk of bleeding
              Iron

               

              Quinolone and tetracycline antibiotics Decreased levels of antibiotics due to decreased absorption

              Take antibiotics 2 hours before or 4-6 hours after iron

              Magnesium

               

              Bisphosphonates Decreased absorption

               

              Levodopa/carbidopa Decreased bioavailability of levodopa/carbidopa
              Niacin

               

               

               

              Statins Increased risk of myopathy or rhabdomyolysis
              Thyroid hormones Antagonize the effects of thyroid hormone replacement
              Antihypertensive medications Increased risk of hypotension due to niacin’s vasodilating effects
              St. John’s Wort Alprazolam Decreased effects of alprazolam
              Oral Contraceptives Decreased efficacy

              Counsel patients to use other forms of contraception

              Digoxin Decreased levels of digoxin
              Omeprazole Decreased effects of omeprazole
              Valerian CNS depressant drugs Additive sedative effects
              Vitamin B6

               

              Phenytoin Decrease levels and clinical effects of phenytoin
              Vitamin D

               

              Atorvastatin Decreased absorption of atorvastatin
              Vitamin E

               

              Anticoagulants Increased risk of bleeding
              Zinc

               

              Quinolone antibiotics Decreased levels and effects of antibiotics

              Take antibiotic 2 hours prior or 4-6 hours after zinc

               

              Pharmacy training emphasizes the importance of drug-drug interactions. It is important to remember that any substance introduced to the body, including food, beverages, and dietary supplements, has the potential to interact with medications.

              Situation: It is another busy day in the pharmacy; prescriptions cover the bench, the phone rings constantly, and a pickup queue extends around the corner. A technician nervously approaches the pharmacist about a patient at the counter with a question regarding a supplement. The pharmacist throws down the spatula, muttering angrily about lacking the knowledge and training to answer the question properly. Sighing, he says, "I’ll just Google it."

               

              Secret #7: Many websites provide clinically backed information on dietary supplements (and Google is not one of them!).

               

              The vast amount of health information available via the Internet with just a few clicks of the keyboard is both a blessing and a curse. Google is now a verb, and a simple search returns millions of results in seconds. While this may seem like a blessing, the curse lies in the searcher's inability to recognize valid, accurate sources of information. In many searches, ads appear as search results adding to the confusion.

               

              In addition to the Internet, consumers turn to social media for health information. Social media use increased from 27% in 2009 to 86% in 2019.45 Information posted on social media provides communication about healthcare issues, potentially resulting in improved health care.45 Unfortunately, inaccurate information abounds on the Internet and social media platforms, leading to consumer misinformation.47-49

               

              The FDA recently launched a new dietary supplement education initiative geared towards consumers, healthcare professionals, and teachers. The program, Supplement Your Knowledge, presents information about dietary supplements through a series of three videos. Educational materials, including fact sheets and infographics, are available in English and Spanish.50

               

              Many government agencies provide free access to information about dietary supplements and their side effects, toxicity, and drug interactions. There are also several paid subscription resources available. Table 6 lists many of the available information options.

               

              Table 6. Sources of Information about Dietary Supplements

               

              Resource Website Information
              Dietary Supplement Education Program https://www.fda.gov/food/healthcare-professionals/dietary-supplement-continuing-medical-education-program

               

              • Continuing medical education program
              • Collaboration between FDA and AMA
              • Series of 3 videos about dietary supplements
              • Also contains links to educational materials and other websites with information about dietary supplements
              Dietary Supplement Label Database https://dsld.od.nih.gov

               

              • Current and historical label information on dietary supplement products marketed in the United States
              • Useful to determine the contents of dietary supplement products
              Food and Drug Administration https://www.fda.gov/food/dietary-supplements/information-consumers-using-dietary-supplements

               

              • Information for consumers on using dietary supplements
              • Links to educational resources and materials, consumer updates, alerts, recalls and other information
              Google Scholar

               

              https://scholar.google.com/

               

              • Source of information from many avenues including journals, books, and conference proceedings
              Lexi-Comp

              Natural Products Database

              Available via mobile app
              • Requires a paid subscription
              • Alphabetical, searchable natural product database
              Memorial Sloane Kettering Cancer Center https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs

               

              • Information on herbs, botanicals, and other products for both consumers and healthcare professionals
              • Dietary supplement monographs
              • IOS app: About Herbs
              • Part of an online integrative medicine resource center
              National Cancer Institute Office of Cancer Complementary and Alternative Medicine https://cam.cancer.gov

               

              • Information for consumers and healthcare professionals about CAM as it relates to cancer therapy
              • Information on current NCI CAM research
              National Center for Complementary and Integrative Health https://www.nccih.nih.gov

               

              • Information for both consumers and healthcare professionals about complementary health products and practices
              National Library of Medicine - Medline Plus https://medlineplus.gov/druginfo/herb_All.html

               

              • Online health information about drugs, herbs, and supplements for consumers
              • Information sourced from the National Center for Complementary and Integrative Health and Natural Medicines Comprehensive Database
              Natural Medicines Comprehensive Database https://naturalmedicines.therapeuticresearch.com

               

              • Requires a paid subscription
              • Professional monographs including information about effectiveness, safety, adverse effects, and interactions
              • Information on specific commercial products
              • Interaction checker
              • Patient handouts in English, Spanish and French
              Office of Dietary Supplements https://ods.od.nih.gov
              • Information for both consumers and healthcare professionals
              • General supplement information
              • Information on supplements for specific purposes
              • Fact sheets on dietary supplements and their ingredients
              PubMed https://pubmed.ncbi.nlm.nih.gov

               

              • Search engine for the National Library of Medicine
              • Source of information from journals
              United States Department of Agriculture https://www.nutrition.gov/topics/dietary-supplements

               

              • Links to general information and resources on dietary supplements

               

               

              Performing an Internet search via Google may seem like the quickest and easiest way to find the answer to an inquiry. Engaging with the patient, gaining additional information, and knowing where to look ultimately saves time. It is not necessary for one to be an expert in all dietary supplements, just to self-educate one supplement at a time.

               

              Pause and Ponder: A patient shares the unfortunate news about a recent cancer diagnosis. He asks you about the use of herbs in the treatment of cancer. What advice would you give? 

              Conclusion

              You may have noticed a recurring theme throughout this activity. Education. Dietary supplement education is essential to patient safety given the current usage patterns and accessibility of the retail pharmacy team. Education needs to include the entire pharmacy team. Technicians are often the first point of contact at the pharmacy, commonly fielding patient questions. Knowing when to answer questions and when to involve the pharmacist is a necessary skill. Understanding the differences in oversight, the physiological effects of dietary supplement consumption, and the potential for drug interactions allows effective management and counseling of patients. It is important for healthcare providers to solicit information regarding patient consumption of dietary supplements.

               

               

              Sidebar: Tips for Counseling Patients about Dietary Supplements

               

              Carefully inspect the product to ensure intact product labeling

              Ensure the safety seal is intact

              Check for an expiration date or best used by date

              Check for customer service or return information before ordering

              Buy direct from a reputable company; many reputable companies sell through Amazon, avoid 3rd party resellers

              Check for the presence of a third-party certification seal

              Before purchase, check the company’s website for information on quality standards

              Pay attention to the appearance and smell of the product upon opening

              Child-resistant packaging is not a requirement for dietary supplements; advise on proper storage of product

              Reinforce the importance of including dietary supplements on a current medication list

               

               

               

               

              Pharmacist Post Test (for viewing only)

              Seven Secrets for Patient Safety with Dietary Supplements

              Pharmacist post-test

              After completing this continuing education activity, pharmacists will be able to:

              1. Discuss the importance of knowing about a patient’s dietary supplement usage (K)
              2. Identify commonly used dietary supplements, their regulation, and the value of certification (K, or A?)
              3. Recognize potential medication-dietary supplement interactions (K)
              4. Demonstrate the ability to locate different sources of information about dietary supplements (A)

              1. According to The National Health and Nutrition Examination Survey more than what percentage of adults have used a dietary supplement in the last 30 days?

              A. 45%
              B. 50%
              C. 55%

              2. Which of the following is a commonly used dietary supplement?

              A. Boswellia
              B. Turmeric
              C. Quercetin

              3. Which government agencies regulate dietary supplements?

              A. USDA, FDA
              B. FTC, DEA
              C. FTC, FDA

              4. Patient MW fills a new prescription for bumetanide. Which potential nutrient depletion may occur?

              A. Magnesium
              B. Vitamin D
              C. Vitamin B12

              5. While completing an inventory reconciliation of the vitamin section, a technician inquires, ‘Why does the FDA approve so many different products?’ Which of the following is the most appropriate answer?

              A. ‘The FDA does not have the authority to approve dietary supplements, the FTC approves dietary supplements, including vitamins.’
              B. ‘The FDA does not have the authority to approve dietary supplements before they are marketed, allowing manufacturers to flood the market with products.’
              C. ‘You know, I’m not sure, probably just to make it more confusing for us.’

              6. Which of the following companies offer independent third-party dietary supplement certification services?

              A. Consumer Reports
              B. NSF International
              C. Certified Naturally Grown

              7. Patient ED is a 58-year-old male new to your pharmacy. He provides the pharmacy team with a list of his current medications including:
              • Warfarin 3 mg PO QD
              • Atorvastatin 10 mg PO QD
              • Donepezil 10 mg PO QHS
              • Metformin 1,000 mg PO BID
              Use of which of the following supplements would be cause for concern in this patient?

              A. Ginkgo
              B. Omega-3 fatty acids
              C. Niacin

              8. A patient calls with questions about a supplement recommended by a friend. The name of the supplement is Mind and Memory Essentials, and the patient does not know the product ingredients. Where would you go to find this information?

              A. Dietary Supplement Label Database
              B. Office of Dietary Supplements
              C. United States Department of Agriculture

              9. A patient asks you about the potential side effects of taking turmeric. Where would you go to find this information?

              A. Google
              B. PubMed
              C. Office of Dietary Supplements

              10. You are verifying a new birth control prescription for a patient, recalling that the patient strongly believes in alternative medicine and dietary supplementation. Thankfully her profile contains a list of dietary supplements. You see St. John’s Wort listed and suspect a drug-supplement interaction. Where would you go to find more information?

              A. Natural Medicines Database
              B. Google Scholar
              C. National Library of Medicine

              11. One of your regular patients stops by the counter to ask your opinion on a dietary supplement product purchased on the Internet. What should you assess when looking over the product?

              A. Product labeling, color of bottle, structure/function disclaimer, certification
              B. Certification, expiration date, product labeling, intact seal
              C. Expiration date, product price, certification, product labeling

              12. Pharmacy patient ML approaches the pharmacy counter to purchase several bottles of oral glucose tablets. When questioned, the patient reveals the recent occurrence of several hypoglycemic episodes. The patient confirms compliance with taking their prescription for metformin 1 gm PO BID. ML reports no changes in other prescriptions or dietary habits but does state they started taking a dietary supplement a few days ago but cannot recall the name. Which product would you suspect based on the information provided?

              A. Vitamin E
              B. Valerian
              C. Ginseng

              Pharmacy Technician Post Test (for viewing only)

              Pharmacy Technician

              After completing this continuing education activity, pharmacy technicians will be able to:

              1. Discuss the importance of knowing about a patient’s dietary supplement usage (K)
              2. Identify commonly used dietary supplements (A)
              3. Define dietary supplement oversight and different levels of quality (K)
              4. Recognize the need for pharmacist counseling when a patient is taking a dietary supplement (K)

              1. Why is it important to ask about a patient’s usage of dietary supplements?

              A. It is not important to ask about dietary supplement usage.
              B. To identify which dietary supplements the pharmacy should feature on the front counter.
              C. Dietary supplements potentially interact with prescription medications.

              2. Which of the following is a commonly used dietary supplement?

              A. Boswellia
              B. Turmeric
              C. Quercetin

              3. Which government agencies regulate dietary supplements?

              A. USDA, FDA
              B. FTC, DEA
              C. FTC, FDA

              4. A patient approaches the counter with 2 different magnesium products and asks your opinion on which to purchase. Which of the following is an appropriate answer?

              A. Let’s look at these a little closer.
              B. Neither, it’s better to buy supplements online.
              C. The one that’s on sale.

              5. Reasons for dietary supplementation include which of the following?

              A. To supplement a poor diet.
              B. Promotion of optimal immune health
              C. No one needs to take dietary supplements.

              6. Which of the following companies offer independent third-party dietary supplement certification services?

              A. Consumer Reports
              B. NSF International
              C. Certified Naturally Grown

              7. You are entering a new patient into the pharmacy system. In addition to asking about allergies, demographics, and current medications, what else should you ask?

              A. How many hours of sleep do you average a night?
              B. Do you take any over-the-counter medications or dietary supplements?
              C. How many children do you have and how old are they?

              8. You are finally heading out for a lunch break and walk past a pharmacy patient in the aisle looking at 2 different brands of St. John’s Wort. What should you do?

              A. Keep going, you already punched out and only have 30 min to eat your lunch.
              B. Stop and offer to accompany them to the pharmacy to talk to the pharmacist.
              C. Stop and help them make a choice between the products.

              9. A patient picks up a medication and purchases a bottle of magnesium at the same time. What should you do?

              A. Advise the patient that there may be an interaction between the prescription and the magnesium.
              B. Ring out the patient as usual.
              C. Touch base with the pharmacist to make sure there are no potential interactions between the products.

              10. Where should adverse reactions or issues with dietary supplements be reported?

              A. FDA Safety Reporting Portal
              B. Federal Trade Commission
              C. Office of Dietary Supplements

              References

              Full List of References

              References

                1. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670-3695. doi:10.1016/j.bbagen.2013.02.008

                2. Jones AW. Early drug discovery and the rise of pharmaceutical chemistry. Drug Test Anal. 2011;3(6):337-344. doi:10.1002/dta.301

                3. Aitken M, Kleinrock M. The Use of Medicines in the U.S. Spending and Usage Trends and Outlook to 2025. IQVIA Institute for Human Data Science. May 2021. Accessed August 5, 2022. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-use-of-medicines-in-the-us/iqi-the-use-of-medicines-in-the-us-05-21-forweb.pdf

                4. OTC Sales Statistics. Consumer Healthcare Products Association. Accessed June 22, 2022. https://www.chpa.org/about-consumer-healthcare/research-data/otc-sales-statistics

                5. Dietary Supplements Market Size, Share & COVID-19 Impact Analysis, By Type (Vitamins, Minerals, Enzymes, Fatty Acids, Proteins, and Others), Form (Tablets, Capsules, Liquids, and Powders), and Regional Forecasts, 2021-2028. Fortune Business Insights. Accessed June 22, 2022. https://www.fortunebusinessinsights.com/dietary-supplements-market-102082

                6. Moynihan R, Sanders S, Michaleff ZA, et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021;11(3):e045343. Published 2021 Mar 16. doi:10.1136/bmjopen-2020-045343

                7. Dietary Supplements in the Time of COVID-19. Fact Sheet for Health Professionals. National Institutes of Health, Office of Dietary Supplements. Accessed July 20, 2022. https://ods.od.nih.gov/factsheets/COVID19-HealthProfessional/.

                8. Adams KK, Baker WL, Sobieraj DM. Myth Busters: Dietary Supplements and COVID-19. Ann Pharmacother. 2020;54(8):820-826. doi:10.1177/1060028020928052

                9. US Department of Health and Human Services, National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Label Database (DSLD). Accessed August 5, 2022. https://ods.od.nih.gov/Research/Dietary_Supplement_Label_Database.aspx

                10. About the National Health and Nutrition Examination Survey. National Center for Health Statistics. Accessed July 20, 2022. https://www.cdc.gov/nchs/nhanes/about_nhanes.htm

                11. Mishra S, Stierman B, Gahche JJ, Potischman N. Dietary supplement use among adults: United States, 2017–2018. NCHS Data Brief, no 399. Hyattsville, MD: National Center for Health Statistics. 2021. DOI: https://doi.org/10.15620/cdc:101131external icon

                12. Gahche JJ, Bailey RL, Potischman N, et al. Federal Monitoring of Dietary Supplement Use in the Resident, Civilian, Noninstitutionalized US Population, National Health and Nutrition Examination Survey. J Nutr. 2018;148(Suppl 2):1436S-1444S. doi:10.1093/jn/nxy093

                13. 2019 CRN Consumer Survey on Dietary Supplements. Council for Responsible Nutrition. https://www.crnusa.org/2019survey. Published September 30, 2019. Accessed June 1, 2022.

                14. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/. Accessed August 5, 2022.

                15. Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections. Nutrients. 2020;12(4):1181. Published 2020 Apr 23. doi:10.3390/nu12041181

                16. Hamulka J, Jeruszka-Bielak M, Górnicka M, Drywień ME, Zielinska-Pukos MA. Dietary Supplements during COVID-19 Outbreak. Results of Google Trends Analysis Supported by PLifeCOVID-19 Online Studies. Nutrients. 2020;13(1):54. Published 2020 Dec 27. doi:10.3390/nu13010054

                17. Natural Medicines. Therapeutic Research Center. Accessed August 2, 2022. https://naturalmedicines.therapeuticresearch.com.

                18. Office of Dietary Supplements Dietary Supplement Fact Sheets. Accessed August 2, 2022. https://ods.od.nih.gov/factsheets/list-all/

                19. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. 9th Edition. December 2020. Available at DietaryGuidelines.gov. https://www.dietaryguidelines.gov/sites/default/files/2021-03/Dietary_Guidelines_for_Americans-2020-2025.pdf

                20. Thakkar S, Anklam E, Xu A, et al. Regulatory landscape of dietary supplements and herbal medicines from a global perspective. Regul Toxicol Pharmacol. 2020;114:104647. doi:10.1016/j.yrtph.2020.104647
                21. FDA 101: Dietary supplements. United States Food and Drug Administration. Accessed July 31, 2022. https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements.
                22. Questions and Answers on Dietary Supplements. U.S. Food and Drug Administration. Accessed July 31, 2022. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements.

                23. Facts About the Current Good Manufacturing Practices (cGMPs). U.S. Food and Drug Administration. Accessed July 22, 2022.
                https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps

                24. Safety Reporting Portal. Food and Drug Administration. Accessed August 10, 2022. https://www.safetyreporting.hhs.gov/SRP2/en/Home.aspx?sid=da6dc761-7962-4743-82cd-2e62985492d0

                25. Veatch-Blohm ME, Chicas I, Margolis K, Vanderminden R, Gochie M, Lila K. Screening for consistency and contamination within and between bottles of 29 herbal supplements. PLoS One. 2021;16(11):e0260463. Published 2021 Nov 23. doi:10.1371/journal.pone.0260463

                26. Ćwieląg-Drabek M, Piekut A, Szymala I, et al. Health risks from consumption of medicinal plant dietary supplements. Food Sci Nutr. 2020;8(7):3535-3544. Published 2020 May 19. doi:10.1002/fsn3.1636

                27. Genuis SJ, Schwalfenberg G, Siy AK, Rodushkin I. Toxic element contamination of natural health products and pharmaceutical preparations. PLoS One. 2012;7(11):e49676. doi:10.1371/journal.pone.0049676

                28. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings [published correction appears in JAMA Netw Open. 2018 Nov 2;1(7):e185765]. JAMA Netw Open. 2018;1(6):e183337. Published 2018 Oct 5. doi:10.1001/jamanetworkopen.2018.3337

                29. Health Fraud Product Database. United States Food and Drug Administration. Accessed August 10, 2022. https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database

                30. Warning Letter: Amcyte Pharma, Inc. United States Food and Drug Administration. January 03, 2022. Accessed August 12, 2022. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amcyte-pharma-inc-623474-01032022

                31. Public Notification: Adam’s Secret Extra Strength Amazing Black contains hidden drug ingredient. United States Food and Drug Administration. July 15, 2022. Accessed August 12, 2022. https://www.fda.gov/drugs/medication-health-fraud/public-notification-adams-secret-extra-strength-amazing-black-contains-hidden-drug-ingredient

                32. Coward, RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag. 2008;4(6):1315-1329. Accessed October 3, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643112/pdf/TCRM-4-1315.pdf

                33. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings [published correction appears in JAMA Netw Open. 2018 Nov 2;1(7):e185765]. JAMA Netw Open. 2018;1(6):e183337. Published 2018 Oct 5. doi:10.1001/jamanetworkopen.2018.3337

                34. Akabas SR, Vannice G, Atwater JB, Cooperman T, Cotter R, Thomas L. Quality Certification Programs for Dietary Supplements. J Acad Nutr Diet. 2016;116(9):1370-1379. doi:10.1016/j.jand.2015.11.003

                35. Dietary Supplement Labeling Guide, U.S. Food and Drug Administration. https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/dietary-supplement-labeling-guide Accessed July 15, 2022.

                36. Frequently Asked Questions for Industry on Nutrition Facts Labeling Requirements. United States Food and Drug Administration. Accessed August 12, 2022. https://www.fda.gov/media/99158/download

                37. Cooperman, T. 6 Red Flags to Watch Out For When Buying Vitamins & Supplements. October 9, 2021. Accessed August 12, 2022. https://www.consumerlab.com/answers/what-to-watch-out-for-when-buying-vitamins-and-supplements/vitamin-and-supplement-red-flags

                38. Research explores the impact of menopause on women’s health and aging. National Institute of Aging. May 6, 2022. Accessed September 6, 2022. https://www.nia.nih.gov/news/research-explores-impact-menopause-womens-health-and-aging

                39. Geller AI, Shehab N, Weidle NJ, et al. Emergency Department Visits for Adverse Events Related to Dietary Supplements. N Engl J Med. 2015;373(16):1531-1540. doi:10.1056/NEJMsa1504267

                40. Code of Federal Regulations. Title 16, Chapter II, Subchapter E, Part 1700. Amended September 6, 2022. Accessed September 6, 2022. https://www.ecfr.gov/current/title-16/chapter-II/subchapter-E/part-1700/section-1700.14

                41. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392(6):1093-1108. doi:10.1007/s00216-008-2291-6

                42. Matura JM, Shea LA, Bankes VA. Dietary supplements, cytochrome metabolism, and pharmacogenetic considerations [published online ahead of print, 2021 Nov 4]. Ir J Med Sci. 2021;10.1007/s11845-021-02828-4. doi:10.1007/s11845-021-02828-4

                43. Chrubasik-Hausmann S, Vlachojannis J, McLachlan AJ. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content. J Pharm Pharmacol. 2019;71(1):129-138. doi:10.1111/jphp.12858

                44. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol. 2004;18(2):262-276. doi:10.1177/0269881104042632

                45. Chen J, Wang Y. Social Media Use for Health Purposes: Systematic Review. J Med Internet Res. 2021;23(5):e17917. Published 2021 May 12. doi:10.2196/17917

                46. Moorhead SA, Hazlett DE, Harrison L, Carroll JK, Irwin A, Hoving C. A new dimension of health care: systematic review of the uses, benefits, and limitations of social media for health communication. J Med Internet Res. 2013;15(4):e85. Published 2013 Apr 23. doi:10.2196/jmir.1933

                47. Swire-Thompson B, Lazer D. Public Health and Online Misinformation: Challenges and Recommendations. Annu Rev Public Health. 2020;41:433-451. doi:10.1146/annurev-publhealth-040119-094127

                48. Chou WS, Oh A, Klein WMP. Addressing Health-Related Misinformation on Social Media. JAMA. 2018;320(23):2417-2418. doi:10.1001/jama.2018.16865

                49. Suarez-Lledo V, Alvarez-Galvez J. Prevalence of Health Misinformation on Social Media: Systematic Review. J Med Internet Res. 2021;23(1):e17187. Published 2021 Jan 20. doi:10.2196/17187

                50. Supplement Your Knowledge. Dietary Supplement Education Initiative. United States Food and Drug Administration. May 25, 2022. Accessed July 20, 2022. Reference the Supplement your knowledge program

                Ketamine and Its Kissing Cousins

                Learning Objectives

                 

                After completing this application-based continuing education activity, pharmacists and pharmacy technicians will be able to

                ·       Identify patient populations in which ketamine use is justified based on its FDA approved indications and for off-labeled use where it has been sufficiently studied
                ·       Compare the different formulations of ketamine and its “kissing cousins”
                ·       Describe potential risks associated with ketamine use

                 

                Image depicting chemical structure of ketamine.

                Release Date:

                Release Date: October 27, 2025

                Expiration Date: October 27, 2028

                Course Fee

                Pharmacists: $7

                Pharmacy Technicians: $4

                There is no grant funding for this CE activity

                ACPE UANs

                Pharmacist: 0009-0000-25-071-H08-P

                Pharmacy Technician: 0009-0000-25-071-H08-T

                Session Codes

                Pharmacist:  22YC62-FXK22

                Pharmacy Technician:  22YC62-KXT46

                Accreditation Hours

                2.0 hours of CE

                Accreditation Statements

                The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-25-071-H08-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

                 

                Disclosure of Discussions of Off-label and Investigational Drug Use

                The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

                Faculty

                Alexis Hicks, PharmD.
                CVS Health
                West Hartford, CT

                Canyon Hopkins, PharmD.
                Medical Professional Ethos Cannabis
                Pittsburgh, PA

                Alexis Redfield, PharmD.
                CVS
                Vernon, CT

                Ashley Walsh, PharmD.
                Mohegan Pharmacy
                Uncasville, CT


                 

                Faculty Disclosure

                In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

                Drs. Hicks, Hopkins, Redfield, and Walsh do not have any relationships with ineligible companies and therefore have nothing to disclose.

                 

                ABSTRACT

                Ketamine is Food and Drug Administration-approved as a general anesthetic. Researchers found higher dose ketamine therapy had a more desirable adverse effect profile than the previously used anesthetic phencyclidine (PCP). N-methyl-D-aspartate (NMDA) antagonism from subanesthetic ketamine doses produces dissociative and analgesic effects. As such, prescribers are exploring off-label uses for ketamine in patients with agitation, depression, and pain while considering potential risks to multiple organ systems. Ketamine has the potential to cause complications and providers need to monitor patients closely. Illicit and inappropriate use by abusers and untrained law enforcement officers highlight ketamine’s potentially harmful effects. Educating patients and healthcare providers is vital to allow potential benefits while minimizing harm.

                CONTENT

                Content

                Introduction

                 

                Consider this: It’s 10:30 PM on a Friday night, 30 minutes before you leave for the weekend. Suddenly, from across the emergency department you hear, “Get OFF me! No, I have not t-t-taken anything! If you come ANY CLOSER, things are going to get physical!” Not a moment later, an order pops up for ketamine hydrochloride 500 mg intramuscularly (IM) for severe agitation. Concerned, a colleague asks you, “Is this safe? Is this effective? I have never seen a dose this high before. Isn’t this just for horses?”

                 

                Ketamine made its debut in human clinical practice in the 1960s when several chemists at Parke Davis Company were searching for an anesthetic with similar effects to phencyclidine (PCP). PCP, ketamine’s notorious kissing cousin, was a promising new anesthetic in the 1950s because of its dissociative effects. However, the chemists quickly became unimpressed with its adverse effect profile (i.e., long-lasting psychoactive effects after anesthesia). Humans experienced intense prolonged emergence delirium following PCP anesthesia, relegating its use to veterinary practice.1 Chemists searched for a better anesthetic and found ketamine, which has similar dissociative effects without PCP’s negative consequences. Ketamine is a more desirable anesthetic because it has a shorter half-life (2.5 hours) compared to PCP (21 hours) and it causes less delirium.1,2

                 

                Prescribers have begun using ketamine for several off-label uses and patients have also started using the drug or structural analogs in a variety of formulations illicitly. Pharmacists and technicians can ensure ketamine’s safe use by keeping current with new formulations and indications, both approved and unapproved. This continuing education activity will dive into the clinical and social consequences of ketamine use.

                 

                What’s Ketamine?

                Ketamine is a schedule III-controlled substance approved by the U.S. Food and Drug Administration (FDA) for use as a general anesthetic for diagnostic and surgical procedures.2 Ketamine is commercially available in the United States as a solution/injection under its brand (Ketalar) and as generic ketamine.2 Healthcare providers most often use intravenous (IV) ketamine, but it may be used IM or compounded into an oral solution. 

                 

                Healthcare providers also use ketamine off-label for analgesia, agitation, and major depressive disorder. These indications emanate from ketamine’s mechanism of action: it acts specifically on the N-methyl-D-Aspartate (NMDA) receptor as a non-competitive antagonist to block glutamate binding.3 Glutamate, a major excitatory neurotransmitter, binds to receptors throughout the nervous system. The NMDA receptor is an ionotropic receptor responsible for the brain’s neuroplasticity, memory, learning, and recovery.4-6 Blocking this receptor with high ketamine doses (ranging from 0.5 to 2 mg/kg) results in dissociation, decreases in spinal reflexes, and produces a cataleptic state (loss of voluntary movements and reduced consciousness) that is applicable to its current clinical use in anesthesia.2 However, at low doses, ketamine can produce analgesia and stimulate new pathways within the brain that reduce depressive symptoms and improve mood.

                 

                Although ketamine has useful applications in medicine, prescribers must be aware of the adverse effects and risk factors associated with use and should consider how these effects apply to their patients before initiating the medication. Ketamine adversely impacts multiple organ systems (see Table 1), including but not limited to the cardiovascular system. Increases in blood pressure and heart rate are important cardiovascular effects associated with ketamine therapy.2 These cardiovascular effects make it a drug of choice for anesthesia induction in patients with cardiovascular shock, where it anesthetizes patients while improving blood pressure and improving organ perfusion. However, clinicians must avoid ketamine use in patients with preexisting hypertensive conditions or other patients who have limited baroreceptor buffering capacity (baroreceptor buffering is the body’s ability to sense blood pressure) because of those same effects mentioned above.6

                 

                Table 1. General Adverse Effects of Ketamine2,6

                System Adverse effects
                Cardiovascular Cardiac arrhythmias, increased blood pressure,* increased heart rate
                Central nervous system Prolonged emergence from anesthesia,* psychosis,* dissociation,* drug dependence, increased intracranial pressure
                Dermatologic Injection site irritation
                Gastrointestinal Nausea,* vomiting, anorexia
                Genitourinary Lower urinary tract dysfunction, bladder dysfunction
                Respiratory Laryngospasm,* respiratory depression,* apnea
                Immunologic Anaphylaxis
                Other Hypersalivation, diplopia (double vision), nystagmus (uncontrollable rapid eye movement)

                *Common or serious adverse effects of ketamine use

                 

                Further contraindications include hypersensitivity to ketamine or its components.7 The American College of Emergency Physicians (ACEP) does not recommend ketamine use in patients with schizophrenia or in children younger than three months of age. The ACEP also advises against solely using ketamine as an anesthetic in procedures involving the pharynx, larynx, and bronchial tree. This recommendation primarily applies to patients with airway instability because ketamine can cause laryngospasms.5 Table 2 lists additional considerations in special populations.

                Table 2. Special Population Considerations with Ketamine2,6-8

                Special population Concerns Recommendation
                Pregnancy Crosses the placenta; may have potential risk to fetus Avoid use; evaluate benefits vs risk
                Breastfeeding Compatibility and safety unknown Avoid breastfeeding to children with respiratory risk factors
                Pediatrics Can be given with anticholinergics to minimize hypersalivation Refer to pediatric dosing. Avoid in infants < 3 months of age
                Elderly May be sensitive to dissociative adverse effects Refer to adult dosing
                Kidney dysfunction No additional concerns Refer to dosing parameters
                Liver dysfunction Hepatobiliary dysfunction with recurrent use Refer to dosing parameters; monitor LFTs with repeated ketamine use
                LFTs = liver function tests

                 

                Healthcare providers should monitor patients' vital signs closely during treatment with ketamine. Anesthesiologists and pharmacists must continuously watch patients undergoing surgical or diagnostic procedures for proper induction and maintenance of dissociative effects.2 In patients who must take repeated doses of ketamine (e.g., for chronic pain management or psychiatric disorders), healthcare providers should order liver function tests at baseline and every one to two days during treatment.2,6,9,10

                 

                Ketamine’s Kissing Cousins

                As shown in Figure 1, ketamine is structurally related to many compounds. The drugs in Figure 1 antagonize the NMDA receptor and exhibit a dissociative effect.1 PCP is one of the most notoriously abused drugs. Compared with ketamine, PCP is 10 times more potent and has a longer duration of action due to its strong affinity for the NMDA receptor. Both ketamine and PCP can replicate schizophrenia’s positive, negative, and cognitive symptoms and exacerbate underlying schizophrenia. But because ketamine has lower potency and a shorter duration of action, it induces fewer severe psychiatric effects than PCP.1

                Image depicting the molecular structure of ketamine and structurally related drugs.

                Figure 1. Molecular structure of ketamine and structurally related dissociative drugs11

                           

                Although ketamine’s labeling includes many precautions, it is an emerging option because of its therapeutic benefits. Xi Biopharmaceuticals is developing a sublingual wafer to treat acute pain while Janssen Pharmaceuticals has developed a nasal spray formulation for treatment resistant depression.12,13 Table 3 compares the current ketamine formulations that are FDA-approved or under investigation.

                 

                Table 3. Ketamine Counterparts12-14

                 Cousins Formulation Use & Dose Approval or Trial Phase
                Ketalar (ketamine hydrochloride) Injectable Anesthesia

                0.25 – 0.35 mg/kg followed by CIVI 1 mg/kg/hr

                FDA-approved
                Wafermine (ketamine) Sublingual Wafer Acute Pain

                25 mg, 50 mg & 75 mg PRN for 12 hrs

                End-of-Phase 2 Clinical Trials
                Spravato (esketamine) Nasal Spray Treatment Resistant Depressive Disorder

                28 mg, 56 mg, 84 mg twice a week

                FDA-approved
                ABBREVIATION: CIVI = continuous intravenous infusion

                 

                ABUSE, ADDICTION, DEPENDENCE

                 

                Why is Ketamine Dangerous?

                Long-term ketamine abuse is associated with memory, attention, and judgment impairment. The actual risk of ketamine abuse in the general population is low compared to other substances of abuse, but patients with polysubstance abuse disorder tend to use it.15 A study examining polysubstance abuse conducted in New York City found that polydrug use occurred because of an unexpected opportunity to use ketamine after already consuming other drugs. Researchers also determined that polysubstance abusers purposefully used ketamine with another substance to achieve an individually desired effect. Oftentimes polydrug-using events occurred within a group and each member contributed something: ketamine, knowledge, other drugs, or space to use drugs.16

                 

                Currently, ketamine is only commercially available as an injectable liquid. Dealers illegally sell ketamine as a recreational injectable substance or a white powder that resembles cocaine. The Department of Justice and Drug Enforcement Administration report that illegally distributed ketamine is diverted or stolen from veterinary clinics or smuggled into the United States from Mexico.17 Dealers can then synthesize ketamine into a powder or sell it as an injectable liquid.18 Prices average from $20-$25 per dose (50 mg to 100 mg).19 Drug abusers find ketamine’s dissociative sensations and hallucinations appealing. Users can inject liquid ketamine, or snort or smoke powdered ketamine.17 Ketamine is a popular drug to facilitate physical or sexual assault because it is a colorless, tasteless, and odorless liquid making it difficult for victims to detect. Additionally, ketamine is known to cause impaired coordination, confusion, and memory loss.20

                 

                Ketamine’s IV administration started in the early 1990s. Injection events occur most frequently in large cities with high rates of homelessness, like New York City and Los Angeles.18 Researchers conducted a study with 213 people who abused IV ketamine.18 Among these users, 84% admitted to abusing ‘harder’ drugs first, with heroin predominating. Users reported their first ketamine injection happening among a group of people. This group often included people well known to them who provided knowledge and the materials for injecting.18

                 

                What attracts people to a dissociative drug with unknown psychoactive effects? Exactly that: the unknown. With most abused drugs, the user understands the effects they will experience. When someone takes ketamine, the reaction to each dose is unknown. Some users seek variety. Ketamine users have described an out of body experience that expands internal and external realms and realities.18 On the other hand, abusers also describe a “K-Hole”—an experience that they describe as near-death that results when they ingest too much ketamine.17

                 

                Timothy Wyllie, a spiritualist, describes ketamine doses as a curve over time through realms. He describes the domains abusers experience as they dose ketamine21:

                • The realm “I,” for internal reality, occurs at doses 30 to 75 mg roughly 10 minutes after injection.
                • The extraterrestrial reality realm, “They,” occurs at doses 75 to 150 mg approximately 15 minutes after injection.
                • The realm “We,” for network creation realm, occurs at doses from 150 to 300 mg mg approximately 15 minutes after injection.
                • An unknown realm exists at doses of more than 300 mg.

                The doses studied for depression fall in the realm of internal reality. At these doses, users can see areas needing self-improvement that they were unaware they had the ability to fix. Drug users prefer subanesthetic doses but those that are higher than doses studied for treating depression. As the dose increases, users become so far removed from reality that “extraterrestrial” experiences begin.21

                 

                 

                KETAMINE USES

                 

                Anesthesia

                Patients unable to maintain and protect their airways require endotracheal intubation. Healthcare providers use ketamine as a sedative to facilitate rapid sequence induction and intubation (RSII), by inducing an anesthetized state, prior to paralyzing the patient. The decision to intubate is based on the patient’s Glasgow Coma Score.22,23 A score of 8 or less qualifies a patient to receive endotracheal intubation.23 Healthcare providers follow a RSII strict algorithm, shown in Table 4, detailing the order in which medications should be administered based upon the onset and duration of action.

                Table 4. Algorithm of Rapid Sequence Induction & Intubation22,23

                Step of RSII What and Why Medications Used
                Premedication* Airway manipulation causes a sympathetic activation due to a pressor response. This sympathetic response leads to an increase in intracranial pressure and mean arterial pressure. alfentanil, fentanyl, lidocaine, sufentanil
                Sedation Used to induce an anesthetic state before a paralytic is used and the airway manipulated. Crucial that a patient is properly sedated before paralyzed. Also known as induction agents: etomidate, ketamine, midazolam, propofol
                Paralytics± Neuromuscular blocking agents are given to relax pharyngeal and diaphragmatic muscles allowing for an endotracheal tube to be placed. rocuronium, succinylcholine, vecuronium

                *: Based upon time constraints/needs this step may be omitted

                ±: It is imperative to confirm a patient is properly sedated before beginning paralysis because if the patient is awake, they may feel the tube insertion

                 

                The drugs used in RSII possess unique characteristics, including IV use, quick onset, and short duration of action.23 Traditionally, etomidate has been the gold standard for RSII, but ketamine is quickly becoming a commonly used alternative.23 Table 5 highlights the differences between etomidate and ketamine.

                 

                Table 5. Comparison of Etomidate and Ketamine22,23

                  Etomidate Ketamine
                Dose for Induction 0.3 mg/kg 1.5 mg/kg or 0.1-0.5 mg/kg/min with 10% given as induction bolus
                Onset of Action 10-15 seconds < 30 seconds
                Duration of Action 4-10 minutes 10-15 minutes
                Benefits Stable hemodynamic profile, decreases metabolic rate, decreases cerebral blood flow, increases generalized seizure threshold Sedative and analgesic properties,* cardiovascular and respiratory stimulation, and smooth muscle relaxation (beneficial in reactive airway disease, hypotensive, volume depleted, and septic patients)
                Risks Adrenal suppression, do not use in septic shock, lowers focal seizure threshold, increased incidence of ARDS Potentiates effect of epinephrine, increases cardiac oxygen demand, may increase ICP,** emergent reactions, infusion related respiratory depression, hypersalivation
                ABBREVIATIONS: ARDS = acute respiratory distress syndrome, ICP = intracranial pressure

                 

                * Ketamine can be used as a combined premedication and induction step

                ** Data is conflicting, however, may not be suitable for patients with head trauma

                 

                The differences between etomidate and ketamine create a significant role in RSII for both drugs, but for different presenting conditions. Ketamine is gaining popularity for its use in septic patients, hypotensive patients, and those with reactive airway diseases. Choosing etomidate is preferable for patients with a hemodynamically stable profile and patients with traumatic brain injury where it could be cerebroprotective.

                 

                Analgesia (pain)

                 

                Ketamine’s use in pain management is controversial due to limited data, but this dataset is growing.15,24 Before considering subanesthetic ketamine doses, prescribers should collaborate with patients and other clinical team members to try other approved pain regimens.25 Using ketamine for its analgesic properties should be based on patient-specific criteria. The prescriber must assess the patient’s treatment goals, current medical conditions, pain types, and available protocols.

                 

                Ketamine is not discussed in available pain guidelines. Some literature recommends its use after unsuccessful trials of at least two opioids. Data supporting ketamine’s use in both acute and chronic pain management is mixed in its findings.26,27 Most trials conclude ketamine can reduce acute pain exacerbations but note that prescribers must be cautious of its adverse effects.15 Data from small trials indicate using ketamine to overcome opioid withdrawal and opioid-induced-hyperalgesia (neuropathic pain) may be possible. Ketamine has a unique ability to counteract the unfavorable responses patients might experience on chronic high-dose opioids by its mechanism of action.24,28 Overstimulated opioid receptors from high dose opioid use causes more hyperalgesia. Several small case reports describe patients on high-dose chronic opioid therapy who reduced their opioid doses after low-dose ketamine administration.29

                 

                An open labeled audit determined that IV ‘burst’ ketamine therapy improved analgesia in neuropathic pain and painful bone metastases. Researchers enrolled 39 cancer patients who were refractory to opioid therapy. Patients received bursts of low-dose ketamine (100 to 500 mg/day) over three to five days and reported somatic and neuropathic pain relief for up to eight weeks.15

                 

                Limited evidence supports oral ketamine’s effect in chronic pain and most studies that examine its use are case reports or non-comparative trials. Compared to IV administration, lower oral ketamine concentrations are associated with analgesic effects. Oral ketamine has been associated with higher serum levels of its metabolite, norketamine. This metabolite seems to contribute to oral ketamine’s analgesic effects due to its shorter half-life and ability to reach much higher peak plasma concentrations than after IV administration. However, researchers have not extensively explored this in current literature.29

                 

                Healthcare providers and patients face many hurdles when using ketamine for pain relief. Prescribers should avoid high ketamine doses that may cause a range of serious adverse effects. Unlike opioids, ketamine has a ceiling effect and maximum dose. Oral ketamine administration has a low bioavailability and is directly linked with a high rate of adverse effects.15,27

                 

                Agitation

                Due to ketamine’s dissociative properties, clinicians are increasingly using ketamine for treating pre-hospital and in-hospital agitation. Lacking a uniform definition for agitation, healthcare providers, institutions, and organizations may use different criteria to choose medication intervention in an agitated patient. Although the picture of agitation may change depending on the situation, validated scales like the Altered Mental Status Scale (AMSS) can define agitation’s severity.30 The AMSS translates agitation into a quantifiable, real concept. The line between agitation and delirium is often unclear but has major ramifications for a patient’s treatment and outcome.30 For example, excited delirium, an agitation subtype, classifies a patient’s agitation past the emotional component and includes psychomotor, metabolic, and contributing disease states as possible reasons for agitation.30

                 

                As with most psychiatric disorders, identifying and treating agitation has been suboptimal. Since the 1980s, a popular cocktail of medications, known among emergency department physicians as the “B-52” order, has been the mainstay of agitation treatment in psychiatric facilities and emergency departments.31 When examining the B-52 order’s components, it is easy to see the correlation between the regimen and the American jet-powered strategic bomber from which it derives its name: Benadryl 50 mg IM, haloperidol 5 mg IM, lorazepam 2 mg IM.31 The B-52 order serves as a reminder of the suboptimal approach traditionally taken when confronted with an agitated patient.

                 

                Ketamine’s different routes of administration have benefits and disadvantages. Although less invasive, oral ketamine takes a longer time to reach the therapeutic range, something that is undesirable in an overly aggressive patient. Intravenous administration has the quickest onset but is the most invasive. Securing IV access may not always be possible. The IM route is the most often used method for agitation control for its quick “on/off” onset and duration of action, and its applicable dosage form.

                 

                A review explains ketamine’s uses and benefits in comparison to other, more traditional agitation treatments.30 In terms of agitation efficacy, ketamine provides the same, if not better, response when compared to its more traditional counterparts.30 Ketamine has a significantly faster onset of action when compared to haloperidol (5 minutes versus 17 minutes) and requires less redosing (5% of patients re-dosed versus 20% of patients re-dosed, respectively).30 However, ketamine continues to show a higher incidence of adverse effects when compared to its anti-psychotic counterpart (percent incidence calculated from six studies where adverse events were recorded as a secondary outcome):30

                • emergence reaction 12.3% (8/65 patients)
                  • An “emergence reaction” is an often hostile, psychiatric episode brought about by ketamine use
                • hypersalivation 31.8% (22/69 patients)
                • nausea and vomiting 8.5% (7/82 patients)
                • respiratory complications 7.6% (9/118 patients)

                 

                Although studies report a higher incidence of adverse reactions when using ketamine for agitation, it is important to consider study limitations: small patient populations, co-administration of drugs, and lack of adverse event reporting (only half of 12 studies included adverse reactions).30 If used properly, ketamine can be a safe, quick-acting drug to stop agitation when compared to traditional treatments.

                 

                Some law enforcement agencies use ketamine. However, when they use ketamine improperly, or when adverse effects arise, ketamine can have dangerous consequences. Over a four-day period during late August of 2019 in Colorado, police gave 23-year-old Elijah McClain and 25-year-old Elijah McKnight excessive ketamine doses for agitation.32 McClain died from cardiac arrest and McKnight survived but required life support in the hospital.32 It is inappropriate to allow untrained police officers to inject ketamine as a law enforcement tool. However, police defend using ketamine saying suspects with mental health issues or suspects taking drugs can be belligerent and dangerous. A Minnesota whistleblower lawsuit filed by a former emergency medical services worker claims police pressured them to allow ketamine use uneccessarily.32 In Minneapolis, ketamine used by police rose from four incidents per year in 2015 to 62 in 2017.32 This marked increase in ketamine use is upsetting many healthcare professionals. Dr. Mary Dale Peterson, president of the American Society of Anesthesiologists, says that ketamine can have “dangerous complications,” just like any other anesthetic. Dr. Peterson points out that justifiably using ketamine occurs very rarely.32

                 

                Whistleblowers cite complications from unwarranted ketamine use are associated with emergence reactions, and improper dosages.32 McClain died when he was given a ketamine dose for a 200-pound man but only weighed 143 pounds.32 Pharmacists can play a role in educating other healthcare professionals about proper dosing and management of ketamine’s serious adverse effects.

                 

                Major Depressive Disorders

                Generally, major depressive disorder’s (MDD) treatment focuses on pathophysiology and regulates serotonin, norepinephrine, and dopamine.32 Medications such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibits (SNRIs), tricyclics, tetracyclics, and serotonin modulators all target an increase in synaptic neurotransmitter levels.32 Unfortunately, these drugs are not consistently effective for all patients, require an 8-week trial period, and have unfavorable adverse effects. For many providers and their patients, MDD treatment can feel like an awful waiting game—one that they sometimes lose.

                 

                Ketamine is becoming increasingly popular for its use in treating refractory depression. However, it requires healthcare providers to understand how it works to avoid putting patients into a “K-hole.” It offers a different approach to the current FDA-approved drugs for MDD. Ketamine prevents glutamate reuptake; excess glutamate produces an antidepressant effect. Ketamine, at subanesthetic doses, produces euphoria, and improves symptoms within 24 hours after infusion.4,14,32,33 Depressive symptoms improve rapidly, but the effects last only a few days to weeks. As a result, ketamine is most useful as an adjunctive treatment option. Patients feel better for a brief period, giving their antidepressants a chance to start working.

                 

                In addition, prescribers have few options for patients with MDD who have suicidal behaviors and ideation. Ketamine seems promising for patients at an elevated risk for self-harm. The Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression trial examined ketamine’s potential benefits for 80 suicidal patients with MDD. The results of this randomized controlled study showed that ketamine was superior to midazolam in improving the Scale for Suicidal Ideation (SCI). Patients’ SCI scores improved 4.96 points within 24 hours after a ketamine infusion of 0.5 mg/kg over 40 minutes.32 This suggests clinical use of ketamine as an adjuvant agent for acute episodes of suicide ideation in patients maintained on guideline recommended therapy for MDD may be appropriate. However, patient safety remains a concern (e.g., dissociative effects, abuse potential, respiratory, and cardiovascular effects).

                 

                As mentioned earlier, esketamine (Spravato) is ketamine’s S-enantiomer and FDA-approved for treatment-resistant depression.33 In the TRANSFORM-1 randomized controlled trial, the antidepressant/esketamine groups did not have a statistically significant change in Montgomery-Asberg Depression Rating Scale (MADRS) total score (from baseline to study day 28) when compared to the antidepressant placebo group.34,35 However, the changes based on the MADRS were clinically meaningful and showed that esketamine has a beneficial role in treatment-resistant depression when used as an adjuvant agent.36,37 The combination of esketamine with an antidepressant produced desirable outcomes while minimizing adverse effects. Although adverse effects were low, several adverse effects are possible: vertigo, nausea, vomiting, anxiety, sedation, abuse potential, increased blood pressure, dissociation, and suicidal thoughts/behaviors.33

                 

                CONCLUSION

                To paraphrase the father of toxicology, Paracelsus, it’s all about the dose. Ketamine is the poster child drug for this statement. Ketamine has the potential to be an important adjuvant therapy for the treatment of a range of conditions. Those listed in this CE—anesthesia, analgesia, and major depressive disorder—are currently the most studied disorders where ketamine and its derivatives may be useful. Due to ketamine’s dissociative and analgesic effects through NMDA antagonism, there may be additional future potential uses for ketamine in pain control and psychiatric disorders. Simply, ketamine treats not only the physical manifestations of these conditions but the emotional component that providers can easily overlook. However, the current data sets are small, many use rating scales instead of final health outcomes, and a larger and longer term series of trials are required to fully determine the place of ketamine in the treatment armamentarium for patients.

                 

                Pharmacists and other healthcare providers will need to distinguish between therapeutic use and addiction. Often, these lines are muddled. Providing education is a first step to preventing abuse. Usually, addiction is a manifestation of an untreated, or undertreated, medical condition. Pharmacist intervention helps patients and healthcare providers to make the safest, most informed decisions possible to ensure the best possible outcomes.

                 

                Pharmacist Post Test (for viewing only)

                Pharmacist Post-Test
                Objectives:
                1. Identify patient populations in which ketamine use is justified based on its FDA approved indications and for off-labeled use where it has been sufficiently studied
                2. Compare the different formulations of ketamine and its “kissing cousins”
                3. Describe potential risks associated with ketamine use

                1. Patient AV has a GCS score of 8 and requires intubation. He presents with volume depletion, hypotension, and sepsis. What drug would the anesthesiologist probably use for sedation?
                a. Fentanyl
                b. Etomidate
                c. Ketamine

                2. In which patients would you avoid recommending ketamine?
                a. Patients with reactive airway disease
                b. Patients with sepsis or hypotension
                c. Patients with traumatic brain injury

                3. Which formulation of esketamine is FDA-approved for treatment resistant depressive disorder?
                a. Injectable
                b. Nasal spray
                c. Infusion

                4. What is the most commonly used route of administration when using ketamine for agitation?
                a. IV
                b. IM
                c. PO

                5. A clinician asks you about ketamine’s adverse effects. What would you say to start?
                a. Ketamine can cause cardiac arrythmias.
                b. Ketamine can decrease blood pressure.
                c. Ketamine can worsen peptic ulcers.

                6. What is the correct order of administration for RSII medications?
                a. Premedication, sedative, paralytic
                b. Premedication, paralytic, sedative
                c. Sedative, premedication, paralytic

                7. When should prescribers monitor liver function in patients who receive repeated ketamine doses?
                a. At baseline and every 1 to 2 months
                b. At baseline and every 1 to 2 weeks
                c. At baseline and every 1 to 2 days

                8. What is a “K-hole?”
                a. A networking experience
                b. A near-death experience
                c. An extraterrestrial experience

                9. What is a limitation of using ketamine in MDD?
                a. Depressive symptoms improve slowly
                b. Requires an 8-week trial period first
                c. Effects last only a few days to weeks

                10. A police officer asks you to discuss ketamine and asks why you refer to similar drugs as “kissing cousins.” How would you explain it?
                a. They all have similar potency and antagonize NMDA receptor
                b. They are used in similar doses and act as a NMDA receptor agonist
                c. They are structurally similar and antagonize NMDA receptor

                Pharmacy Technician Post Test (for viewing only)

                Technician Post-Test
                Objectives:
                1. Identify patient populations in which ketamine use is justified based on its FDA approved indications and for off-labeled use where it has been sufficiently studied
                2. Compare the different formulations of ketamine and its “kissing cousins”
                3. Describe potential risks associated with ketamine use

                1. In which patient should prescribers avoid using ketamine?
                a. patient with serious peptic ulcer
                b. patient older than 3 months old
                c. patient with uncontrolled hypertension

                2. What ketamine dose results in dissociation?
                a. 0.1 to 0.5 mg/kg
                b. 0.5 to 2 mg/kg
                c. 2 to 3.5 mg/kg

                3. What is a risk associated with using ketamine in RSII?
                a. adrenal suppression
                b. increase ARDS incidence
                c. emergent reactions

                4. What ketamine formulation is currently available by prescription?
                a. sublingual tablet
                b. injectable solution
                c. 24-hour patch

                5. What risk is associated with ketamine use?
                a. exacerbates underlying schizophrenia
                b. lowers focal seizure threshold
                c. increases incidence of ARDS

                6. What is a key difference between PCP and ketamine?
                a. PCP has a shorter duration of action than ketamine
                b. PCP is 10 time more potent than ketamine
                c. PCP has less severe psychiatric effects than ketamine

                7. What is a benefit of using ketamine for agitation in comparison to haloperidol?
                a. faster onset
                b. more redosing
                c. fewer side effects

                8. What is ketamine’s FDA-approved indication?
                a. agitation
                b. analgesia
                c. anesthesia

                9. What can be expected when people use oral ketamine?
                a. high bioavailability
                b. high rate of adverse effects
                c. low plasma peak concentrations

                10. What is ketamine’s role in RSII?
                a. premedication
                b. sedative
                c. paralytic

                References

                Full List of References

                References

                   
                  1. Li L, Vlisides PE. Ketamine: 50 Years of modulating the mind. Front Hum Neurosci. 2016;10:612. Published 2016 Nov 29. doi:10.3389/fnhum.2016.00612

                  2. Ketalar. Prescribing information. Par Pharmaceutical; 2022. Accessed July 25, 2022. https://www.parpharm.com/pdfs/catalog/sterile/Ketalar_PI_20220613.pdf

                  3. Institute of Medicine (US) Forum on Neuroscience and Nervous System Disorders. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary. Washington (DC): National Academies Press (US); 2011.

                  4. Aleksandrova LR, Phillips AG, Wang YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. Journal of Psychiatry Neuroscience. 2017;42(4):222-229. DOI: 10.1503/jpn.160175.

                  5. Vyklicky V, Korinek M, Smejkalova T, et al. Structure, function, and pharmacology of NMDA receptor channels. Physiol Res. 2014;63(Suppl 1):S191-S203. doi:10.33549/physiolres.932678

                  6. Godwin SA, Burton JH, Gerardo CJ, et al. American College of Emergency Physicians. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med. 2014;63(2):247-258.e18. doi:10.1016/j.annemergmed.2013.10.015[PubMed 24438649]

                  7. Ellingson A, Haram K, Sagen N, Solheim E. Transplacental passage of ketamine after intravenous administration. Acta Anaesthesiol Scand. 1977;21(1):41-44.[PubMed 842268]

                  8. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 2006;60(7):341-348. doi:10.1016/j.biopha.2006.06.021

                  9. Zhu X, Kohan LR, Goldstein RB. substantial elevation of liver enzymes during ketamine infusion: a case report. A Pract. 2020;14(8):e01239. doi:10.1213/XAA.0000000000001239

                  10. Wilkinson ST, Sanacora G. Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders. JAMA. 2017;318(9):793-794. doi:10.1001/jama.2017.10697

                  11. Ho JH, Dargan PI. Arylcyclohexamines (Ketamine, Phencyclidine, and Analogues). In: Critical Care Toxicology. Brent J, Burkhart K, Dargan P, Hatten B, Megarbane B, Palmer R, eds. Springer; 2016. https://doi.org/10.1007/978-3-319-20790-2_124-1

                  12. Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacology. 2015;172(17):4254-4276. doi:10.1111/bph.13222

                  13. Study of Wafermine™ for post-bunionectomy or abdominoplasty pain. ClinicalTrials.gov identifier: NCT03246971. Updated July 23, 2018. Accessed Jul 25, 2022. https://clinicaltrials.gov/ct2/show/study/NCT03246971

                  14. Treating major depressive disorder: a quick reference guide. American Psychiatric Association. Published October 2010. Accessed July 25, 2022. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd-guide.pdf

                  15. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 2006;60(7):341-348. doi:10.1016/j.biopha.2006.06.021

                  16. Lankenau SE, Clatts MC. Patterns of polydrug use among ketamine injectors in New York City. Subst Use Misuse. 2005;40(9-10):1381-1397. doi:10.1081/JA-200066936

                  17. Drug Fact Sheet: Ketamine. Department of Justice and Drug Enforcement Administration. Published April 2020. Accessed July 25, 2022. https://www.dea.gov/sites/default/files/2020-06/Ketamine-2020.pdf

                  18. Lankenau SE, Sanders B, Bloom JJ, et al. First injection of ketamine among young injection drug users (IDUs) in three U.S. cities. Drug Alcohol Depend. 2007;87(2-3):183-193. doi:10.1016/j.drugalcdep.2006.08.015

                  19. Average Cost of Illicit Street Drugs. AddictionResource.net. Updated June 21, 2021. Accessed July 25, 2022. https://www.addictionresource.net/cost-of-drugs/illicit/

                  20. Świądro M, Stelmaszczyk P, Lenart I, Wietecha-Posłuszny R. The Double Face of Ketamine-The Possibility of Its Identification in Blood and Beverages. Molecules. 2021;26(4):813. Published 2021 Feb 4. doi:10.3390/molecules26040813

                  21. Morris, H. Hamilton’s Pharmacopeia Ketamine: Realms and Realities. [Video]. Vice TV. December 26, 2017. Accessed July 25, 2022. https://www.vicetv.com/en_us/video/hamiltons-pharmacopeia-ketamine-realms-and-realities/59cd5d0b7752d1ac3e90aacf

                  22. Kurdi MS, Theerth KA, Deva RS. Ketamine: Current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8(3):283-290. doi:10.4103/0259-1162.143110

                  23. Scarponcini TR, Edwards CJ, Rudis MI, Jasiak KD, Hays DP. The role of the emergency pharmacist in trauma resuscitation. J Pharm Pract. 2011;24(2):146-159. doi:10.1177/0897190011400550

                  24. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145-161.

                  25. Johnstone-Petty, M. Ketamine use for complex pain in the palliative care population. J Hosp Palliat Nurs. 2018;20(6):561-567. doi: 10.1097/NJH.0000000000000488.

                  26. Mercadante S, Caruselli A., Casuccio A. The use of ketamine in a palliative-supportive care unit: a retrospective analysis. Ann Palliat Med. 2018;7(2): 205-210. doi: 10.21037/apm.2018.01.01

                  27. Bell RF, Kalso EA. Ketamine for pain management. Pain Rep. 2018;3(5):e674. Published 2018 Aug 9. doi:10.1097/PR9.0000000000000674

                  28. Lalanne L, Nicot C, Lang JP, et al. Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case report. BMC Psychiatry. 2016;16(1):395. doi:10.1186/s12888-016-1112-2

                  29. Blonk MI, Koder BG, Van Den Bemt PMLA, Huygen FJPM. Use of oral ketamine in chronic pain management: a review. Eur J Pain. 2012;14(5): 466-472. https://doi-org.ezproxy.lib.uconn.edu/10.1016/j.ejpain.2009.09.005

                  30. Linder LM, Ross CA, Weant KA. Ketamine for the acute management of excited delirium and agitation in the prehospital setting. Pharmacotherapy. 2018;38(1):139-151. doi:10.1002/phar.2060

                  31. Lulla AA, Singh M. The Art of the ED Takedown. emDOCs.net - Emergency Medicine Education. Published March 4, 2015. Accessed July 25, 2022. http://www.emdocs.net/the-art-of-the-ed-takedown/

                  32. Young R, McMahon S. Some States Allow Authorities to Use Ketamine to Subdue Suspects in The Field. But Is It Safe? Some States Allow Authorities to Use Ketamine to Subdue Suspects in The Field. But Is It Safe? | Here & Now. Published September 8, 2020. Accessed July 25, 2022. https://www.wbur.org/hereandnow/2020/09/08/ketamine-police-safety-elijah-mcclain

                  33. Ketamine. In: Lexi-Drugs. Lexi-Comp, Inc. Updated July 20, 2022. Accessed July 25, 2022. http://usj-ezproxy.usj.edu:2099/lco/action/doc/retrieve/docid/patch_f/7135?cesid=a8n33eDrj1M&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dketamine%26t%3Dname%26acs%3Dfalse%26acq%3Dketamine#rfs

                  34. Montgomery-Asperg Depression Rating Scale. Accessed July 27, 2022. https://www.mdcalc.com/calc/4058/montgomery-asberg-depression-rating-scale-madrs

                  35. Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616-630. doi:10.1093/ijnp/pyz039

                  36. Spravato. Prescribing information. Janssen Pharmaceutical Companies; 2019. Accessed July 25, 2022. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf

                  37. Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616-630. doi:10.1093/ijnp/pyz039

                  Arthur E. Schwarting Symposium LIVE Event 2027 TBD

                  Arthur E. Schwarting was an internationally recognized leader in the transformation of pharmacognosy from a plant-based discipline to a science based on the chemistry of natural products. He also was the preeminent pharmacognosist in the U.S. to engage in the study of medicinal agents from microorganisms, and he was a pioneer in the use of radio isotopes to elaborate the biochemical pathways by which plants and microorganisms make medicinally active products. The Arthur E. Schwarting Symposium is now an educational conference focused on pharmacy practice for pharmacists in many settings.

                  Measure Twice, Cut Once: A Carpentry Approach to Pharmacy

                  Five hours of live streaming CE including Law, Patient Safety, and Immunization

                  2026 AGENDA

                  11:00am-12:00 pm 

                  Load-Bearing Walls: Getting Cardiovascular Therapy Right the First Time
                  Katelyn Galli, PharmD, BCCP, UConn School of Pharmacy, Storrs, CT
                  Type of Activity: Application
                  ACPE UAN 0009-0000-26-009-L01-P
                  Learning Objectives: At the end of this presentation the learner will:

                  • Identify high-risk cardiovascular medications that are most commonly associated with preventable adverse drug events amid transitions of care
                  • Describe evidence-based principles for precise cardiovascular medication dosing, including clinically relevant pharmacokinetic considerations that influence drug and dose selection
                  • Explain the benefits and limitations of clinical decision support tools in cardiovascular pharmacotherapy
                  • Recognize common system-level and cognitive factors contributing to cardiovascular medication near misses and adverse effects

                   

                  12:05-1:05 pm 

                  LAW: The Legal Blueprint: Designing Error-Proof Pharmacy Policies
                  Dylan DeCandia, PharmD, RPh, Franklyn’s Pharmacy in Ho-Ho-Kus, New Jersey
                  Type of Activity: Application
                  ACPE UAN 0009-0000-26-010-L03-P
                  Learning Objectives: At the end of this presentation the learner will:

                  • Describe the roles and responsibilities of each pharmacy staff member
                  • Articulate when a pharmacist should seek legal clarification
                  • Identify common pharmacy mistakes that may leave pharmacists liable
                  • Construct policies and procedures that prevent future pharmacy errors

                   

                  1:10-2:10 pm 

                  Patient Safety: Blueprints Before Builds: Patient Assessment in Clinical Decision-Making
                  Devra Dang, PharmD, CDCES, FNAP, Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT  
                  Type of Activity: Application
                  ACPE UAN 0009-0000-26-013-L05-P
                  Learning Objectives:

                  • Explain the Pharmacists’ Patient Care Process and strategies to optimize the “Collect” and “Assess” steps to improve assessment and clinical decision-making
                  • Identify common pitfalls that affect optimal patient assessment across healthcare settings
                  • List strategies to incorporate patient-centered approaches into patient assessment and clinical decision-making

                   

                  2:15-3:15 pm 

                  Immunization: The Right Tool for the Job: Precision and Preparation in Immunization Practice
                  Thomas E. Buckley, RPh, MPH, FNAP; Associate Clinical Professor Emeritus, UConn School of Pharmacy, Storrs, CT
                  Type of Activity: Application
                  ACPE UAN 0009-0000-26-011-L06-P
                  Learning Objectives: At the end of this presentation the learner will:

                  • Analyze contraindications as the “measurement” step
                  • Determine the correct vaccine, dose, route, and needle length
                  • Document and report finishing work
                  • Detect administration errors and adverse events
                  • Illustrate reliable vaccine information

                   

                  3:20-4:20 pm 

                  Right Fit, Tight Seal: Building Better Cancer Care
                  Thomas M Levay, PharmD, CSP, Yale New Haven Health, New Haven, CT
                  Type of Activity: Application
                  ACPE UAN 0009-0000-26-012-L01-P
                  Learning Objectives: At the end of this presentation the learner will:

                  • Recognize ways that general education and consultation contributes to better care
                  • Identify crucial elements of a patient’s non-clinical care for patients with cancer
                  • Demonstrate different ways to help patients at each phase of care

                   

                  Handouts will be posted 72 hours prior to the event  in 2 slides per page and 6 slides per page below:

                  11:00am-12:00 pm Load-Bearing Walls: Getting Cardiovascular Therapy Right the First Time

                  12:05-1:05 pm LAW: The Legal Blueprint: Designing Error-Proof Pharmacy Policies

                  1:10-2:10 pm Patient Safety: Blueprints Before Builds: Patient Assessment in Clinical Decision-Making

                  2:15-3:15 pm Immunization: The Right Tool for the Job: Precision and Preparation in Immunization Practice

                  3:20-4:20 pm Right Fit, Tight Seal: Building Better Cancer Care

                  ACPE Logo“The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.”

                  Continuing Education Units

                  The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of Credit will be awarded at CE Finale based on full sessions attended and completed online evaluations. Pharmacists can earn up to 5 contact hours (0.50 CEU) one of which is a law credit, one is an Immunization Credit, and one is a Patient Safety Credit.

                  Please Note: Pharmacists who wish to receive credit for the presentations MUST ACCURATELY complete the registration and online evaluations within 45 days of the live program (before February 1, 2026).  Participants are accountable for their own continuing education requirements for license renewal and are required to follow up with Heather.Kleven@uconn.edu to resolve a discrepancy in a timely manner. PLEASE CHECK YOUR CPE MONITOR PROFILE within 3 days of submission to ensure that your credits have been properly uploaded.  Requests for exceptions will be handled on a case-by-case basis and may result in denial of credit.

                  Registration Fees: 50% discount for UConn faculty/preceptors

                  Long-Acting Injectable Medication Products

                  About this Course

                  Pharmacists possess the training and skills necessary to administer certain long-acting injectable (LAI) medications used in the management of mental illnesses and substance use disorders. Through collaborative practice agreements, pharmacists can administer Long Acting Injectables in almost every state. In some states, including the state of Connecticut, this occurs via collaborative agreements, and necessary injection and disease state training.  Administration of these medications by pharmacists can increase accessibility of care for patients.

                  UConn has developed web-based continuing pharmacy education activity to enhance pharmacists’ skills and help them make sound clinical decisions about long acting injectables administration. This course includes eight hours of CPE (or eight hours of credit), required by the State of Connecticut.  Successful completion of these eight hours (with four activities consisting of three hours online pre-requisite work and five hours of LIVE CE) will earn the pharmacist a Certificate in Long-Acting Injectables of Psychotropic Medication.

                  The three activities below are available separately for $17/hour each, or as pre-requisites for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program at $299 which includes both the prerequisites and the full day of LIVE training.

                  Target Audience

                  Pharmacists who are interested in administering long acting injectable psychotropic medications to their patients.

                  This activity is NOT accredited for technicians.

                  Pharmacist Learning Objectives

                  At the end of this application-based continuing education activity, the learner will be able to:

                  Compare and contrast among different long-acting injectable (LAI) medications currently available for the

                  treatment of schizophrenia, bipolar disorder and substance use disorders including:

                  ·        Dosing

                  ·        Generic and brand names

                  ·        Adverse effects

                  ·        Administration schedule

                  ·        Overlap with oral medications

                  ·        FDA-approved indications

                  Release Date

                  Released:  11/15/2023
                  Expires:  11/15/2026

                  Course Fee

                  $17

                  ACPE UAN

                  0009-0000-23-052-H01-P

                  Accreditation Hours

                  1.0 hours of CE

                  Session Code

                  23LA52-WXT36

                  Bundle Options

                  If desired, pharmacists can register for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program

                  or for the individual activities.   The Certificate consists of three activities in our online selection, and a 5 hour LIVE activity.

                  You may register for individual topics at $17/CE Credit Hour, or for the Entire LAIA Certificate at $299.00 which includes 5 hours of LIVE CE and the 3 online pre-requisites listed below.

                  You must register for ALL 4 activities to receive the bundled pricing of $299.00

                  Accreditation Statement

                  ACPE logo

                  The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit 1.0 hours (or 0.1 CEUS) for the online activity ACPE #0009-0000-23-052-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

                  Grant Funding

                  There is no grant funding for this activity.

                  Requirements for Successful Completion

                  To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

                  Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

                  Faculty

                  Kristin Waters, PharmD, BCPS, BCPP,
                  Assistant Clinical Professor
                  UConn School of Pharmacy
                  Storrs, CT

                  Faculty Disclosure

                  In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

                  Dr. Waters is a consultant with Janssen Pharmaceuticals. She will discuss all drugs without bias. All financial interests with ineligible companies (as noted) have been mitigated.

                  Disclaimer

                  This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

                  Program Content

                  Program Handouts

                  Post Test Evaluation

                  View Questions for Long-Acting Injectable Medication Products

                  Additional Courses Available for Long Acting Injectable Training

                   

                  Mental Illness and Substance Use Disorders: Background - 1 hour

                  Guideline-Driven Treatment for Mental Illnesses and Substance Abuse Disorders– 1 hour